var title_f43_10_44192="Patient position for exenteration";
var content_f43_10_44192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Patient position for exenteration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient in modified dorsal lithotomy position. Arrow indicates thermal drape used to prevent excessive heat loss during procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44192=[""].join("\n");
var outline_f43_10_44192=null;
var title_f43_10_44193="Patient information: Breast biopsy (The Basics)";
var content_f43_10_44193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86546\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/2/7203\">",
"         Ultrasound-guided breast biopsy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16977\">",
"          Stereotactic breast biopsy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Breast biopsy (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H698267185\">",
"      <span class=\"h1\">",
"       What is a breast biopsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A breast biopsy is procedure that checks an abnormal area of tissue in the breast. Doctors use different methods to do breast biopsies. They can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Use a large needle to take 1 or more small samples of tissue from the breast.",
"       </li>",
"       <li>",
"        Do an operation to take out part or all of the abnormal tissue.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You might get a breast biopsy if you or your doctor can feel a change in your breast, or if an area looks abnormal on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A mammogram &ndash; This is a special kind of X-ray.",
"       </li>",
"       <li>",
"        A breast ultrasound &ndash; This test uses sound waves to create pictures of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H698267200\">",
"      <span class=\"h1\">",
"       What happens during a breast biopsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your experience will depend on the type of biopsy you have. The choice is based on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The size and location of the abnormal area",
"       </li>",
"       <li>",
"        What the abnormal area looks like on your mammogram or ultrasound",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      For all breast biopsies, you will get an injection (shot) to numb the area of your breast that will be biopsied.",
"     </p>",
"     <p>",
"      The 3 main types of biopsies are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Fine needle biopsy &ndash; For this type of biopsy, the doctor uses a needle to remove a small amount of tissue or fluid from the abnormal area.",
"       </li>",
"       <li>",
"        Core needle biopsy &ndash; For this type of biopsy, the doctor uses a needle with a special tip. Often the doctor will also use special imaging equipment to find the abnormal area to take the biopsy.",
"        <br/>",
"        <br/>",
"        One option is an &ldquo;ultrasound-guided&rdquo; breast biopsy. If you have this type of biopsy, you will lie on your back or side and the doctor will hold the ultrasound device against your breast to guide the needle (",
"        <a class=\"graphic graphic_figure graphicRef86543 \" href=\"mobipreview.htm?7/2/7203\">",
"         figure 1",
"        </a>",
"        ).",
"        <br/>",
"        <br/>",
"        The other option is a &ldquo;stereotactic&rdquo; biopsy. If you have this type of biopsy, you will lie face down on a table. The table has an opening for your breast, which is pressed between 2 metal plates, just like it is during a mammogram. During this type of biopsy, the doctor takes an X-ray to decide where to insert the needle (",
"        <a class=\"graphic graphic_figure graphicRef86544 \" href=\"mobipreview.htm?16/37/16977\">",
"         figure 2",
"        </a>",
"        ).",
"        <br/>",
"        <br/>",
"        After a core needle biopsy, your doctor will place a tiny piece of metal, called a clip, in your breast. The clip can be seen on an ultrasound or X-ray, so that in the future, doctors can see where the biopsy was taken. You cannot feel the clip and it will not cause problems during future imaging tests, including airport screening tests.",
"       </li>",
"       <li>",
"        Surgical biopsy &ndash; For this type of biopsy, you will have a small tube (&ldquo;IV&rdquo;) in your arm to give you medicines to help you relax and feel sleepy. The surgeon will make a small cut (incision) in your breast and take out the abnormal tissue.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H698267251\">",
"      <span class=\"h1\">",
"       What happens after a breast biopsy?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After a biopsy, you might have bruising, bleeding, or get an infection. These problems are less common with fine or core needle biopsy than after a surgical biopsy.",
"     </p>",
"     <p>",
"      You will likely get the results of your biopsy in about a week.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H698267271\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?43/10/44193?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86546 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-125.39.66.146-C1CFDD43C6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44193=[""].join("\n");
var outline_f43_10_44193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698267185\">",
"      What is a breast biopsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698267200\">",
"      What happens during a breast biopsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698267251\">",
"      What happens after a breast biopsy?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698267271\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86546\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/2/7203\">",
"      Ultrasound-guided breast biopsy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/37/16977\">",
"       Stereotactic breast biopsy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44194="Podophyllum resin: Pediatric drug information";
var content_f43_10_44194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Podophyllum resin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30851?source=see_link\">",
"    see \"Podophyllum resin: Drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Podocon-25&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Podofilm&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Keratolytic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30851?source=see_link\">",
"      see \"Podophyllum resin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical: 10% to 25% solution in compound benzoin tincture; use 1 drop at a time allowing drying between drops until area is covered; total volume should be limited to &lt;0.5 mL to an area &lt;10 cm",
"     <sup>",
"      2",
"     </sup>",
"     for genital or perianal warts or &lt;2 cm",
"     <sup>",
"      2",
"     </sup>",
"     for vaginal warts per treatment session; therapy may be repeated once weekly for up to 4 applications for the treatment of genital or perianal warts; use 10% solution when applied to or near mucous membranes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Verrucae: 25% solution is applied directly to the wart; remove drug from area of application within 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Podocon-25&reg;: 25% (15 mL) [in benzoin tincture]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Clean and dry affected area prior to application. Use applicator provided with product. When applying for the first time leave on for only 30-40 minutes to determine patient sensitivity. After first use may leave on 1-4 hours depending on severity of lesion; systemic absorption may occur with prolonged contact. Do not treat large areas or many warts at one time. Remove drug with alcohol or soap and water once treatment time has elapsed.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; avoid exposure to excessive heat",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of benign growths including external genital and perianal warts (condylomata acuminata), papillomas, fibroids",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F210996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Coma, fever, polyneuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Paralytic ileus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Leukopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Death",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not to be used on birthmarks, moles, or warts with hair growth; cervical, urethral, oral warts; not to be used by diabetic patients or patients with poor circulation; pregnant women; do not apply to normal tissue",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use of large amounts of drug should be avoided. Do not apply to moles, birthmarks, or unusual warts; do not use if wart or surrounding tissue is inflamed/irritated. To be applied by a physician only.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . For external use only. Avoid contact with the eyes as it can cause severe corneal damage; 25% solution should not be applied to or near mucous membranes; podophyllum resin has caused teratogenic effects (skin tags, polyneuritis, limb malformations, septal heart defects) and fetal death when used during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reports in pregnant women have shown evidence of fetal abnormalities, fetal death, and stillbirth; use is contraindicated in women who are or may become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Directly affects epithelial cell metabolism by arresting mitosis through binding to a protein subunit of spindle microtubules (tubulin)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if undue skin irritation develops",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;1993 Sexually Transmitted Diseases Treatment Guidelines,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1993, 42(RR-14):1-102.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44194/abstract-text/8145706 /pubmed\" id=\"8145706 \" target=\"_blank\">",
"        8145706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfarb MT, Gupta AK, Gupta MA, et al, &ldquo;Office Therapy for Human Papillomavirus Infection in Nongenital Sites,&rdquo;",
"      <i>",
"       Dermatol Clin",
"      </i>",
"      , 1991, 9(2):287-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44194/abstract-text/1711941/pubmed\" id=\"1711941\" target=\"_blank\">",
"        1711941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12714 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-04C97D187A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44194=[""].join("\n");
var outline_f43_10_44194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210976\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210977\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049439\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049433\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210967\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210955\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049442\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049435\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049441\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210996\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049444\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049432\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049431\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299894\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293343\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049430\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049437\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12714|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/8/30851?source=related_link\">",
"      Podophyllum resin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44195="Proximal subungual onychomycosis - toenails";
var content_f43_10_44195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44195=[""].join("\n");
var outline_f43_10_44195=null;
var title_f43_10_44196="Pamidronate: Patient drug information";
var content_f43_10_44196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pamidronate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     see \"Pamidronate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39781?source=see_link\">",
"     see \"Pamidronate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aredia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aredia&reg;;",
"     </li>",
"     <li>",
"      Pamidronate Disodium Omega;",
"     </li>",
"     <li>",
"      Pamidronate Disodium&reg;;",
"     </li>",
"     <li>",
"      PMS-Pamidronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691890",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high calcium levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Paget's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691312",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used when treating some cancers.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3448744",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop bone loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pamidronate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697250",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had thyroid or parathyroid surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698081",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697868",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia and low white blood cell count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698212",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A broken leg may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698193",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the jaw bone may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699013",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad bone, joint, or muscle pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2927623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad groin or thigh pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11240 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44196=[""].join("\n");
var outline_f43_10_44196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205911\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205912\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025100\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025099\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025104\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025105\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025107\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025102\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025109\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=related_link\">",
"      Pamidronate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/54/39781?source=related_link\">",
"      Pamidronate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44197="Acarbose: Drug information";
var content_f43_10_44197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acarbose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/14/27876?source=see_link\">",
"    see \"Acarbose: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/46/25316?source=see_link\">",
"    see \"Acarbose: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Precose&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Glucobay&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Alpha-Glucosidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Type 2 diabetes: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Initial:",
"     </i>",
"     25 mg 3 times/day with the first bite of each main meal; to reduce GI effects, some patients may benefit from initiating at 25 mg once daily with gradual titration to 25 mg 3 times/day as tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maintenance dose:",
"     </i>",
"     Should be adjusted at 4- to 8-week intervals based on 1-hour postprandial glucose levels and tolerance until maintenance dose is reached; maintenance dose: 50-100 mg 3 times/day. Dosage must be individualized on the basis of effectiveness and tolerance while not exceeding the maximum recommended dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Maximum:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &le;60 kg: 50 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;60 kg: 100 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patients receiving sulfonylureas or insulin:",
"     </b>",
"     Acarbose given in combination with a sulfonylurea or insulin will cause a further lowering of blood glucose and may increase the hypoglycemic potential of the sulfonylurea or insulin. If hypoglycemia occurs, appropriate adjustments in the dosage of these agents should be made.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;25 mL/minute: No dosage adjustment necessary. Although acarbose is primarily excreted unchanged, the increased plasma levels in renal impairment are not expected to affect efficacy (clinical response is localized to the GI tract); however, the effects on adverse effects are unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute or S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2 mg/dL: Use not recommended (not adequately studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Precose&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F129113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with the first bite of each main meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adjunct to diet  and exercise to lower blood glucose in patients with type 2 diabetes mellitus (noninsulin dependent, NIDDM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Precose&reg; may be confused with PreCare&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Precose&reg; [U.S., Malaysia] may be confused with Precosa brand name for",
"       <i>",
"        Saccharomyces boulardii",
"       </i>",
"       [Finland, Sweden]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (31%) and abdominal pain (19%) tend to return to pretreatment levels over time; frequency and intensity of flatulence (74%) tend to abate with time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Edema, erythema, exanthema, hepatitis, ileus/subileus, jaundice, liver damage, pneumatosis cystoides intestinalis, rash, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acarbose or any component of the formulation; patients with diabetic ketoacidosis or cirrhosis; patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or in patients predisposed to intestinal obstruction; patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption, and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated serum transaminases: Treatment-emergent elevations of serum transaminases (AST and/or ALT) occurred in up to 14% of acarbose-treated patients in long-term studies. These serum transaminase elevations appear to be dose related. At doses &gt;100 mg 3 times/day, the incidence of serum transaminase elevations greater than 3 times the upper limit of normal was 2-3 times higher in the acarbose group than in the placebo group. These elevations were asymptomatic, reversible, more common in females, and, in general, were not associated with other evidence of liver dysfunction. Fulminant hepatitis has been reported rarely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use not recommended in patients with significant impairment (S",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;2 mg/dL); use with caution in other patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue acarbose and administer insulin if the patient is exposed to stress (ie, fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonylureas/insulin: In combination with a sulfonylurea or insulin will cause a further lowering of blood glucose and may increase the hypoglycemic potential of the sulfonylurea or insulin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Acarbose may decrease the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neomycin: May enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Limit ethanol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been reported in animal reproduction studies; therefore, acarbose is classified as pregnancy category B. Low amounts of acarbose are absorbed systemically which should limit fetal exposure. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is above the normal range. Diabetes can also be associated with adverse effects in the mother. Poorly-treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the mother and the fetus. Acarbose has been studied for its potential role in treating GDM; however, only limited information is available describing pregnancy outcomes. Until additional safety and efficacy data are obtained, the use of oral agents is generally not recommended as routine management of GDM or type 2 diabetes mellitus during pregnancy. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6209166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if acarbose is found in breast milk; however, low amounts of acarbose are absorbed systemically in adults, which may limit the amount that could distribute into breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6700147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with food (first bite of meal).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Acarbose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $89.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $97.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $115.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Precose Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $106.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $115.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $137.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F129107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Postprandial glucose, glycosylated hemoglobin levels, serum transaminase levels should be checked every 3 months during the first year of treatment and periodically thereafter, renal function (serum creatinine); blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6258748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Accarb (NZ);",
"     </li>",
"     <li>",
"      Acrose (IL);",
"     </li>",
"     <li>",
"      Carlipin (HK);",
"     </li>",
"     <li>",
"      Decarbay (TW);",
"     </li>",
"     <li>",
"      Deglu (TW);",
"     </li>",
"     <li>",
"      Dibose (MY);",
"     </li>",
"     <li>",
"      Eclid (ID);",
"     </li>",
"     <li>",
"      Garbose (MY);",
"     </li>",
"     <li>",
"      Glibos (TW);",
"     </li>",
"     <li>",
"      Glicobase (IT);",
"     </li>",
"     <li>",
"      Glucobay (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EG, ES, ET, FI, GB, GH, GM, GN, GT, GY, HK, HN, HR, HU, ID, IE, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Glucor (FR);",
"     </li>",
"     <li>",
"      Glucorid (MY);",
"     </li>",
"     <li>",
"      Glumida (ES);",
"     </li>",
"     <li>",
"      Incardel (MX);",
"     </li>",
"     <li>",
"      Kaboping (CL);",
"     </li>",
"     <li>",
"      Kertonbose (TW);",
"     </li>",
"     <li>",
"      Prandase (IL);",
"     </li>",
"     <li>",
"      Precose (MY, TW);",
"     </li>",
"     <li>",
"      Rebose (IN);",
"     </li>",
"     <li>",
"      Sincrosa (MX);",
"     </li>",
"     <li>",
"      Tardensone (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitive inhibitor of pancreatic &alpha;-amylase and intestinal brush border &alpha;-glucosidases, resulting in delayed hydrolysis of ingested complex carbohydrates and disaccharides and absorption of glucose; dose-dependent reduction in postprandial serum insulin and glucose peaks; inhibits the metabolism of sucrose to glucose and fructose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;2% as active drug; ~35% as metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Exclusively via GI tract, principally by intestinal bacteria and digestive enzymes; 13 metabolites identified (major metabolites are sulfate, methyl, and glucuronide conjugates)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Low systemic bioavailability of parent compound; acts locally in GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Active drug: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~34% as inactive metabolites, &lt;2% parent drug and active metabolite); feces (~51% as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Balfour JA and McTavish D, &ldquo;Acarbose: A Reappraisal,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1993, 46(6):1025-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/7510610/pubmed\" id=\"7510610\" target=\"_blank\">",
"        7510610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bischoff H, &ldquo;Pharmacology of &alpha;-Glucosidase Inhibition,&rdquo;",
"      <i>",
"       Eur J Clin Invest",
"      </i>",
"      , 1994, 24(Suppl 3):3-10.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handelsman Y, Mechanick JI, Blonde L, et al, &ldquo;American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for Developing a Diabetes Mellitus Comprehensive Care Plan,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2011, 17(Suppl 2):1-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/21474420/pubmed\" id=\"21474420\" target=\"_blank\">",
"        21474420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44197/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scheen AJ, de Magalhaes AC, Salvatore T, et al, &ldquo;Reduction of the Acute Bioavailability of Metformin by the &alpha;-Glucosidase Inhibitor Acarbose in Normal Man,&rdquo;",
"      <i>",
"       Eur J Clin Invest",
"      </i>",
"      , 1994, 24(Suppl 3):50-4.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9219 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44197=[""].join("\n");
var outline_f43_10_44197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129130\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129131\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129171\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129135\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129136\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129137\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682639\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129109\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129094\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129113\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129112\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129178\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129169\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129116\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129098\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298633\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129103\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129126\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129105\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129119\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129141\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6209166\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6700147\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129118\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129107\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6258748\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129120\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129097\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129115\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9219\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9219|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?27/14/27876?source=related_link\">",
"      Acarbose: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/46/25316?source=related_link\">",
"      Acarbose: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44198="Benign solid nodule";
var content_f43_10_44198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Benign solid nodule on mammogram and ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well defined ovoid nodule (arrow) is seen in the lateral aspect of the breast on CC and spot CC views (Panels A and B). On ultrasound (Panel C) it has benign features and is consistent with a fibroadenoma.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44198=[""].join("\n");
var outline_f43_10_44198=null;
var title_f43_10_44199="Pulmonary artery catheterization: Interpretation of tracings";
var content_f43_10_44199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary artery catheterization: Interpretation of tracings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Frank E Silvestry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Scott Manaker, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44199/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/10/44199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flow-directed pulmonary artery catheter (ie, Swan-Ganz catheter) permits the clinician to measure pressures and sample blood from the right atrium, right ventricle, and pulmonary artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It can also estimate the left atrial pressure by measuring the pulmonary artery wedge pressure (also called the pulmonary capillary wedge pressure or pulmonary artery occlusion pressure). This involves inflating a balloon at the tip of the catheter, allowing the balloon to occlude a branch of the pulmonary artery, and then measuring the pressure during occlusion.",
"   </p>",
"   <p>",
"    Pulmonary artery catheterization can be used for a variety of clinical purposes. It can differentiate among the types of shock, identify etiologies of respiratory and cardiac failure, and diagnose and manage a range of conditions in critically ill patients (",
"    <a class=\"graphic graphic_table graphicRef68139 \" href=\"mobipreview.htm?30/49/31516\">",
"     table 1",
"    </a>",
"    ). In addition, inspection of the pressure waveforms can detect cardiac tamponade, cardiac constriction, restrictive cardiomyopathy, mitral valvular regurgitation, tricuspid valvular regurgitation, intracardiac shunts (eg, atrial or ventricular septal defects), mechanical events related to the atria and ventricles, and intravascular volume status.",
"   </p>",
"   <p>",
"    The interpretation of pulmonary artery catheter pressure tracings is described here. The effect of invasive hemodynamic monitoring on clinical outcomes is discussed separately, as are the insertion technique, indications, and complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25221?source=see_link\">",
"     \"Insertion of pulmonary artery catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=see_link\">",
"     \"Pulmonary artery catheterization: Indications and complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ZEROING AND REFERENCING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery catheter must be appropriately zeroed and referenced to obtain accurate diagnostic information. Zeroing and referencing are done in one step, but they represent two separate processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zeroing involves opening the system to the air to establish atmospheric pressure as zero.",
"     </li>",
"     <li>",
"      Referencing (or leveling) is accomplished by placing the air-fluid interface of the catheter or transducer at a specific point to negate the effects of the weight of the catheter tubing and fluid column [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/2\">",
"       2",
"      </a>",
"      ]. This point is usually the intersection of a frontal plane passing midway between the anterior and posterior surface of the chest and a transverse plane lying at the junction of the 4th intercostal space and the sternal margin (",
"      <a class=\"graphic graphic_figure graphicRef69197 \" href=\"mobipreview.htm?26/39/27249\">",
"       figure 1",
"      </a>",
"      ). It is important to note that this \"phlebostatic level\" changes with differences in the position of the patient (",
"      <a class=\"graphic graphic_figure graphicRef77194 \" href=\"mobipreview.htm?10/3/10288\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PLACEMENT OF THE CATHETER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the pulmonary artery catheter has been zeroed and referenced, it is positioned using either pressure waveform or fluoroscopic guidance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With pressure waveform guidance, the balloon at the distal tip of the catheter is inflated and the catheter is advanced until the pulmonary artery wedge pressure waveform is identified by a decrease in the pressure combined with a change in the waveform. The balloon is then deflated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25221?source=see_link\">",
"       \"Insertion of pulmonary artery catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      With fluoroscopic guidance, the catheter is visualized by fluoroscopy as it is advanced. Fluoroscopic guidance is recommended for patients with marked right atrial or ventricular dilatation, severe tricuspid regurgitation, or a left bundle branch block.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once it is in position, the right atrial pressure waveform can be simultaneously recorded with either the pulmonary artery pressure waveform (balloon deflated) or pulmonary artery wedge pressure waveform (balloon inflated). Inflation of the balloon should always be gradual, while watching the pressure waveform, until the pulmonary artery wedge pressure waveform is identified. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Pressure waveforms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF THE DYNAMIC RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following catheter placement, the dynamic response of the monitoring system to physiologic pressure swings should be assessed. The dynamic response is determined by two factors: the resonant frequency and the damping coefficient of the system. Both of these factors can be assessed at the bedside using the fast-flush test, which involves briefly opening and closing the valve in the continuous flush device [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/5\">",
"     5",
"    </a>",
"    ]. This produces a square wave displacement on the oscilloscope, followed by ringing and a return to baseline (",
"    <a class=\"graphic graphic_figure graphicRef56073 \" href=\"mobipreview.htm?4/57/5021\">",
"     figure 3",
"    </a>",
"    ). Underdamping exists if there is excessive ringing and overdamping exists if there is no ringing.",
"   </p>",
"   <p>",
"    Common causes of underdamping include tubing connected with stopcocks, excessive tubing lengths, and patient factors (eg, tachycardia, high output states). These factors should be systematically addressed. In contrast, the most common cause of overdamping is air bubbles in the tubing, which can be cleared by flushing the system through the stopcock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRESSURE WAVEFORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure waveforms can be obtained from several locations, including the right atrium, right ventricle, and pulmonary artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Right atrial waveform",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of a competent tricuspid valve, the right atrial (RA) pressure waveform reflects both venous return to the right atrium during ventricular systole and right ventricular end-diastolic pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link\">",
"     \"Examination of the jugular venous pulse\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are normally three positive components and two negative deflections in the RA waveform (",
"    <a class=\"graphic graphic_figure graphicRef58343 \" href=\"mobipreview.htm?35/53/36701\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The",
"      <strong>",
"       a",
"      </strong>",
"      wave reflects contraction in atrial systole, while the",
"      <strong>",
"       x",
"      </strong>",
"      descent reflects the fall in right atrial pressure following this event.",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       c",
"      </strong>",
"      wave, often small, reflects the closure of the tricuspid valve.",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       v",
"      </strong>",
"      wave represents ventricular systole, as well as passive atrial filling in atrial diastole.",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       y",
"      </strong>",
"      descent reflects the fall in right atrial pressure following opening of the tricuspid valve and the initiation of passive filling of the right ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Electrocardiographic (ECG) correlation is required for correct identification of these events. In the right atrium, there is an 80 to 100 ms delay in the detection of mechanical events from their appearance on the ECG due to the length of tubing in the system.",
"   </p>",
"   <p>",
"    Normal right atrial pressures vary from 0 to 7 mmHg (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"mobipreview.htm?42/43/43709\">",
"     table 2",
"    </a>",
"    ). Elevations in RA pressure are seen in a number of conditions, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Right ventricular infarction",
"     </li>",
"     <li>",
"      Pulmonary hypertension",
"     </li>",
"     <li>",
"      Pulmonic stenosis",
"     </li>",
"     <li>",
"      Left to right shunts",
"     </li>",
"     <li>",
"      Tricuspid valvular disease",
"     </li>",
"     <li>",
"      Cardiac tamponade",
"     </li>",
"     <li>",
"      Constrictive pericardial disease",
"     </li>",
"     <li>",
"      Restrictive cardiomyopathies",
"     </li>",
"     <li>",
"      Volume overload",
"     </li>",
"     <li>",
"      Impaired right ventricular contractile function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among these causes of elevated RA pressure, a few have characteristic RA pressure waveforms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricuspid regurgitation produces prominent, tall v waves due to blood that is regurgitated into the RA during ventricular systole (",
"      <a class=\"graphic graphic_waveform graphicRef72217 \" href=\"mobipreview.htm?21/40/22158\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Cardiac tamponade, constrictive pericardial disease, and restrictive cardiomyopathy are characterized by equalization of the RA pressure, right ventricular end-diastolic pressure, and pulmonary artery wedge pressure (",
"      <a class=\"graphic graphic_waveform graphicRef61839 \" href=\"mobipreview.htm?18/47/19198\">",
"       waveform 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=see_link\">",
"       \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of cardiac rhythm disturbances can also produce characteristic abnormalities in the RA pressure waveform:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation is associated with lack of organized atrial activity and therefore loss of the normal a wave.",
"     </li>",
"     <li>",
"      Atrial flutter may produce characteristic sawtooth waves in the RA tracing (as well as on the ECG) at a rate of 240 to 340 beats per minute.",
"     </li>",
"     <li>",
"      Conditions associated with atrioventricular dissociation (such as ventricular tachycardia, ventricular pacing, or complete heart block) may manifest cannon a waves (or giant a waves) due to the simultaneous contraction of the atrium and ventricle while the tricuspid valve is closed (",
"      <a class=\"graphic graphic_figure graphicRef71529 \" href=\"mobipreview.htm?7/39/7806\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Supraventricular tachycardias associated with simultaneous contraction of the atrium and ventricle (such as AV nodal tachycardia) may also manifest cannon a waves for the same reason.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Right ventricular waveform",
"    </span>",
"    &nbsp;&mdash;&nbsp;On the right ventricular (RV) pressure waveform, ventricular systole is represented by the prominent upstroke and downstroke, while ventricular diastole is represented by a more gradual upstroke that consists of an early rapid filling phase (during which approximately 60 percent of filling occurs), a slow filling phase (during which another 25 percent of filling occurs), and an atrial systolic phase (which produces the a wave in the RV tracing). End diastole occurs immediately after the a wave. An illustrative RV pressure waveform is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef72775 \" href=\"mobipreview.htm?0/32/526\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Two pressures are typically measured from the RV pressure waveform, the peak right ventricular systolic pressure and the right ventricular end-diastolic pressure. These values cannot be measured from an indwelling pulmonary artery catheter; rather, they are measured during catheter insertion using the distal tip of the catheter.",
"   </p>",
"   <p>",
"    Normal right ventricular systolic pressure varies from 15 to 25 mmHg and normal right ventricular end-diastolic pressure varies from 3 to 12 mmHg (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"mobipreview.htm?42/43/43709\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An elevated RV systolic pressure is seen in pulmonary hypertension, pulmonic stenosis, or pulmonary embolism. Pulmonic stenosis is characterized by a systolic pressure gradient between the right ventricle and the pulmonary artery. Acute pulmonary embolism is characterized by elevated RV systolic pressures that rarely exceed 40 to 50 mmHg, although the pressures can be higher with chronic pulmonary embolism.",
"     </li>",
"     <li>",
"      An increase in RV end-diastolic pressure is seen in cardiomyopathy, right ventricular ischemia, infarction, cardiac constriction, cardiac tamponade, or RV failure secondary to pulmonary hypertension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pulmonary artery waveform",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main components of the pulmonary artery (PA) tracing are the systolic and diastolic pressures and the dicrotic notch, which represents closure of the pulmonic valve (",
"    <a class=\"graphic graphic_figure graphicRef51162 \" href=\"mobipreview.htm?25/55/26493\">",
"     figure 7",
"    </a>",
"    ). The PA tracing is similar in appearance to the systemic arterial pressure tracing, except that the pulmonary arterial pressures are normally much lower.",
"   </p>",
"   <p>",
"    Normal pulmonary artery systolic pressures vary from 15 to 25 mmHg, while pulmonary artery diastolic pressures vary from 8 to 15 mmHg (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"mobipreview.htm?42/43/43709\">",
"     table 2",
"    </a>",
"    ). Elevations in PA pressures are seen with volume overload or with a variety of conditions in which pulmonary vascular resistance is elevated. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Left heart failure of any cause",
"     </li>",
"     <li>",
"      All forms of primary lung disease",
"     </li>",
"     <li>",
"      Mitral valvular disease",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Hypoxemia with pulmonary vasoconstriction",
"     </li>",
"     <li>",
"      Idiopathic pulmonary arterial hypertension",
"     </li>",
"     <li>",
"      Left to right shunts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Causes of elevated pulmonary artery pressure are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Etiologies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PA systolic pressure, like right ventricular systolic pressure, rarely exceeds 40 to 50 mmHg in acute pulmonary embolism. Fluctuation in the PA pressure may be seen in irregular heart rhythms (eg, atrial fibrillation) because of variability in the diastolic filling time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pulmonary artery wedge pressure waveform",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pulmonary artery wedge pressure tracing is obtained by inflating the balloon at the distal tip of the catheter and then allowing the balloon to obstruct blood flow through a branch of the pulmonary artery. This creates a static column of blood between the catheter tip and the left atrium. Pressure at both ends of the column equilibrates, after which the pressure at the distal end of the catheter is equal to the pressure of the left atrium. The pressure at the distal end of the catheter is termed the pulmonary artery wedge pressure (PAWP), which is also known as the pulmonary capillary wedge pressure or pulmonary artery occlusion pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/1\">",
"     1",
"    </a>",
"    ]. Normal pulmonary artery wedge pressures vary from 6 to 15 mmHg, with a mean of 9 mmHg (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"mobipreview.htm?42/43/43709\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The PAWP usually estimates the left ventricular end-diastolic pressure (ie, the left ventricular preload) if there is no obstruction to flow between the left atrium and left ventricle. However, it does NOT directly measure the left ventricular end-diastolic volume, capillary hydrostatic pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/6\">",
"     6",
"    </a>",
"    ], or transmural pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. And, there are several situations in which the PAWP and left ventricular end-diastolic pressure are discordant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Examples are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef53620 \" href=\"mobipreview.htm?28/2/28715\">",
"     table 3",
"    </a>",
"    ) and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased left ventricular compliance may cause left ventricular end-diastolic pressure to be transiently higher than the PAWP (due to premature mitral valve closure) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/10\">",
"       10",
"      </a>",
"      ]. Causes of decreased left ventricular compliance include diastolic dysfunction, positive pressure ventilation, myocardial ischemia or infarction, cardiac tamponade, and a variety of drugs.",
"     </li>",
"     <li>",
"      Severe aortic insufficiency may also cause the left ventricular end-diastolic pressure can be greater than the PAWP, due to premature closure of the mitral valve with regurgitant ventricular filling.",
"     </li>",
"     <li>",
"      Conversely, pulmonary disease and respiratory failure may cause the PAWP to exceed the left ventricular end-diastolic pressure due to constriction of small veins in hypoxic lung segments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The PAWP tracing is similar to that seen in the right atrium (",
"    <a class=\"graphic graphic_figure graphicRef62943 \" href=\"mobipreview.htm?38/16/39181\">",
"     figure 8",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The a wave reflects contraction in atrial systole, while the x descent reflects the fall in left atrial pressure that follows.",
"     </li>",
"     <li>",
"      The c wave, reflecting the closure of the mitral valve, is often not seen.",
"     </li>",
"     <li>",
"      The v wave represents both ventricular systole and passive atrial filling in atrial diastole.",
"     </li>",
"     <li>",
"      The y descent reflects the fall in left atrial pressure following opening of the mitral valve and the initiation of passive filling of the left ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrical and mechanical correlation between the ECG and PAWP tracings is also similar to that seen in the right atrium, except the electromechanical delay is longer. This is due to the time necessary for left atrial mechanical events to be transmitted through the pulmonary vasculature to the distal tip of the catheter.",
"   </p>",
"   <p>",
"    Elevation of the a wave in the PAWP tracing can be seen with increased resistance to left ventricular filling of any cause. Potential causes include mitral stenosis, left ventricular systolic dysfunction, primary left ventricular diastolic dysfunction, left ventricular volume overload, and myocardial ischemia or infarction with decreased left ventricular compliance.",
"   </p>",
"   <p>",
"    Elevations in the v wave of the PAWP tracing may represent mitral regurgitation (",
"    <a class=\"graphic graphic_waveform graphicRef63067 \" href=\"mobipreview.htm?41/27/42429\">",
"     waveform 3",
"    </a>",
"    ), although elevated v waves are neither sensitive nor specific for mitral regurgitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/14\">",
"     14",
"    </a>",
"    ]. An acute volume load to the left atrium (eg, an acute ventricular septal defect complicating myocardial infarction) can also elevate the v wave in the PAWP tracing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lung zones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lungs can be conceptually divided into three physiologic zones of blood flow. These zones are based upon the alveolar pressure, mean pulmonary artery pressure, and pulmonary capillary pressure (",
"    <a class=\"graphic graphic_figure graphicRef50235 \" href=\"mobipreview.htm?24/62/25569\">",
"     figure 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zone 1 is the least dependent zone. In this zone, the mean alveolar pressure exceeds the mean arterial pressure, which exceeds the mean pulmonary capillary pressure.",
"     </li>",
"     <li>",
"      Zone 2 is the middle zone. In this zone, the mean arterial pressure exceeds the mean alveolar pressure, which exceeds the mean pulmonary capillary pressure. &nbsp;",
"     </li>",
"     <li>",
"      Zone 3 is the most dependent zone. In this zone, the mean arterial pressure exceeds the mean pulmonary capillary pressure, which exceeds the alveolar pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tip of the catheter should ideally be positioned below the level of the left atrium, although this only occurs in approximately 60 percent of catheter insertions. Indicators that the catheter has been placed into a zone other than zone 3 include an abnormal position on the lateral chest radiograph, marked respiratory variation in the PAWP tracing, and an increase in the PAWP due to positive end-expiratory pressure that exceeds 50 percent of the amount of applied positive end-expiratory pressure. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Positive end-expiratory pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Respiratory effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;During spontaneous ventilation, pleural and alveolar pressure (relative to atmospheric pressure) decrease during inspiration and increase during expiration. Conversely, during positive pressure ventilation, pleural and alveolar pressure increase during inspiration and decrease during expiration. Such changes affect pulmonary artery pressure and PAWP measurements. This is the reason that the PAWP should be measured at end-expiration, when all intrathoracic pressures are equal to atmospheric pressure, regardless of the mode of ventilation.",
"   </p>",
"   <p>",
"    Most intensive care units use electronic pressure monitors that are designed to measure pressure in time intervals of four seconds and to display three different pressures: the systolic (peak), diastolic (trough), and electronic mean pressure. The wedge pressure can be followed serially on such monitors by selecting the systolic pressure for those breathing spontaneously and the diastolic pressure for those who are receiving positive pressure ventilation. This approach avoids false depression or elevation of intravascular pressure measurements due to fluctuations in pressure during respiration. Alternatively, many ICU monitors allow measurement of the pulmonary artery wedge pressure by manually moving a cursor to end-expiration on the pressure waveform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Positive end-expiratory pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive end-expiratory pressure (PEEP) prevents alveolar pressure from returning to atmospheric pressure at end-expiration. The effects of PEEP on the PAWP are variable and depend largely upon the compliance of the lung, regardless of whether the PEEP was applied therapeutically or the result of incomplete expiration and air trapping (ie, auto-PEEP).",
"   </p>",
"   <p>",
"    Generally speaking, the effects of PEEP are felt to be clinically insignificant for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the catheter is properly positioned in zone 3, the airway pressure should not be transmitted to the vasculature. Respiratory variation of the PAWP waveform that is greater than respiratory variation of the pulmonary artery pressure waveform suggests that the catheter may not be in zone 3 and, therefore, the PAWP may be unreliable (",
"      <a class=\"graphic graphic_figure graphicRef62645 \" href=\"mobipreview.htm?11/26/11681\">",
"       figure 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The intravascular pressure is the pressure ostensibly transmitted back from the left atrium. PEEP may alter intravascular pressures, but those pressures are the effective filling pressures for the patient under those clinical circumstances.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The true intravascular pressures can be estimated in the presence of PEEP by subtracting one-half of the PEEP level from the PAWP if lung compliance is normal, or one-quarter of the PEEP level if lung compliance is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/16\">",
"     16",
"    </a>",
"    ]. As an example, for a patient with acute respiratory distress syndrome (decreased lung compliance) who is receiving an applied PEEP of 10 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O and has a PAWP of 12 mmHg, the estimated intravascular pressure would be 9.5 mmHg. This small difference indicates that the effects of PEEP are usually small and, therefore, rarely affect clinical management. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=see_link&amp;anchor=H18#H18\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even though PEEP affects intravascular pressure measurements, it is not advisable to eliminate (ie, turn off) PEEP temporarily while pressure measurements are being made. Doing so may induce hemodynamic instability due to changes in venous return and the arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ). It also will not accurately reflect the patient's hemodynamic status when PEEP is being used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=see_link\">",
"     \"Positive end-expiratory pressure (PEEP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H939587\">",
"    <span class=\"h1\">",
"     CALCULATION OF CARDIAC OUTPUT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to providing pressure measurements, the pulmonary artery catheter facilitates measurement of the cardiac output via either the indicator thermodilution method or the assumed Fick method. Normal hemodynamic measures are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef70326 \" href=\"mobipreview.htm?42/43/43709\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H939594\">",
"    <span class=\"h2\">",
"     Indicator dilution method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indicator dilution principle predicts that, when an indicator substance is added to a stream of flowing blood, the blood flow rate will be inversely proportional to the mean concentration of the indicator at a downstream site. In the case of thermodilution, the indicator is approximately 5 mL of either dextrose or saline that is cooler than blood. It is injected as a bolus through the proximal port of the pulmonary artery catheter, where it mixes with blood in the right ventricle. The mixing lowers the temperature of intraventricular blood. As the blood flows past the distal thermistor port, the thermistor records the temperature change over time and can electronically display a temperature-time curve. The area under this curve is inversely proportional to the flow rate in the pulmonary artery. This flow rate should be equal to cardiac output, assuming that there is no intracardiac shunt.",
"   </p>",
"   <p>",
"    Once the cardiac output has been determined, the systemic vascular resistance and pulmonary vascular resistance can be estimated (",
"    <a class=\"graphic graphic_figure graphicRef69422 \" href=\"mobipreview.htm?12/23/12670\">",
"     figure 11",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/59/28593?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The estimation is based upon Ohm's Law, which states that the resistance in a circuit is equal to the pressure drop across the circuit divided by flow:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic vascular resistance is the difference between the mean arterial pressure and the right atrial pressure, divided by the cardiac output, and then multiplied by 80.",
"     </li>",
"     <li>",
"      Pulmonary vascular resistance is the difference between the mean pulmonary artery pressure and the left atrial pressure, divided by the cardiac output, and then multiplied by 80.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the calculations of vascular resistance are based upon direct measurements (ie, pressures) and indirect measurements (ie, cardiac output), each of which has its own intrinsic sources of error, vascular resistance values are the least accurate of all the values obtained from the pulmonary artery catheter. They are also the most sensitive to minor inaccuracies in data acquisition.",
"   </p>",
"   <p>",
"    The thermodilution method has been well-validated, as compared with the calculation of cardiac output using the Fick method. However, there are several important sources of error that clinicians should be aware of:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tricuspid regurgitation leads to an underestimation of cardiac output. This is a consequence of the cold injectate refluxing back into the vena cava, with resultant decreased pulmonary artery cooling (attenuated peak) and delayed appearance of injectate that has moved retrograde into the vena cava and is then recirculated (prolonged washout).",
"     </li>",
"     <li>",
"      Right-to-left and left-to-right intracardiac shunts can produce falsely elevated cardiac output measurements by the thermodilution technique. Right-to-left intracardiac shunts produce shunting of cold injectate into the left heart, which reduces pulmonary artery cooling, attenuates the peak of the temperature-time curve, and overestimates cardiac output. Left-to-right intracardiac shunts produce increased right heart volumes and dilution of the injectate, which attenuates the height of the temperature-time curve and results in an overestimation of cardiac output.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H939615\">",
"    <span class=\"h3\">",
"     Newer catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous thermodilution catheters are available and correlate reasonably well with bolus thermodilution methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/17\">",
"     17",
"    </a>",
"    ]. Newer catheter designs incorporate continuous oximetric monitoring of pulmonary artery oxygen saturation using fiberoptic reflectance spectrophotometry, thereby enabling continuous estimation of cardiac output. This technology has been shown to have reasonable correlation with mixed venous oxygen saturation determined using co-oximetry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/18\">",
"     18",
"    </a>",
"    ]. However, these catheters are more expensive and did not result in improved patient outcomes in a multicenter observational study of over 3,200 patients undergoing cardiac surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H941101\">",
"    <span class=\"h2\">",
"     Fick method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Fick method of calculating the cardiac output is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef56651 \" href=\"mobipreview.htm?17/47/18173\">",
"     figure 12",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    Fick cardiac output = (oxygen consumption)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    (10 &times; arteriovenous oxygen difference).",
"   </p>",
"   <p>",
"    Oxygen consumption is either measured by exhaled breath analysis or estimated from a nomogram that is based upon age, sex, height, and weight. The arteriovenous oxygen difference requires additional calculations:",
"   </p>",
"   <p>",
"    Arteriovenous oxygen difference = 1.34 &times; hemoglobin concentration &times; (arterial oxygen saturation &ndash; mixed venous oxygen saturation)",
"   </p>",
"   <p>",
"    The hemoglobin concentration and arterial oxygen saturation are measured, while the mixed venous oxygen saturation is calculated as described in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DETECTION OF LEFT TO RIGHT SHUNTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood sampling from the RA, RV, PA, superior vena cava, and inferior vena cava is helpful when evaluating a suspected left-to-right intracardiac shunt. Sampling is typically performed during insertion of the catheter under fluoroscopic guidance to insure that samples are drawn from the proper sites. Detection of an oxygen saturation \"step-up\" allows confirmation of the shunt and determination of its location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. A step-up is defined as &gt;10 percent rise in oxygen saturation, when the saturation of blood in the RA, RV or PA is compared to the calculated mixed venous oxygen saturation.",
"   </p>",
"   <p>",
"    The mixed venous oxygen saturation is calculated as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a patient at rest: three times the oxygen saturation of blood from the superior vena cava plus the oxygen saturation of blood from the inferior vena cava, all divided by four [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an exercising patient: two times the oxygen saturation of blood from the inferior vena cava plus the oxygen saturation of blood from the superior vena cava, all divided by three [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44199/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The site of the step-up defines the level of the shunt. The degree of left to right shunting can then be quantitated by calculating a ratio of pulmonary flow (Qp) to systemic flow (Qs) (",
"    <a class=\"graphic graphic_figure graphicRef78106 \" href=\"mobipreview.htm?41/32/42510\">",
"     figure 13",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=see_link&amp;anchor=H15#H15\">",
"     \"Identification and assessment of atrial septal defects in adults\", section on 'Estimation of shunt flow ratio and volume'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H939984\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain steps must be performed before a pulmonary artery catheter (also called a Swan-Ganz or right heart catheter) is used to measure hemodynamic variables. The steps include zeroing, referencing, positioning, and assessing the dynamic response. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Zeroing and referencing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Placement of the catheter'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Assessment of the dynamic response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pulmonary artery catheter can obtain pressure waveforms from several locations, including the right atrium, right ventricle, and pulmonary artery. In addition, it can measure a pulmonary artery wedge pressure (also called a pulmonary capillary wedge pressure or pulmonary artery occlusion pressure). The pulmonary artery wedge pressure estimates the left atrial pressure, but it can be affected by the lung zone into which the catheter is placed, various respiratory factors, and positive end-expiratory pressure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Pressure waveforms'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A pulmonary artery catheter can also be used to measure the cardiac output and to detect a left-to-right intracardiac shunt. (See",
"      <a class=\"local\" href=\"#H939587\">",
"       'Calculation of cardiac output'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Detection of left to right shunts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/1\">",
"      Swan HJ, Ganz W, Forrester J, et al. Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 1970; 283:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/2\">",
"      Summerhill EM, Baram M. Principles of pulmonary artery catheterization in the critically ill. Lung 2005; 183:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/3\">",
"      Bridges EJ, Woods SL. Pulmonary artery pressure measurement: state of the art. Heart Lung 1993; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/4\">",
"      Winsor, T, Burch, GE. Phlebostatic axis and phlebostatic level, reference levels for venous pressure measurements in man. Proc Soc Exp Biol Med 1945; 58:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/5\">",
"      Kleinman B, Powell S, Kumar P, Gardner RM. The fast flush test measures the dynamic response of the entire blood pressure monitoring system. Anesthesiology 1992; 77:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/6\">",
"      Weed HG. Pulmonary \"capillary\" wedge pressure not the pressure in the pulmonary capillaries. Chest 1991; 100:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/7\">",
"      O'Quin R, Marini JJ. Pulmonary artery occlusion pressure: clinical physiology, measurement, and interpretation. Am Rev Respir Dis 1983; 128:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/8\">",
"      Putterman, C. The Swan-Ganz catheter: A decade of hemodynamic monitoring. J Crit Care 1989; 4:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/9\">",
"      Sharkey SW. Beyond the wedge: clinical physiology and the Swan-Ganz catheter. Am J Med 1987; 83:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/10\">",
"      Raper R, Sibbald WJ. Misled by the wedge? The Swan-Ganz catheter and left ventricular preload. Chest 1986; 89:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/11\">",
"      Nemens EJ, Woods SL. Normal fluctuations in pulmonary artery and pulmonary capillary wedge pressures in acutely ill patients. Heart Lung 1982; 11:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/12\">",
"      Pinsky MR. Pulmonary artery occlusion pressure. Intensive Care Med 2003; 29:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/13\">",
"      Pinsky MR. Clinical significance of pulmonary artery occlusion pressure. Intensive Care Med 2003; 29:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/14\">",
"      Snyder RW 2nd, Glamann DB, Lange RA, et al. Predictive value of prominent pulmonary arterial wedge V waves in assessing the presence and severity of mitral regurgitation. Am J Cardiol 1994; 73:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/15\">",
"      WEST JB, DOLLERY CT, NAIMARK A. DISTRIBUTION OF BLOOD FLOW IN ISOLATED LUNG; RELATION TO VASCULAR AND ALVEOLAR PRESSURES. J Appl Physiol 1964; 19:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/16\">",
"      Teboul, JL, Besbes, M, Andrivet, P, et al. A bedside index assessing the reliability of pulmonary artery occlusion pressure measurements during mechanical ventilation with positive end-expiratory pressure. J Crit Care 1992; 7:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/17\">",
"      Yelderman ML, Ramsay MA, Quinn MD, et al. Continuous thermodilution cardiac output measurement in intensive care unit patients. J Cardiothorac Vasc Anesth 1992; 6:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/18\">",
"      Armaganidis A, Dhainaut JF, Billard JL, et al. Accuracy assessment for three fiberoptic pulmonary artery catheters for SvO2 monitoring. Intensive Care Med 1994; 20:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/19\">",
"      London MJ, Moritz TE, Henderson WG, et al. Standard versus fiberoptic pulmonary artery catheterization for cardiac surgery in the Department of Veterans Affairs: a prospective, observational, multicenter analysis. Anesthesiology 2002; 96:860.",
"     </a>",
"    </li>",
"    <li>",
"     Gore, JM, Alpert, JS, Benotti, JR, et al. Handbook of Hemodynamic Monitoring, 1st, Little Brown, Boston 1985.",
"    </li>",
"    <li>",
"     Cardiac Catheterization and Angiography, 4th, Grossman, W (Eds), Lea &amp; Febiger, Philadelphia 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44199/abstract/22\">",
"      Flamm MD, Cohn KE, Hancock EW. Measurement of systemic cardiac output at rest and exercise in patients with atrial septal defect. Am J Cardiol 1969; 23:258.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1595 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.131.240.2-0CE6B713CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44199=[""].join("\n");
var outline_f43_10_44199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H939984\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ZEROING AND REFERENCING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PLACEMENT OF THE CATHETER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSESSMENT OF THE DYNAMIC RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRESSURE WAVEFORMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Right atrial waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Right ventricular waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pulmonary artery waveform",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pulmonary artery wedge pressure waveform",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lung zones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Respiratory effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Positive end-expiratory pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H939587\">",
"      CALCULATION OF CARDIAC OUTPUT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H939594\">",
"      Indicator dilution method",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H939615\">",
"      - Newer catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H941101\">",
"      Fick method",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DETECTION OF LEFT TO RIGHT SHUNTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H939984\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1595\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1595|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/39/27249\" title=\"figure 1\">",
"      PA catheter leveling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/3/10288\" title=\"figure 2\">",
"      Patient position and catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/57/5021\" title=\"figure 3\">",
"      Arterial catheter rapid flush test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/53/36701\" title=\"figure 4\">",
"      Right atrial pressure tracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/39/7806\" title=\"figure 5\">",
"      Ventricular pacemaker tracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/32/526\" title=\"figure 6\">",
"      Right ventricular tracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/55/26493\" title=\"figure 7\">",
"      Pulmonary artery tracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/16/39181\" title=\"figure 8\">",
"      Pulmonary artery wedge tracing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/62/25569\" title=\"figure 9\">",
"      Swan Ganz lung zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/26/11681\" title=\"figure 10\">",
"      PEEP and pulmonary hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/23/12670\" title=\"figure 11\">",
"      Calculation vascular resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/47/18173\" title=\"figure 12\">",
"      Calculation Fick cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/32/42510\" title=\"figure 13\">",
"      Fick shunt calculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1595|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/49/31516\" title=\"table 1\">",
"      Indications for catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/43/43709\" title=\"table 2\">",
"      Hemodynamic values of normal recumbent adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/2/28715\" title=\"table 3\">",
"      Interpretation of PAW and LVEDP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1595|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?21/40/22158\" title=\"waveform 1\">",
"      Right atrial pressure tracings in tricuspid regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?18/47/19198\" title=\"waveform 2\">",
"      Pressure tracings pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/27/42429\" title=\"waveform 3\">",
"      Prominent v waves in mitral regurgitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?27/59/28593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Pulmonary Vascular Resistance",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/48/5896?source=related_link\">",
"      Identification and assessment of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25221?source=related_link\">",
"      Insertion of pulmonary artery catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/31/27128?source=related_link\">",
"      Pulmonary artery catheterization: Indications and complications",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44200="Sunitinib: Drug information";
var content_f43_10_44200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sunitinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/41/30358?source=see_link\">",
"    see \"Sunitinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10432264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2525534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sutent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5558623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sutent&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2525538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2526125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosage modifications should be done in increments or decrements of 12.5 mg; individualize based on safety and tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Gastrointestinal stromal tumor (GIST):",
"     </b>",
"     Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      GIST unlabeled dosing:",
"     </i>",
"     Oral: 37.5 mg once daily, continuous daily dosing (George, 2009,",
"     <i>",
"      EJC",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Pancreatic neuroendocrine tumors, advanced (PNET):",
"     </b>",
"     Oral: 37.5 mg once daily, continuous daily dosing (maximum daily dose used in clinical trials: 50 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Renal cell cancer, advanced (RCC):",
"     </b>",
"     Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Soft tissue sarcoma, non-GIST (unlabeled use):",
"     </b>",
"     Oral: 37.5 mg once daily, continuous daily dosing (George, 2009,",
"     <i>",
"      JCO",
"     </i>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Thyroid cancer, refractory (unlabeled use):",
"     </b>",
"     Oral: 50 mg once daily for 4 weeks of a 6-week treatment cycle (4 weeks on, 2 weeks off) (Cohen, 2008; Ravaud, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <i>",
"      Dosage adjustment with concurrent CYP3A4 inhibitor:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inhibitors (eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors, telithromycin, voriconazole); if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction to a minimum of 37.5 mg/day (GIST, RCC) or 25 mg/day (PNET).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment with concurrent CYP3A4 inducer:",
"     </i>",
"     Avoid concomitant administration with strong CYP3A4 inducers (eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St John&rsquo;s wort); if concomitant administration with a strong CYP3A4 inducer cannot be avoided, consider a dosage increase (with careful monitoring) to a maximum of 87.5 mg/day (GIST, RCC) or 62.5 mg/day (PNET).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2526126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2526127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild, moderate, or severe impairment: No initial adjustment required; subsequent adjustments may be needed based on safety and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     ESRD on hemodialysis: No initial adjustment required; subsequent dosage",
"     <b>",
"      increases",
"     </b>",
"     (up to 2 fold) may be required due to reduced (47%) exposure",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2526128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary with mild-to-moderate (Child-Pugh class A or B) hepatic impairment; not studied in patients with severe (Child-Pugh class C) hepatic impairment. Studies excluded patients with ALT or AST &gt;2.5 x ULN, or if due to liver metastases, ALT or AST &gt;5 x ULN.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F6825472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage modifications should be done in increments or decrements of 12.5 mg; individualize based on safety and tolerability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac toxicity:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ejection fraction &lt;50% and &gt;20% below baseline without evidence of CHF: Interrupt treatment and/or reduce dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     LV dysfunction with CHF clinical manifestations: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatotoxicity: Hepatic adverse events &ge; grade 3 or 4: Withhold treatment; discontinue if hepatotoxicity does not resolve. Do not reinitiate in patients with severe changes in liver function tests or other signs/symptoms of liver failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hypertension: Temporarily interrupt treatment until hypertension is controlled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nephrotic syndrome or pancreatitis: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reversible posterior leukoencephalopathy (RPLS) or thrombotic microangiopathy: Temporarily withhold treatment; after resolution, may resume with discretion.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2526134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sutent&reg;: 12.5 mg, 25 mg, 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2525536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F10437825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM219111.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM219111.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2526129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2525541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of gastrointestinal stromal tumor (GIST) intolerant to or with disease progression on imatinib; treatment of advanced renal cell cancer (RCC); treatment of advanced, metastatic or unresectable pancreatic neuroendocrine tumors (PNET)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7689562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of advanced thyroid cancer; treatment of non-GIST soft tissue sarcomas",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3402058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       SUNItinib may be confused with axitinib, dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, pazopanib, regorafenib, SORAfenib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dosing schedules vary by indication; some treatment regimens are continuous daily dosing; other treatment schedules are daily dosing for 4 weeks of a 6 week cycle (4 weeks on, 2 weeks off)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2525553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (15% to 34%; grade 3: 4% to 13%), peripheral edema (24%), LVEF decreased (11% to 16%; grades 3/4: 1% to 3%), heart failure (&le;15%), chest pain (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (33% to 62%), headache (&le;23%), fever (&le;22%), insomnia (15% to 18%), chills (14%), depression (11%), dizziness (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin discoloration (25% to 30%), rash (14% to 29%), hand-foot syndrome (14% to 29%; grades 3/4: 4% to 8%), hair color changes (7% to 29%), dry skin (&le;23%), alopecia (5% to 14%), erythema (12%), pruritus (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (23% to 71%), hyperuricemia (&le;46%), hypocalcemia (34% to 42%), hypoalbuminemia (28% to 41%), hypophosphatemia (&le;36%), hyponatremia (&le;29%), hypoglycemia (17% to 22%), hypokalemia (12% to 21%), hypomagnesemia (&le;19%), hyperkalemia (&le;18%), hypothyroidism (4% to 16%; grades 3/4: &le;2%), hypercalcemia (13%), hypernatremia (10% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (40% to 66%), nausea (45% to 58%), lipase increased (17% to 56%), anorexia (33% to 48%), mucositis/stomatitis (29% to 48%), taste perversion (21% to 47%), abdominal pain (39%), vomiting (34% to 39%), amylase increased (17% to 35%), dyspepsia (15% to 34%), constipation (20% to 23%), weight loss (16%), flatulence (14%), oral pain (6% to 14%), xerostomia (13%), GERD/reflux (12%), glossodynia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (26% to 79%; grades 3/4: &le;8%), leukopenia (78%; grades 3/4: 8%), neutropenia (53% to 77%; grades 3/4: 10% to 17%), lymphopenia (38% to 68%; grades 3/4: &le;18%), thrombocytopenia (38% to 68%; grades 3/4: 5% to 9%), hemorrhage/bleeding (18% to 37%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (39% to 72%; grades 3/4: 2% to 5%), alkaline phosphatase increased (24% to 63%; grades 3/4: 2% to 10%), ALT increased (39% to 61%; grades 3/4: 2% to 4%), hyperbilirubinemia (10% to 37%; grades 3/4 &le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Creatine kinase increased (49%), limb pain (14% to 40%), weakness (22% to 34%), arthralgia (15% to 30%), back pain (&le;28%), myalgia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (12% to 70%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (27%), dyspnea (26%), epistaxis (21%), nasopharyngitis (14%), upper respiratory tract infection (11%)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Venous thrombotic events (1% to 3%), DVT (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Hemorrhoids (10%), pancreatitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Pulmonary embolism (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, adrenal dysfunction, angioedema, aortic dissection, arterio thrombotic events, atrial flutter, cardiomyopathy, cerebral hemorrhage, cerebral infarction, cerebrovascular accident, coma, epistaxis, febrile neutropenia, fistula formation, gastrointestinal perforation, glomerular sclerosis (segmental), hepatic failure, hepatotoxicity, hypersensitivity, hyperthyroidism, hypotension, infection, macrocytosis, microangiopathic hemolytic anemia (when used in combination with bevacizumab), MI, myocardial disorders, myopathy, myxedema coma, nephrotic syndrome, neutropenic infection, osteonecrosis of the jaw (ONJ), pneumonitis (recall), preeclampsia-like syndrome (proteinuria and reversible hypertension), proteinuria, pulmonary hemorrhage, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, renal impairment, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, seizure, septic shock, thrombotic microangiopathy, torsade de pointes, transient ischemic attack, tumor hemorrhage, tumor lysis syndrome, tumor necrosis, ventricular arrhythmia, wound healing complications",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2525548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to sunitinib or any component of the formulation; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2525549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal toxicity: Has been reported; monitor for adrenal insufficiency for patients with stress such as trauma, severe infection, or undergoing surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: Hemorrhagic events have been reported including epistaxis, rectal, gingival, upper GI, wound bleeding, urinary tract, genital, brain,  tumor-related, and hemoptysis/pulmonary hemorrhage; may be serious and/or fatal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depigmentation: May cause skin and/or hair depigmentation or discoloration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal complications: Serious and fatal gastrointestinal complications, including gastrointestinal perforation, have occurred (rarely). Pancreatitis has been observed in RCC patients; discontinue sunitinib if symptoms are present.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Hepatotoxicity, which may be severe and/or result in fatal liver failure, has been observed in clinical trials and in postmarketing surveillance.",
"     </b>",
"     Signs of liver failure include jaundice, elevated transaminases, and/or hyperbilirubinemia, in conjunction with encephalopathy, coagulopathy and/or renal failure. Monitor liver function tests at baseline, with each treatment cycle and if clinically indicated. Withhold treatment for grade 3 or 4 hepatotoxicity; discontinue if hepatotoxicity does not resolve. Do not reinitiate in patients with severe changes in liver function tests or other signs/symptoms of liver failure. Sunitinib has not been studied in patients with ALT or AST &gt;2.5 times ULN (or &gt;5 times ULN if due to liver metastases).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: May cause hypertension; monitor and control with antihypertensives if needed; interrupt therapy until hypertension is controlled for severe hypertension. Use caution and closely monitor in patients with underlying or poorly-controlled hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Left ventricular dysfunction/heart failure: May cause a decrease in left ventricular ejection fraction (LVEF), including grade 3 reductions; consider obtaining LVEF evaluation prior to treatment.  Mean onset of symptomatic heart failure (HF) is 22 days from treatment initiation. Interrupt therapy and/or decrease dose with LVEF &lt;50% or &gt;20% reduction from baseline. Discontinue with clinical signs and symptoms of HF. Cardiovascular events (some fatal), including symptomatic HF, myocardial disorders and cardiomyopathy have been reported with use. Use with caution in patients with cardiac dysfunction; monitor for clinical signs/symptoms of HF, obtain baseline and periodic LVEF evaluation; patients with MI, bypass grafts, symptomatic HF, vascular diseases (including CVA and TIA), and PE were excluded from clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw: Osteonecrosis of the jaw (ONJ) has been observed with sunitinib. Concurrent bisphosphonate use or dental disease may increase the risk for ONJ. If possible, avoid invasive dental procedures in patients with current or prior bisphosphonate use.  Consider a dental exam and appropriate prophylactic dentistry prior to treatment initiation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proteinuria/nephrotic syndrome: Proteinuria and (rare) cases of nephrotic syndrome have been reported; discontinue treatment in patients with nephrotic syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation: QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation and torsade de pointes have been observed (dose dependent); use caution in patients with a history of QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, with medications known to increase sunitinib levels or prolong the QT interval, or patients with pre-existing (relevant) cardiac disease, bradycardia, or electrolyte imbalance. A baseline and periodic 12-lead ECG should be obtained; correct electrolyte abnormalities prior to treatment and monitor and correct potassium, calcium, and magnesium levels during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Reversible posterior leukoencephalopathy syndrome (RPLS): Has been reported (rarely). Symptoms of RPLS include confusion, headache, hypertension, lethargy, seizure, blindness and/or other vision, or neurologic disturbances; interrupt treatment and begin management of hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Hypothyroidism may occur; the risk for hypothyroidism appears to increase with therapy duration. Hyperthyroidism, sometimes followed by hypothyroidism, has also been reported. Monitor thyroid function at baseline and if symptomatic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor lysis syndrome: Tumor lysis syndrome (TLS), including fatalities, has been reported, predominantly in patients with RCC or GIST. Risk for TLS is higher in patients with a high tumor burden prior to treatment; monitor closely. Correct clinically significant dehydration and treat high uric acid levels prior to initiation of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wound healing complications: Impaired wound healing has been reported with sunitinib; temporarily withhold treatment for patients undergoing major surgical procedures. The optimal time to resume treatment after a procedure has not been determined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal insufficiency: An increased incidence of fatigue, thyroid dysfunction and treatment-induced hypertension was reported in patients with renal insufficiency (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;60 mL/minute) who received sunitinib for the treatment of renal cell cancer (Gupta, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bevacizumab: Microangiopathic hemolytic anemia (MAHA) and dose-limiting hypertension have been reported when sunitinib has been used in combination with bevacizumab.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors/inducers: Use with caution in patients concurrently taking strong CYP3A4 inhibitors (may increase sunitinib levels; eg, clarithromycin, erythromycin, itraconazole, ketoconazole, nefazodone, protease inhibitors, telithromycin, voriconazole) or inducers (may decrease sunitinib levels; eg, carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, St. John&rsquo;s wort); dosage adjustments of sunitinib may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents: Concurrent use with other drugs which may prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval may increase the risk of potentially-fatal arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Dosing schedules vary by indication; some treatment regimens are continuous daily dosing; other treatment schedules are daily dosing for 4 weeks of a 6-week cycle (4 weeks on, 2 weeks off).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2525560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2525559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: SUNItinib may enhance the adverse/toxic effect of Bevacizumab. Specifically, the risk for a specific form of anemia, microangiopathic hemolytic anemia (MAHA), may be increased. Bevacizumab may enhance the hypertensive effect of SUNItinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased. Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of SUNItinib. Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of SUNItinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: May enhance the adverse/toxic effect of SUNItinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2525563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Grapefruit juice may increase the levels/effects of sunitinib. Food has no effect on the bioavailability of sunitinib. Management: Avoid grapefruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may increase metabolism and decrease sunitinib concentrations. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2525543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2525544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenicity, embryotoxicity, and fetal loss. Because sunitinib inhibits angiogenesis, a critical component of fetal development, adverse effects on pregnancy would be expected. Women of childbearing potential should be advised to avoid pregnancy if receiving sunitinib.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2525546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2525547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue breast-feeding or discontinue sunitinib should take into account the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2525566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food. Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5685504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Sutent Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (28): $3501.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (28): $7002.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (28): $12913.87",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2526131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     LVEF, baseline (and periodic with cardiac risk factors), ECG (12-lead; baseline and periodic), blood pressure; adrenal function CBC with differential and platelets (prior to each treatment cycle), liver function tests (baseline, with each cycle and if clinically indicated), serum chemistries including magnesium, phosphate, and potassium (prior to each treatment cycle), urinalysis (for proteinuria development or worsening); consider dental exam prior to treatment initiation; symptoms of hypothyroidism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid function testing (Hamnvik, 2011):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pre-existing levothyroxine therapy: Obtain baseline TSH levels, then monitor every 4 weeks until levels and levothyroxine dose are stable, then monitor every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Without pre-existing thyroid hormone replacement: TSH at baseline, then every 4 weeks for 4 months, then every 2-3 months",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Sutene (KP);",
"     </li>",
"     <li>",
"      Sutent (AR, AT, AU, BE, BG, BR, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2525975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits antitumor and antiangiogenic properties by inhibiting multiple receptor tyrosine kinases, including platelet-derived growth factors (PDGFR&alpha; and PDGFR&beta;), vascular endothelial growth factors (VEGFR1, VEGFR2, and VEGFR3), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor type 1 (CSF-1R), and glial cell-line-derived neurotrophic factor receptor (RET).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2525977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     /F: 2230 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Sunitinib: 95%; SU12662: 90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic; primarily metabolized by CYP3A4 to the N-desethyl metabolite SU12662 (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Terminal: Sunitinib: 40-60 hours; SU12662: 80-110 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (61%); urine (16%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Appleby L, Morrissey S, Bellmunt J, et al, &ldquo;Management of Treatment-Related Toxicity With Targeted Therapies for Renal Cell Carcinoma: Evidence-Based Practice and Best Practices,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2011, 25(4):893-915.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/21763973/pubmed\" id=\"21763973\" target=\"_blank\">",
"        21763973",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arnaud L, Schartz NE, Bousquet G, et al, &ldquo;Transient Sunitinib-Induced Coma in a Patient With Fibromyxoid Sarcoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(9):1569-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18349416/pubmed\" id=\"18349416\" target=\"_blank\">",
"        18349416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Castellano D, del Muro XG, P&eacute;rez-Gracia JL, et al, &ldquo;Patient-Reported Outcomes in a Phase III, Randomized Study of Sunitinib Versus Interferon-{alpha} as First-Line Systemic Therapy for Patients With Metastatic Renal Cell Carcinoma in a European Population,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2009, 20(11):1803-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19549706/pubmed\" id=\"19549706\" target=\"_blank\">",
"        19549706",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cella D, Michaelson MD, Bushmakin AG, et al, &ldquo;Health-Related Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib vs Interferon-Alpha in a Phase III Trial: Final Results and Geographical Analysis,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2010, 102(4):658-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/20104222/pubmed\" id=\"20104222\" target=\"_blank\">",
"        20104222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chu TF, Rupnick MA, Kerkela R, et al, &ldquo;Cardiotoxicity Associated With Tyrosine Kinase Inhibitor Sunitinib,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9604):2011-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18083403/pubmed\" id=\"18083403\" target=\"_blank\">",
"        18083403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen EE, Needles BM, Cullen KJ, et al, &ldquo;Phase 2 Study of Sunitinib in Refractory Thyroid Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):6025 [abstract 6025 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costero O, Picazo ML, Zamora P, et al, &ldquo;Inhibition of Tyrosine Kinases by Sunitinib Associated With Focal Segmental Glomerulosclerosis Lesion in Addition to Thrombotic Microangiopathy,&rdquo;",
"      <i>",
"       Dial Nephrol Transplant",
"      </i>",
"      , 2010, 25(3):1001-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/20019017/pubmed\" id=\"20019017\" target=\"_blank\">",
"        20019017",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demetri GD, van Oosterom AT, Garret CR, et al, &ldquo;Efficacy and Safety of Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumour After Failure of Imatinib: A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 368(9544):1329-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/17046465/pubmed\" id=\"17046465\" target=\"_blank\">",
"        17046465",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Desai J, Yassa L, Marqusee E,  et al, &ldquo;Hypothyroidism After Sunitinib Treatment for Patients With Gastrointestinal Stromal Tumors,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2006, 145(9):660-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/17088579/pubmed\" id=\"17088579\" target=\"_blank\">",
"        17088579",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edeline J, Laguerre B, Rolland Y, et al, &ldquo;Aortic Dissection in a Patient Treated by Sunitinib for Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(1):186-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19875754/pubmed\" id=\"19875754\" target=\"_blank\">",
"        19875754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faivre S, Delbaldo C, and Vera K, &ldquo;Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(1):25-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/16314617/pubmed\" id=\"16314617\" target=\"_blank\">",
"        16314617",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Baum MS, Ginsberg MS, et al, &ldquo;Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(9):1432-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19224847/pubmed\" id=\"19224847\" target=\"_blank\">",
"        19224847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Ginsberg MS, Baum M, et al, &ldquo;Phase I Trial of Bevacizumab Plus Sunitinib in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):5100 [abstract 5100 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldman DR, Martorella AJ, Robbins RJ, et al, &ldquo;Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2007, 99(12):974-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/17565156/pubmed\" id=\"17565156\" target=\"_blank\">",
"        17565156",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldt S, Sch&uuml;ssel K, Quinzler R, et al, &ldquo;Incidence of Thyroid Hormone Therapy in Patients Treated With Sunitinib or Sorafenib: A Cohort Study,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2012, 48(7):974-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/22382202/pubmed\" id=\"22382202\" target=\"_blank\">",
"        22382202",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Garcia-Donas J, Esteban E, Leandro-Farcia LJ, et al, &ldquo;Single Nucleotide Polymorphism Associations With Response and Toxic Effects in Patients With Advanced Renal-Cell Carcinoma Treated With First-Line Sunitinib: a Multicentre, Observational, Prospective Study,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(12):1143-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/22015057/pubmed\" id=\"22015057\" target=\"_blank\">",
"        22015057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      George S, Blay JY, Casali PG, et al, &ldquo;Clinical Evaluation of Continuous Daily Dosing of Sunitinib Malate in Patients With Advanced Gastrointestinal Stromal Tumour After Imatinib Failure,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2009, 45(11):1959-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19282169/pubmed\" id=\"19282169\" target=\"_blank\">",
"        19282169",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      George S, Merriam P, Maki RG, et al, &ldquo;Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3154-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19451429/pubmed\" id=\"19451429\" target=\"_blank\">",
"        19451429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goulart B, Carr L, Martins RG, et al, &ldquo;Phase II Study of Sunitinib in Iodine Refractory, Well-Differentiated Thyroid Cancer (WDTC) and Metastatic Medullary Thyroid Carcinoma (MTC),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):6062 [abstract 6062 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta S, Parsa VB, Heilbrun LK, et al, &ldquo;Safety and Efficacy of Molecularly Targeted Agents in Patients With Metastatic Kidney Cancer With Renal Dysfunction,&rdquo;",
"      <i>",
"       Anticancer Drugs",
"      </i>",
"      , 2011, 22(8):794-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/21799472/pubmed\" id=\"21799472\" target=\"_blank\">",
"        21799472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khakoo AY, Kassiotis CM, Tannir N, et al, &ldquo;Heart Failure Associated With Sunitinib Malate,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 112(11):2500-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18386829/pubmed\" id=\"18386829\" target=\"_blank\">",
"        18386829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lacouture ME, Wu S, Robert C, et al, &ldquo;Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated With the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2008, 13(9):1001-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18779536/pubmed\" id=\"18779536\" target=\"_blank\">",
"        18779536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motzer RJ, Hutson TE, Olsen MR, et al, &ldquo;Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma.,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(12):1371-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/22430274/pubmed\" id=\"22430274\" target=\"_blank\">",
"        22430274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motzer RJ, Hutson TE, Tomczak P, et al, &ldquo;Sunitinib Versus Interferon Alfa in Metastatic Renal-Cell Cancer,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(2):115-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/17215529/pubmed\" id=\"17215529\" target=\"_blank\">",
"        17215529",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Motzer RJ, Michaelson MD, and Redman BG, &ldquo;Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor, in Patients With Metastatic Renal Cell Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2006, 24(1):16-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/16330672/pubmed\" id=\"16330672\" target=\"_blank\">",
"        16330672",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Navid F, Christensen R, Minkin P, et al, &ldquo;Stability of Sunitinib in Oral Suspension,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(7):962-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18577759/pubmed\" id=\"18577759\" target=\"_blank\">",
"        18577759",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Niccoli P, Raoul J, Bang  Y, et al, &ldquo;Updated Safety and Efficacy Results of the Phase III Trial of Sunitinib (SU) Versus Placebo (PBO) for Treatment of Pancreatic Neuroendocrine Tumors (NET),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(15s):4000 [abstract 4000 from 2010 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Farrell AM, Foran JM, Fiedler W, et al, &ldquo;An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2003, 9(15):5465-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/14654525/pubmed\" id=\"14654525\" target=\"_blank\">",
"        14654525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel TV, Morgan JA, Demetri GD, et al, &ldquo;A Preeclampsia-Like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2008, 100(4):282-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18270341/pubmed\" id=\"18270341\" target=\"_blank\">",
"        18270341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ravaud A, de la Fouchardiere C, Courbon F, et al, &ldquo;Sunitinib in Patients With Refractory Advanced Thyroid Cancer: The THYSU Phase II Trial,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(Supp):6058 [abstract 6058 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Raymond E, Dahan L, Raoul JL, et al, &ldquo;Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 364(6):501-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/21306237/pubmed\" id=\"21306237\" target=\"_blank\">",
"        21306237",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rini BI, Choueiri TK, Elson P, et al, &ldquo;Sunitinib-Induced Macrocytosis in Patients With Metastatic Renal Cell Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2008, 113(6):1309-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18618496/pubmed\" id=\"18618496\" target=\"_blank\">",
"        18618496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rini BI, Tamaskar I, Shaheen P, et al, &ldquo;Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2007, 99(1):81-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/17202116/pubmed\" id=\"17202116\" target=\"_blank\">",
"        17202116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schutz FA, Je Y, Richards CJ, et al, \"Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(8):871-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/22312105/pubmed\" id=\"22312105\" target=\"_blank\">",
"        22312105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Seidel C, Janssen S, Karstens JH, et al, &ldquo;Recall Pneumonitis During Systemic Treatment With Sunitinib,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(10):2119-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/20720089/pubmed\" id=\"20720089\" target=\"_blank\">",
"        20720089",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Telli ML, Witteles RM, Fisher GA, et al, &ldquo;Cardiotoxicity Associated With the Cancer Therapeutic Agent Sunitinib Malate,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(9):1613-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/18436521/pubmed\" id=\"18436521\" target=\"_blank\">",
"        18436521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Erp NP, Baker SD, Zandvliet AS, et al, &ldquo;Marginal Increase of Sunitinib Exposure by Grapefruit Juice,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2011, 67(3):695-703.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/20512335/pubmed\" id=\"20512335\" target=\"_blank\">",
"        20512335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zastrow S, Froehner M, Platzek I, et al, &ldquo;Treatment of Metastatic Renal Cell Cancer With Sunitinib During Chronic Hemodialysis,&rdquo;",
"      <i>",
"       Urology",
"      </i>",
"      , 2009, 73(4):868-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?43/10/44200/abstract-text/19167044/pubmed\" id=\"19167044\" target=\"_blank\">",
"        19167044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10305 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44200=[""].join("\n");
var outline_f43_10_44200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10432264\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525534\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5558623\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525538\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526125\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526126\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526127\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526128\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6825472\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526134\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525536\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10437825\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526129\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525541\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7689562\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3402058\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525553\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525548\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525549\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525560\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525559\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525563\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525543\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525544\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525546\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525547\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525566\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5685504\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2526131\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539968\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525975\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525977\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10305\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10305|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/41/30358?source=related_link\">",
"      Sunitinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44201="Emergency care of moderate and severe thermal burns in children";
var content_f43_10_44201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Emergency care of moderate and severe thermal burns in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     Mark D Joffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44201/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/10/44201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burns are the third leading cause of accidental death (following motor",
"    <span class=\"nowrap\">",
"     vehicle/pedestrian",
"    </span>",
"    and drowning injuries) among children in the United States (US) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/1\">",
"     1",
"    </a>",
"    ]. Although mortality and hospitalization from serious burn injuries has declined as the result of advances in burn care and the implementation of prevention strategies, children with moderate and severe burn injuries require intensive treatment and often experience scarring and long-term disability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early identification and treatment of associated injuries, fluid resuscitation, and prompt referral of children with major burns to burn centers improve outcomes.",
"   </p>",
"   <p>",
"    This topic will review the emergency care of moderate and severe thermal burns in children. The care of adult burn patients, minor thermal burns, smoke inhalation, and electrical injuries is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chemical burns to the skin and eye are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link\">",
"     \"Topical chemical burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 120,000 children (20 years of age or younger) receive care in emergency departments (EDs) for fire or burn related injuries annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Many burn injuries are minor and do not require hospital admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The mortality rate for children admitted to burn centers is less than 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Worldwide, scalds account for 60 to 80 percent of burn injuries for young children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/6,7,10-14\">",
"     6,7,10-14",
"    </a>",
"    ]. Among children in the United States less than five years of age with burn injuries reported to the National Burn Repository, 65 percent sustained scalds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/11\">",
"     11",
"    </a>",
"    ]. In comparison, 27 percent of patients 5 to 20 years of age had scald injuries.",
"   </p>",
"   <p>",
"    Older children are more likely to be injured from fire. In the report from the National Burn Repository, 56 percent of children five years of age or older had flame burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/11\">",
"     11",
"    </a>",
"    ]. Inhalational injury contributes significantly to morbidity and mortality for children who are injured in fires [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8,15\">",
"     8,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serious injury",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death occurs frequently among children who are injured in residential fires. In an observational report describing children in Dallas, Texas who were injured in residential fires, 49 percent of injuries were fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/16\">",
"     16",
"    </a>",
"    ]. The majority of deaths (60 percent) occurred in children under five years of age. Pediatric injuries and death were greater when the injury resulted from children playing with fire.",
"   </p>",
"   <p>",
"    Fireworks are a seasonal cause of severe hand burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Children are typically older and more often male. In one retrospective report, 10 percent of children had permanent sequelae from their injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn injuries can be a manifestation of child abuse. Non-accidental burns account for as much as 20 percent of burn unit admissions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Inflicted burns are usually scalds and most children are less than four years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. A pattern of deep burns on the lower extremities in a symmetric stocking distribution is typical of forced submersion (",
"    <a class=\"graphic graphic_picture graphicRef78135 \" href=\"mobipreview.htm?33/14/34016\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link&amp;anchor=H16#H16\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\", section on 'Immersion burns'",
"    </a>",
"    .) Inflicted craniofacial immersion injuries have been infrequently reported, as have accidental mechanisms for stocking distribution extremity burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality from thermal burns is related to the size of the burn and the presence of inhalational injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/25\">",
"     25",
"    </a>",
"    ]. In one observational report describing children admitted to a burn center with &ge;20 percent total body surface area (TBSA) burns, there was a significant difference in mortality between those with and without inhalation injury (15 and 4 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8\">",
"     8",
"    </a>",
"    ]. For children with TBSA burns &gt;80 percent, inhalation injury did not appear to significantly influence mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link\">",
"     \"Smoke inhalation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality from burn injury appears to be highest for young children and the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/1\">",
"     1",
"    </a>",
"    ]. However, reports of mortality rates among young children have been conflicting. In a retrospective series describing children admitted to a burn center, no patients &le;48 months of age died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, a report describing a larger cohort of children, also admitted to a burn center, noted that mortality was highest for children &le;3 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Technological developments have introduced new mechanisms of thermal injury for children, but also offered preventive strategies, as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microwave ovens may overheat infant bottles and lead to upper airway burns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hot water dispensers are increasingly common and now account for 6 percent of scald burns [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoke detectors and clothing flammability standards have reduced burn risks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/28\">",
"       28",
"      </a>",
"      ]. Fire-safe cigarettes have been developed and could reduce residential fires from careless smoking.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Local injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thermal energy denatures and coagulates protein, resulting in irreversible tissue destruction. Surrounding this zone of coagulation is an area of decreased tissue perfusion. Tissue in this zone is potentially salvageable, provided that resuscitative efforts are successful in restoring perfusion to the area. Perfusion is increased at the outer margins of the burn. Tissue in this zone will recover as long as the patient does not experience prolonged hypoperfusion.",
"   </p>",
"   <p>",
"    The intensity and duration of thermal exposure determines the depth of a burn wound. Prolonged skin contact from hot liquids with high specific heat or high viscosity can result in deeper burns. Deeper burns are more common in young children because their skin is thinner than skin of adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately following the burn injury, vasoactive mediators (such as cytokines, prostaglandins, and oxygen radicals) are released from damaged tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/29\">",
"     29",
"    </a>",
"    ]. Increased capillary permeability results in extravasation of fluid into the interstitial space around the burn. Patients with large burns (&ge;15 percent TBSA for young children and &ge;20 percent for older children and adolescents) develop systemic responses to these mediators. For patients with 40 percent TBSA or more, myocardial depression can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/30\">",
"     30",
"    </a>",
"    ]. As a result, patients with major burns may become hypotensive (burn shock) and edematous (burn edema).",
"   </p>",
"   <p>",
"    Systemic capillary leak usually persists for 18 to 24 hours. Protein is lost from the intravascular space during the first 12 to 18 hours after a burn, after which vascular integrity improves.",
"   </p>",
"   <p>",
"    In large burns, up to 15 percent of red blood cells may be destroyed locally and an additional reduction of 25 percent of the red blood cell mass may occur due to decreased red cell survival time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/31\">",
"     31",
"    </a>",
"    ]. This reduction in oxygen carrying capacity may exacerbate burn shock.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolic response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following resuscitation, children with major burns develop a hypermetabolic response that results in a dramatic increase in energy expenditure and protein metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/29\">",
"     29",
"    </a>",
"    ]. Increases in catecholamines, glucagon, and cortisol are correlated with elevation of metabolic rate and catabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/32\">",
"     32",
"    </a>",
"    ]. Levels of anabolic hormones such as human growth hormone and insulin-like growth factor are decreased for several weeks following a significant burn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence suggests that modulation of the hypermetabolic response with therapies such as beta blockers and human growth hormone may improve outcomes for severely burned children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Burn Association (ABA) has classified burns into minor, moderate, and major, based primarily upon burn depth and size (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"mobipreview.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ). The treatment and prognosis of burn victims correlates with this classification. Thus, it is important that clinicians properly characterize the size and severity of their patients' burns. The classification of burns is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Burn size is typically expressed as the percentage of total body surface area (TBSA) that is burned. Superficial burns are not included in this estimation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link&amp;anchor=H11#H11\">",
"     \"Classification of burns\", section on 'Burn depth'",
"    </a>",
"    .) A modification of the Lund and Browder chart is used most often for children (",
"    <a class=\"graphic graphic_figure graphicRef71190 \" href=\"mobipreview.htm?42/35/43575\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67481 \" href=\"mobipreview.htm?22/15/22781\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The system currently being used to classify burn depth is based upon the need for surgical intervention (",
"    <a class=\"graphic graphic_table graphicRef57124 \" href=\"mobipreview.htm?17/7/17532\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73309 \" href=\"mobipreview.htm?24/50/25381\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREHOSPITAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expert consensus suggests the following priorities for prehospital care for patients with moderate and severe thermal burns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide basic life support. Patients should usually receive supplemental oxygen. Children rarely require assisted ventilation. Patients with airway burns and longer transport times may require intubation.",
"     </li>",
"     <li>",
"      Rapidly transfer the patient to a hospital. Minimize interventions that delay transport.",
"     </li>",
"     <li>",
"      Stop the burning process. Burnt clothing and any jewelry should be removed (unless stuck to the patient). Chemical burns may require immediate irrigation.",
"     </li>",
"     <li>",
"      Covering the burn area with a clean sheet or blanket reduces pain and keeps the child warm.",
"     </li>",
"     <li>",
"      Fluid administration is suggested for transport times greater than one hour or burns that involve more than 25 percent of body surface area. Patients with vascular access should receive pain medication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational reports in human burn victims and experimental evidence in animals suggest that cooling immediately after a burn injury limits the area of injury and improves wound healing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Experts recommend that the burn area be cooled with water for 10 to 20 minutes immediately following the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/38\">",
"     38",
"    </a>",
"    ]. The benefit of cooling for longer than 30 minutes after injury is uncertain. Water temperature should be no less than 8&ordm;C. Ice should never be applied to burns. Care must always be taken to prevent patients from becoming hypothermic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial priorities for the management of a burn patient are similar to those for any injured child. Life-threatening conditions (such as airway compromise, respiratory insufficiency,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate circulation) must be rapidly recognized and stabilized. Serious associated injuries must be identified. Children with major burns must receive prompt fluid resuscitation.",
"   </p>",
"   <p>",
"    An initial approach to the injured child, as well as the assessment of airway, ventilatory, and circulatory function in children is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=see_link\">",
"     \"Classification of trauma in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=see_link&amp;anchor=H2#H2\">",
"     \"Initial assessment and stabilization of children with respiratory or circulatory compromise\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"     \"Emergent endotracheal intubation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28948?source=see_link\">",
"     \"Assessment of perfusion in pediatric resuscitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The remainder of this discussion will focus on the evaluation specific to children with moderate and severe thermal burns (",
"    <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"mobipreview.htm?31/40/32385\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial rapid assessment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Airway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with upper airway burns should be intubated early, before airway anatomy becomes distorted by edema. Soot in the mouth, facial burns, and body burns may be more useful predictors of inhalation injury than symptoms of stridor, hoarseness, drooling, and dysphagia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decreased level of consciousness, toxins (such as carbon monoxide or cyanide), or associated injuries can interfere with ventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxygenation. Patients with circumferential burns to the chest or abdomen may develop respiratory compromise as the result of decreased chest wall compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with signs of compromised circulation at initial presentation (such as unexplained tachycardia, poor peripheral perfusion, or hypotension) should be carefully evaluated for associated injuries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=see_link&amp;anchor=H7#H7\">",
"     \"Initial evaluation and stabilization of children with thoracic trauma\", section on 'Initial rapid assessment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of blunt abdominal trauma in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with compromised circulation who are being examined several hours after the burn injury may be experiencing burn shock, with or without associated injuries. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Immediate burn care",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial resuscitation, burn care should be limited to preventing further injury by removing clothing that is hot, burned, or exposed to chemicals. Jewelry that may become constricting should also be removed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features may identify children at risk for any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with flame burns who have been injured in an enclosed space may have experienced smoke inhalation.",
"     </li>",
"     <li>",
"      Children with flame burns may have been exposed to carbon monoxide (as the result of carbon combustion) or cyanide (from the combustion of materials such as polyurethane, acrylonitrile, nylon, wool, or cotton).",
"     </li>",
"     <li>",
"      History of a fall or explosion suggests the possibility of associated injuries.",
"     </li>",
"     <li>",
"      Patients with electrical burns from exposure to &gt;1000 V may have associated conditions such as cardiac arrhythmias, fractures, compartment syndromes, and myoglobinuria. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"       \"Environmental electrical injuries\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemical burns require copious irrigation. Life-threatening hypocalcemia can develop as the result of exposure to concentrated or anhydrous hydrofluoric acid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H18#H18\">",
"       \"Topical chemical burns\", section on 'Hydrofluoric acid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inconsistencies in the history may indicate an inflicted injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete physical examination, including vital signs with pulse oximetry, should be performed. An accurate weight is essential for determining fluid requirements and should be obtained whenever possible. Capnography may be helpful for assessing ventilation and detecting metabolic acidosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link\">",
"     \"Carbon dioxide monitoring (capnography)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     General examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with significant associated injuries such as inhalation, head injury, or blunt abdominal trauma can have normal or nonspecific findings on initial physical examination. The following clinical features, when present, may indicate specific conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A depressed mental status may be the result of hypoxia, hypotension, toxins such as carbon monoxide and cyanide, head injury, or pain medication.",
"     </li>",
"     <li>",
"      Children with signs of upper airway obstruction (such as drooling or stridor) may have upper airway injury. Patients with singed nasal hair or carbonaceous sputum are likely to have upper airway burns. Thermal injury to the epiglottis has been reported in association with scald burns to the face [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Signs of respiratory distress (such as tachypnea, retractions, or grunting) or wheezing suggest an inhalation injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link\">",
"       \"Smoke inhalation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal tenderness, in association with a compatible history, may indicate an intraabdominal injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Evaluation of burn injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size and depth of the burn injury should be determined (",
"    <a class=\"graphic graphic_figure graphicRef71190 \" href=\"mobipreview.htm?42/35/43575\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67481 \" href=\"mobipreview.htm?22/15/22781\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57124 \" href=\"mobipreview.htm?17/7/17532\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful eye examination, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"       fluorescein",
"      </a>",
"      staining to identify corneal burns, should be performed before edema of the eyelids develops.",
"     </li>",
"     <li>",
"      Burns of the external ear should be noted because of the risk for suppurative chondritis.",
"     </li>",
"     <li>",
"      Patients with circumferential burns must be carefully monitored.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Constriction from circumferential burns of an extremity may compromise distal perfusion or cause compartment syndrome. The quality of distal pulses and capillary refill should be noted frequently.",
"     </li>",
"     <li>",
"      Circumferential burns of the chest can interfere with the mechanics of respiration. Chest wall excursion, pulse oximetry, and capnography (when available) should be monitored.",
"     </li>",
"     <li>",
"      Abdominal compartment syndrome may develop in patients with abdominal burns, especially if over-resuscitation leads to intra-abdominal fluid accumulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific patterns (such as a symmetric stocking distribution or branding) may suggest an inflicted burn injury (",
"      <a class=\"graphic graphic_picture graphicRef78135 \" href=\"mobipreview.htm?33/14/34016\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diagnostic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory studies should be considered for children who have sustained major burns:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and electrolytes with blood urea nitrogen and creatinine levels should be obtained as a baseline, in anticipation of major fluid shifts and metabolic changes associated with serious burns.",
"     </li>",
"     <li>",
"      A urinalysis may detect myoglobin in patients who have experienced muscle injury.",
"     </li>",
"     <li>",
"      Children with fire-related burns should receive carbon monoxide levels.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging studies should be obtained as indicated by the mechanism of injury and physical examination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Soft tissue neck radiographs may be useful for children with signs of upper airway obstruction, but should never delay definitive airway management.",
"     </li>",
"     <li>",
"      Children with respiratory symptoms should generally receive plain chest radiographs, although initial imaging may be normal for patients with smoke inhalation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link&amp;anchor=H2020436#H2020436\">",
"       \"Smoke inhalation\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Computed tomography of the head, chest,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abdomen to identify associated injuries should be performed as indicated based on mechanism of injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Initial management decisions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions identified in the initial rapid assessment (such as evidence of airway injury or respiratory distress) must be aggressively managed. Children with major burns must also receive prompt fluid resuscitation and treatment for pain.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with fire-related burns should receive supplemental oxygen.",
"     </li>",
"     <li>",
"      Patients with signs of airway injury should be intubated early, with the following considerations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A difficult airway should be anticipated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=see_link&amp;anchor=H6#H6\">",
"       \"The difficult pediatric airway\", section on 'Acquired conditions'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rapid sequence intubation should be performed for patients who require advanced airway management. A sedative agent that protects blood pressure (such as",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/11/34995?source=see_link\">",
"       etomidate",
"      </a>",
"      ) is recommended.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/58/39845?source=see_link\">",
"       Succinylcholine",
"      </a>",
"      may be used (unless otherwise contraindicated) for patients whose burns are less than 48 hours old, when the risk for hyperkalemia has not yet developed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link&amp;anchor=H16#H16\">",
"       \"Rapid sequence intubation (RSI) in children\", section on 'Sedation and paralysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The endotracheal tube must be fastidiously secured to prevent accidental extubation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reliable vascular access should be obtained, preferably at a site that is not burned. However, observational evidence indicates that catheters may be safely placed through burned skin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/43\">",
"       43",
"      </a>",
"      ]. In addition, central catheters appear to be safe for children with burn injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bladder catheterization should be performed in children who will require significant fluid resuscitation to provide timely and accurate measurement of urine output to monitor fluid status.",
"     </li>",
"     <li>",
"      Tetanus immunization should be administered to children with burns deeper than superficial-thickness, who have not received booster immunizations in &gt;5 years.",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?39/46/40676?source=see_link\">",
"       Tetanus immune globulin",
"      </a>",
"      should be given to patients who have not received a complete primary immunization (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"mobipreview.htm?7/52/8013\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=see_link\">",
"       \"Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=see_link\">",
"       \"Tetanus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=see_link&amp;anchor=H11#H11\">",
"       \"Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age\", section on 'Vaccine schedule'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical consultation should generally be obtained for children with moderate and severe burns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Fluid resuscitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate fluid resuscitation is an essential component of the initial management of children with major burns. Observational evidence and clinical experience suggest that adequate initial fluid resuscitation improves outcomes for these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Estimating fluid requirements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formulas for estimating fluid requirements for children for the first 24 hours following a burn injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Parkland &ndash; 4",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per percent total burn surface area (TBSA). Add maintenance fluid with glucose for children &lt;5 years of age. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Galveston &ndash; 5000",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      per percent TBSA. Add 2000",
"      <span class=\"nowrap\">",
"       mL/m2",
"      </span>",
"      per day for maintenance requirements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Half of the fluid is given over the first eight hours. The remaining half is given over the next 16 hours.",
"   </p>",
"   <p>",
"    Formulas that are used to determine fluid rates provide an estimate of the initial requirements. Observational evidence indicates that they often underestimate the volume of fluid required for adequate resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/45,47-49\">",
"     45,47-49",
"    </a>",
"    ], especially if an inhalation injury has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/50\">",
"     50",
"    </a>",
"    ]. Consequently, volume status must be carefully monitored and fluid therapy adjusted accordingly. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Monitoring fluid status'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Choice of fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ringers lactate (RL) is the resuscitation and maintenance fluid of choice for the first 24 hours at most burn centers. Experts recommend adding 5 percent dextrose to maintenance fluid for children &lt;20 kg to prevent hypoglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/28\">",
"     28",
"    </a>",
"    ]. Colloid is typically added after 24 hours to restore oncotic pressure and preserve intravascular volume.",
"   </p>",
"   <p>",
"    Some experts report improved outcomes adding colloid during the first 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Systematic reviews that compared crystalloid versus colloid and crystalloid versus albumin for fluid resuscitation in critically ill patients (including small numbers of children with burn injury) demonstrated that survival was not improved for patients who received colloid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experience using hypertonic saline for fluid resuscitation in burn victims is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Monitoring fluid status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The volume status of burn patients must be carefully monitored in order to successfully navigate the narrow path between inadequate volume and fluid overload. However, advanced invasive cardiovascular monitoring has not been shown to reduce morbidity and mortality in burn victims when compared to patients treated according to the Parkland formula [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/56\">",
"     56",
"    </a>",
"    ]. The following parameters are helpful (",
"    <a class=\"graphic graphic_table graphicRef50423 \" href=\"mobipreview.htm?38/62/39915\">",
"     table 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urine output should be maintained at 1 to 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for children &lt;30 kg and 0.5 to 1",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour for those &ge;30 kg [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/28,29,36\">",
"       28,29,36",
"      </a>",
"      ]. For outputs that exceed this rate, urine should be tested for glucose. Hyperglycemia (as the result of increased catecholamine levels) can cause an osmotic diuresis that should not be misinterpreted as a reflection adequate volume status. &nbsp;",
"     </li>",
"     <li>",
"      Heart rate is a better monitor of circulatory status in children than is blood pressure. Tachycardia may indicate hypovolemia, but pain can elevate heart rate in euvolemic patients (",
"      <a class=\"graphic graphic_table graphicRef77057 \" href=\"mobipreview.htm?17/33/17947\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef51186 \" href=\"mobipreview.htm?2/30/2540\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Metabolic acidosis can be a marker for inadequate fluid resuscitation, but also occurs with carbon monoxide or cyanide exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children who require large fluid volumes to maintain adequate perfusion or who do not improve with vigorous fluid resuscitation should be carefully evaluated for other conditions that can cause cardiovascular compromise including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Volume loss from occult injuries",
"     </li>",
"     <li>",
"      Neurogenic shock as the result of a spinal cord injury",
"     </li>",
"     <li>",
"      Myocardial depression or decreased vascular tone from inhaled or ingested toxins",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Central venous pressure or pulmonary arterial pressure monitoring may be helpful for some patients. Meticulous care of central venous catheters is required to avoid complications such as infection and deep vein thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thermal injuries are usually extremely painful, burn patients frequently do not receive analgesia in the emergency department [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/57\">",
"     57",
"    </a>",
"    ]. Children with major burns typically require narcotic analgesics for pain relief. Most burn centers use",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    for wound care pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/58\">",
"     58",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/45/35546?source=see_link\">",
"     Fentanyl",
"    </a>",
"    may be a safer choice for initial pain management for patients whose cardiovascular status may be unstable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Initial burn wound management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wounds should initially be cleaned with mild soap and water. Disinfectants are typically avoided because they may inhibit wound healing. Clothing and debris that are embedded in the wounds should be removed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link&amp;anchor=H21593921#H21593921\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Cleansing and debridement'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Debridement of devitalized tissue (including ruptured blisters) decreases the risk of infections. In addition, the depth of burn wounds can be determined with better accuracy when the wound bed is inspected directly. Initial debridement can usually be accomplished with sterile saline soaked gauze.",
"   </p>",
"   <p>",
"    Although the approach to intact blisters is controversial, experts generally recommend that large blisters, those that are likely to rupture, and those that are painful (regardless of size) be removed. Observational reports and experimental evidence suggest that blister fluid has properties that are both protective (such as factors that promote wound healing) and damaging (such as factors that are vasoconstrictive and immunosuppressive) for wound healing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link&amp;anchor=H1054478388#H1054478388\">",
"     \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Burn blisters'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Wound dressing",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are being rapidly transferred to a burn unit, burns should be covered with dry sterile dressings. Ointments or creams should not be applied because they can hinder initial wound assessment at the burn center. Partial and full-thickness burns should be dressed for all other patients. Factors to consider when choosing a dressing include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A moist wound environment should be maintained for optimal healing.",
"     </li>",
"     <li>",
"      The dressing should provide a barrier that reduces the risk of infection.",
"     </li>",
"     <li>",
"      For optimum pain relief, the dressing should maintain maximum contact with the wound without adhering to it. It should also be easy to apply and remove. Specific types of burn dressings are discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link&amp;anchor=H21593997#H21593997\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Dressings'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Topical antibiotics have been used extensively to dress partial thickness burn wounds. They are readily available, generally inexpensive, and reduce the risk of infection. The topical antibiotic is applied to the wound which is then covered with a nonadherent dressing. The dressing is held in place using either a tubular net bandage or gauze wraps. Dressings must be changed frequently. The potential indications and adverse effects of specific antibiotic preparations are presented in the table (",
"      <a class=\"graphic graphic_table graphicRef81801 \" href=\"mobipreview.htm?14/8/14477\">",
"       table 8",
"      </a>",
"      ) and discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=see_link&amp;anchor=H21593928#H21593928\">",
"       \"Local treatment of burns: Topical antimicrobial agents and dressings\", section on 'Topical antimicrobial agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Escharotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circumferential partial and full thickness burns may lead to functional impairment (such as restriction of chest wall movement for chest burns or development of a compartment syndrome for extremity burns) as edema increases over the first 24 hours following a burn injury. An emergency escharotomy (which involves making an incision completely through the depth of the burn eschar) may be required to relieve restriction (as with chest burns) or reduce pressure (as with a compartment syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link&amp;anchor=H25#H25\">",
"     \"Emergency care of moderate and severe thermal burns in adults\", section on 'Escharotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Additional management considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children whose transfers to burn centers are delayed may need to be managed in the emergency department for extended periods of time. They should be carefully monitored in order to detect and treat conditions that develop in response to initial injuries, such as burn shock and worsening respiratory status for those with inhalational injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6246817\">",
"    <span class=\"h3\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tight glycemic control appears to improve outcomes for children with severe burn injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Consequently, children who develop hyperglycemia should be treated with insulin to maintain blood glucose levels within the normal range. Other therapies that appear to improve outcomes (such as early burn wound excision, aggressive nutritional support, and modulating the hypermetabolic response to burn injury) are typically initiated on admission to the burn center.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6246824\">",
"    <span class=\"h3\">",
"     Eyelid and ocular burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician must do a careful assessment of eyelid burns to identify the likelihood of scarring and subsequent lid retraction, and the possibility of direct thermal injury of the globe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/62\">",
"     62",
"    </a>",
"    ]. Key interventions include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Contact lens should be removed.",
"     </li>",
"     <li>",
"      Topical anesthesia (eg, one drop of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?35/19/36146?source=see_link\">",
"       proparacaine",
"      </a>",
"      0.5 percent in each eye) may be used initially but should not be applied long-term.",
"     </li>",
"     <li>",
"      Any debris should be irrigated from the eye and conjunctiva.",
"     </li>",
"     <li>",
"      Scorched eye lashes should be trimmed so that char does not cause ongoing irritation of the eye surface and conjunctiva. This procedure should be performed with fine scissors that have ophthalmic ointment applied to the blades so that the trimmed lashes do not fall into the eye.",
"     </li>",
"     <li>",
"      Burns near the eye require treatment with ophthalmic preparations of topical antibiotic ointment (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/11/38064?source=see_link\">",
"       erythromycin",
"      </a>",
"      0.5 percent ointment) because application of topical antimicrobial preparations (eg,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?9/36/9795?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      ) close to the lid margins may result in eye exposure and excessive absorption of toxic components.",
"     </li>",
"     <li>",
"      Deep burns of the lids that scar can result in retraction and corneal exposure. These injuries need to be followed very closely by an ophthalmologist. If there is incomplete lid closure, tissue loss, or ectropion (outward turning of lid margins), frequent lubrication (eg, minimum four times daily application of carboxymethyl cellulose sodium 1 percent [Celluvisc&reg;] and white petrolatum ointment [Lacrilube&reg;] at night) should be initiated. Combination antibiotic and steroid preparations (eg,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/39/22129?source=see_link\">",
"        tobramycin",
"       </a>",
"       /",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/33/35344?source=see_link\">",
"        dexamethasone",
"       </a>",
"      </span>",
"      ointment), temporary tarsorrhaphy (suturing together of the eyelids)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other surgical interventions, including early skin grafting, may be necessary to prevent corneal ulceration, opacification, and visual loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases where the ocular surface itself is burned and corneal edema is evident, reduction of surface inflammation with topical steroids, in addition to topical lubrication and antibiotic therapy may be initiated by an ophthalmologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/64\">",
"     64",
"    </a>",
"    ]. These patients warrant close observation for signs of infection until the corneal epithelium is healed. Patients with severe surface burns may still have vision restored through amniotic membrane transplantation, autologous limbal stem cell transplantation, or keratoprosthesis.",
"   </p>",
"   <p>",
"    Chemical burns to the eye are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=see_link&amp;anchor=H9#H9\">",
"     \"Topical chemical burns\", section on 'Eye exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational evidence and extensive clinical experience suggest that the complex initial and long-term medical and surgical needs of children with severe burns can be best managed at burn centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8,9,46,65\">",
"     8,9,46,65",
"    </a>",
"    ]. Burn centers can provide the surgical, critical care, medical, nutritional, nursing, and rehabilitation expertise that is not cost-effective to maintain at local hospitals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Burn Association recommends that children with any of the following receive care in a burn center (",
"    <a class=\"graphic graphic_table graphicRef74855 \" href=\"mobipreview.htm?2/13/2268\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;10 years with &gt;10 percent TBSA burn",
"     </li>",
"     <li>",
"      Age &ge;10 years with &gt;20 percent TBSA burn",
"     </li>",
"     <li>",
"      Full thickness burn &gt;5 percent TBSA",
"     </li>",
"     <li>",
"      Inhalational injury",
"     </li>",
"     <li>",
"      Any significant burn to face, eyes, ears, genitalia, or joints",
"     </li>",
"     <li>",
"      Significant associated injuries (fractures or major trauma)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational evidence suggests that, within organized regional systems, patients with serious burn injuries can be safely transferred over long distances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/66\">",
"     66",
"    </a>",
"    ]. Problems that develop commonly include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inability to intubate the patient during transport",
"     </li>",
"     <li>",
"      Difficulty maintaining or achieving vascular access",
"     </li>",
"     <li>",
"      Hypothermia, particularly for patients with large burns",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    American Burn Association indications for admission to the local hospital for observation, intravenous fluid administration, and pain management include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;10 years with 5 to 10 percent TBSA burn (depending on parental capability and social circumstances)",
"     </li>",
"     <li>",
"      Age &ge;10 years with 10 to 20 percent TBSA burn",
"     </li>",
"     <li>",
"      Full thickness burn 2 to 5 percent TBSA",
"     </li>",
"     <li>",
"      High voltage injury",
"     </li>",
"     <li>",
"      Suspected inhalational injury",
"     </li>",
"     <li>",
"      Circumferential burn",
"     </li>",
"     <li>",
"      Medical problem predisposing to infection (such as diabetes or sickle cell disease)",
"     </li>",
"     <li>",
"      Concern for inflicted injury",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with extensive burn injuries who are unlikely to survive cannot be reliably identified at initial evaluation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. High rates of survival well above 90 percent can be anticipated for children with total body surface area burns less than 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44201/abstract/69\">",
"     69",
"    </a>",
"    ]. Even those patients with the most extensive and severe burns have almost 50 percent survival with timely and aggressive management in a modern burn center.",
"   </p>",
"   <p>",
"    In addition, aggressive physical and psychological rehabilitation provided at burn centers has improved the quality of life for severely burned children. Therefore, regardless of burn severity, age, and associated injuries, all children should be resuscitated after thermal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn injuries cause significant morbidity and mortality among children. Early identification and treatment of associated injuries, fluid resuscitation, and prompt referral of children with major burns to burn centers improve outcomes (",
"    <a class=\"graphic graphic_algorithm graphicRef51484 \" href=\"mobipreview.htm?31/40/32385\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Scald injuries are more common among children less than five years of age, while older children are more likely to be injured from fire.",
"     </li>",
"     <li>",
"      Serious injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      death occurs frequently among children who are injured in residential fires. Child abuse is responsible for a significant portion of burn injuries in children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burn shock and edema are caused by vasoactive mediators that have local and systemic effects. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burns are classified by size (",
"      <a class=\"graphic graphic_figure graphicRef53352 \" href=\"mobipreview.htm?29/55/30583\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67481 \" href=\"mobipreview.htm?22/15/22781\">",
"       table 2",
"      </a>",
"      ) and depth (",
"      <a class=\"graphic graphic_table graphicRef57124 \" href=\"mobipreview.htm?17/7/17532\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burn victims should be rapidly transported to the hospital, receiving basic life support as needed. Cooling immediately after the burn may limit the extent of injury. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prehospital care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation includes rapid identification of life-threatening conditions, a careful examination to identify associated injuries, and determination of the extent and severity of burn injury. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of children with moderate and severe burns includes oxygenation, ventilation, and support of blood pressure. Other management considerations include the following (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with upper airway injury must have secure airways. All children must have reliable vascular access.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest that crystalloid fluids be used for the first 24 hours of fluid resuscitation following burn injury (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). During the initial resuscitation, the Parkland formula (which uses weight) may be easier to use than the Galveston formula (which uses surface area). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Fluid resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Response to fluid resuscitation must be carefully monitored (",
"      <a class=\"graphic graphic_table graphicRef50423 \" href=\"mobipreview.htm?38/62/39915\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that large blisters, those that are likely to rupture, and those that are painful (regardless of size) be removed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Debridement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that burns be dressed with silver impregnated dressings (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). When this is not feasible, topical antibiotic ointments with nonadherent dressings may be used. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Wound dressing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with severe burns should receive definitive treatment at burn centers (",
"      <a class=\"graphic graphic_table graphicRef74855 \" href=\"mobipreview.htm?2/13/2268\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Center for Injury Preventions and Control www.cdc.gov/ncipc/wisqars/ (Accessed on April 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/2\">",
"      Duke J, Wood F, Semmens J, et al. A study of burn hospitalizations for children younger than 5 years of age: 1983-2008. Pediatrics 2011; 127:e971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/3\">",
"      Bowman SM, Aitken ME, Maham SA, Sharar SR. Trends in hospitalisations associated with paediatric burns. Inj Prev 2011; 17:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/4\">",
"      Brusselaers N, Monstrey S, Vogelaers D, et al. Severe burn injury in Europe: a systematic review of the incidence, etiology, morbidity, and mortality. Crit Care 2010; 14:R188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/5\">",
"      D'Souza AL, Nelson NG, McKenzie LB. Pediatric burn injuries treated in US emergency departments between 1990 and 2006. Pediatrics 2009; 124:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/6\">",
"      Carlsson A, Ud&eacute;n G, H&aring;kansson A, Karlsson ED. Burn injuries in small children, a population-based study in Sweden. J Clin Nurs 2006; 15:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/7\">",
"      Drago DA. Kitchen scalds and thermal burns in children five years and younger. Pediatrics 2005; 115:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/8\">",
"      Barrow RE, Spies M, Barrow LN, Herndon DN. Influence of demographics and inhalation injury on burn mortality in children. Burns 2004; 30:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/9\">",
"      Sheridan RL, Remensnyder JP, Schnitzer JJ, et al. Current expectations for survival in pediatric burns. Arch Pediatr Adolesc Med 2000; 154:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/10\">",
"      Tse T, Poon CH, Tse KH, et al. Paediatric burn prevention: an epidemiological approach. Burns 2006; 32:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/11\">",
"      Miller SF, Bessey PQ, Schurr MJ, et al. National Burn Repository 2005: a ten-year review. J Burn Care Res 2006; 27:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/12\">",
"      Liu EH, Khatri B, Shakya YM, Richard BM. A 3 year prospective audit of burns patients treated at the Western Regional Hospital of Nepal. Burns 1998; 24:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/13\">",
"      Al-Shehri M. The pattern of paediatric burn injuries in Southwestern, Saudi Arabia. West Afr J Med 2004; 23:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/14\">",
"      Lowell G, Quinlan K, Gottlieb LJ. Preventing unintentional scald burns: moving beyond tap water. Pediatrics 2008; 122:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/15\">",
"      Ryan CM, Schoenfeld DA, Thorpe WP, et al. Objective estimates of the probability of death from burn injuries. N Engl J Med 1998; 338:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/16\">",
"      Istre GR, McCoy M, Carlin DK, McClain J. Residential fire related deaths and injuries among children: fireplay, smoke alarms, and prevention. Inj Prev 2002; 8:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/17\">",
"      Smith GA, Knapp JF, Barnett TM, Shields BJ. The rockets' red glare, the bombs bursting in air: fireworks-related injuries to children. Pediatrics 1996; 98:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/18\">",
"      Jones D, Lee W, Rea S, et al. Firework injuries presenting to a national burn's unit. Ir Med J 2004; 97:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/19\">",
"      Sheridan RL, Ryan CM, Petras LM, et al. Burns in children younger than two years of age: an experience with 200 consecutive admissions. Pediatrics 1997; 100:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/20\">",
"      Hight DW, Bakalar HR, Lloyd JR. Inflicted burns in children. Recognition and treatment. JAMA 1979; 242:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/21\">",
"      Kumar P. Child abuse by thermal injury--a retrospective survey. Burns Incl Therm Inj 1984; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/22\">",
"      Weimer CL, Goldfarb IW, Slater H. Multidisciplinary approach to working with burn victims of child abuse. J Burn Care Rehabil 1988; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/23\">",
"      Daria S, Sugar NF, Feldman KW, et al. Into hot water head first: distribution of intentional and unintentional immersion burns. Pediatr Emerg Care 2004; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/24\">",
"      Titus MO, Baxter AL, Starling SP. Accidental scald burns in sinks. Pediatrics 2003; 111:E191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/25\">",
"      Sheridan RL, Weber JM, Schnitzer JJ, et al. Young age is not a predictor of mortality in burns. Pediatr Crit Care Med 2001; 2:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/26\">",
"      Ali SN, O'Toole G, Tyler M. Milk bottle burns. J Burn Care Rehabil 2004; 25:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/27\">",
"      Chuang SS, Yang JY, Tsai FC. Electric water heaters: a new hazard for pediatric burns. Burns 2003; 29:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/28\">",
"      Sheridan RL. Burns. Crit Care Med 2002; 30:S500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/29\">",
"      Klein GL, Herndon DN. Burns. Pediatr Rev 2004; 25:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/30\">",
"      Reynolds EM, Ryan DP, Sheridan RL, Doody DP. Left ventricular failure complicating severe pediatric burn injuries. J Pediatr Surg 1995; 30:264.",
"     </a>",
"    </li>",
"    <li>",
"     Press, B. Grabb and Smith's Plastic Surgery, 5th edition, Aston, SJ, Beasley, RW, Thorne, CHM (Eds), Lippincott-Raven, Philadelphia 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/32\">",
"      Bessey PQ, Watters JM, Aoki TT, Wilmore DW. Combined hormonal infusion simulates the metabolic response to injury. Ann Surg 1984; 200:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/33\">",
"      Hill GL. Jonathan E. Rhoads Lecture. Body composition research: implications for the practice of clinical nutrition. JPEN J Parenter Enteral Nutr 1992; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/34\">",
"      Aarsland A, Chinkes D, Wolfe RR, et al. Beta-blockade lowers peripheral lipolysis in burn patients receiving growth hormone. Rate of hepatic very low density lipoprotein triglyceride secretion remains unchanged. Ann Surg 1996; 223:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/35\">",
"      Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil 1997; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     Herndon, DN, Pierre, EJ. Pediatric Surgery, Ashcraft (Ed), WB Saunders, Philadelphia 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/37\">",
"      Gilpin DA, Barrow RE, Rutan RL, et al. Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Ann Surg 1994; 220:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/38\">",
"      Allison K, Porter K. Consensus on the prehospital approach to burns patient management. Emerg Med J 2004; 21:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/39\">",
"      Nguyen NL, Gun RT, Sparnon AL, Ryan P. The importance of immediate cooling--a case series of childhood burns in Vietnam. Burns 2002; 28:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/40\">",
"      Jandera V, Hudson DA, de Wet PM, et al. Cooling the burn wound: evaluation of different modalites. Burns 2000; 26:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/41\">",
"      Madnani DD, Steele NP, de Vries E. Factors that predict the need for intubation in patients with smoke inhalation injury. Ear Nose Throat J 2006; 85:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/42\">",
"      Watts AM, McCallum MI. Acute airway obstruction following facial scalding: differential diagnosis between a thermal and infective cause. Burns 1996; 22:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/43\">",
"      Goldstein AM, Weber JM, Sheridan RL. Femoral venous access is safe in burned children: an analysis of 224 catheters. J Pediatr 1997; 130:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/44\">",
"      Sheridan RL, Weber JM. Mechanical and infectious complications of central venous cannulation in children: lessons learned from a 10-year experience placing more than 1000 catheters. J Burn Care Res 2006; 27:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/45\">",
"      Barrow RE, Jeschke MG, Herndon DN. Early fluid resuscitation improves outcomes in severely burned children. Resuscitation 2000; 45:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/46\">",
"      Nguyen NL, Gun RT, Sparnon AL, Ryan P. The importance of initial management: a case series of childhood burns in Vietnam. Burns 2002; 28:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/47\">",
"      Graves TA, Cioffi WG, McManus WF, et al. Fluid resuscitation of infants and children with massive thermal injury. J Trauma 1988; 28:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/48\">",
"      Cartotto RC, Innes M, Musgrave MA, et al. How well does the Parkland formula estimate actual fluid resuscitation volumes? J Burn Care Rehabil 2002; 23:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/49\">",
"      Mitra B, Fitzgerald M, Cameron P, Cleland H. Fluid resuscitation in major burns. ANZ J Surg 2006; 76:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/50\">",
"      Fabia R, Groner JI. Advances in the care of children with burns. Adv Pediatr 2009; 56:219.",
"     </a>",
"    </li>",
"    <li>",
"     Carvajal, HF, Griffith, JA. Burn and inhalation injuries. In: Pediatric critical care, 2006, Furhman, BP, Zimmerman, J (Eds), Mosby Elsevier, Philadelphia 3rd edition. p.1565.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/52\">",
"      Fodor L, Fodor A, Ramon Y, et al. Controversies in fluid resuscitation for burn management: literature review and our experience. Injury 2006; 37:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/53\">",
"      Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004; :CD000567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/54\">",
"      Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev 2004; :CD001208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/55\">",
"      Bunn F, Roberts I, Tasker R, Akpa E. Hypertonic versus near isotonic crystalloid for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2004; :CD002045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/56\">",
"      Holm C, Mayr M, Tegeler J, et al. A clinical randomized study on the effects of invasive monitoring on burn shock resuscitation. Burns 2004; 30:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/57\">",
"      Singer AJ, Thode HC Jr. National analgesia prescribing patterns in emergency department patients with burns. J Burn Care Rehabil 2002; 23:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/58\">",
"      Martin-Herz SP, Patterson DR, Honari S, et al. Pediatric pain control practices of North American Burn Centers. J Burn Care Rehabil 2003; 24:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/59\">",
"      Pham TN, Warren AJ, Phan HH, et al. Impact of tight glycemic control in severely burned children. J Trauma 2005; 59:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/60\">",
"      Thomas SJ, Morimoto K, Herndon DN, et al. The effect of prolonged euglycemic hyperinsulinemia on lean body mass after severe burn. Surgery 2002; 132:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/61\">",
"      Jeschke MG, Kulp GA, Kraft R, et al. Intensive insulin therapy in severely burned pediatric patients: a prospective randomized trial. Am J Respir Crit Care Med 2010; 182:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/62\">",
"      Malhotra R, Sheikh I, Dheansa B. The management of eyelid burns. Surv Ophthalmol 2009; 54:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/63\">",
"      Spector J, Fernandez WG. Chemical, thermal, and biological ocular exposures. Emerg Med Clin North Am 2008; 26:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/64\">",
"      Fish R, Davidson RS. Management of ocular thermal and chemical injuries, including amniotic membrane therapy. Curr Opin Ophthalmol 2010; 21:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/65\">",
"      Gibran NS, Klein MB, Engrav LH, Heimbach DM. UW Burn Center. A model for regional delivery of burn care. Burns 2005; 31 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/66\">",
"      Klein MB, Nathens AB, Emerson D, et al. An analysis of the long-distance transport of burn patients to a regional burn center. J Burn Care Res 2007; 28:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/67\">",
"      Spies M, Herndon DN, Rosenblatt JI, et al. Prediction of mortality from catastrophic burns in children. Lancet 2003; 361:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/68\">",
"      Cancio LC, Reifenberg L, Barillo DJ, et al. Standard variables fail to identify patients who will not respond to fluid resuscitation following thermal injury: brief report. Burns 2005; 31:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44201/abstract/69\">",
"      Kraft R, Herndon DN, Al-Mousawi AM, et al. Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study. Lancet 2012; 379:1013.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6567 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44201=[""].join("\n");
var outline_f43_10_44201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Local injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolic response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREHOSPITAL CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial rapid assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Airway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Circulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Immediate burn care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - General examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Evaluation of burn injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diagnostic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Initial management decisions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Fluid resuscitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Estimating fluid requirements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Choice of fluid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Monitoring fluid status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Initial burn wound management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Debridement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Wound dressing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Escharotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Additional management considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6246817\">",
"      - Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6246824\">",
"      - Eyelid and ocular burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6567\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6567|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?31/40/32385\" title=\"algorithm 1\">",
"      Initial burn management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6567|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/35/43575\" title=\"figure 1\">",
"      Burn class adult child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/50/25381\" title=\"figure 2\">",
"      Burn class depth skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/55/30583\" title=\"figure 3\">",
"      Lund and browder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6567|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/14/34016\" title=\"picture 1\">",
"      Stocking immersion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6567|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/13/2268\" title=\"table 1\">",
"      American Burn Association grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/15/22781\" title=\"table 2\">",
"      Burn extent in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/7/17532\" title=\"table 3\">",
"      Burn depth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/52/8013\" title=\"table 4\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/62/39915\" title=\"table 5\">",
"      Physio goals burn resus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/33/17947\" title=\"table 6\">",
"      Heart rates in normal children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/30/2540\" title=\"table 7\">",
"      Blood pressure children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/8/14477\" title=\"table 8\">",
"      Antimicrobial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/17/28948?source=related_link\">",
"      Assessment of perfusion in pediatric resuscitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/12/7367?source=related_link\">",
"      Classification of trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34233?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/37/5722?source=related_link\">",
"      Diphtheria, tetanus, and pertussis immunization in infants and children 0 through 6 years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/63/27640?source=related_link\">",
"      Initial evaluation and stabilization of children with thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29225?source=related_link\">",
"      Local treatment of burns: Topical antimicrobial agents and dressings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/62/33768?source=related_link\">",
"      Overview of blunt abdominal trauma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/7/15481?source=related_link\">",
"      The difficult pediatric airway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11801?source=related_link\">",
"      Topical chemical burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44202="Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer";
var content_f43_10_44202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy for locally advanced unresectable and metastatic esophageal and gastric cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Johanna Bendell, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Harry H Yoon, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Panos Fidias, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?43/10/44202/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?43/10/44202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancers of the upper gastrointestinal (GI) tract are highly lethal malignancies. The five-year survival rates for esophagus and gastric cancers are among the worst reported for any malignancy. According to data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program, the five-year survival for patients with esophageal and gastric cancer improved only modestly over the last 50 years, from 4 percent in the years 1950 to 1954, to 17 percent during the period 1996 to 2003 for esophageal cancer, and from 12 to 22 percent for gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/1\">",
"     1",
"    </a>",
"    ]. The propensity of upper GI cancers for early metastatic dissemination is well known; even patients with the earliest stage disease are at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Palliative treatments for advanced esophageal or gastric cancer can be either local or systemic. While cytotoxic chemotherapy is the most effective treatment modality for patients with metastatic disease and it may adequately palliate dysphagia, other symptoms such as nausea, pain, obstruction, perforation, or bleeding from a locally advanced or locally recurrent primary tumor often require multidisciplinary management using endoscopic, surgical, radiotherapeutic or other approaches. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19333?source=see_link\">",
"     \"Local palliation for advanced gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=see_link\">",
"     \"Endoscopic palliation of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will cover chemotherapy for advanced unresectable and metastatic esophageal and gastric cancer, which has converged over time, in part due to changes in histologic distribution and tumor location. Neoadjuvant strategies for locoregionally advanced but potentially resectable esophageal and gastric cancer, the use of chemotherapy with and without radiation for patients with localized, potentially resectable disease, and hepatic metastasectomy for the rare patient with isolated gastric cancer liver metastases are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=see_link\">",
"     \"Management of locally advanced unresectable esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=see_link&amp;anchor=H26#H26\">",
"     \"Invasive gastric cancer: Surgery and prognosis\", section on 'Metastasectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTOLOGY, ANATOMIC DISTRIBUTION, AND EVOLUTION OF CHEMOTHERAPY STRATEGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Together, squamous cell carcinoma (SCC) and adenocarcinoma account for 93 percent of all esophageal carcinomas, but histologic and anatomic distribution has changed dramatically over the past 30 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/1\">",
"     1",
"    </a>",
"    ]. In the 1970s, SCC accounted for about 70 percent of all esophageal cancers, and 22 percent of tumors were located in the upper third of the thoracic esophagus or in the cervical esophagus. Since the mid 1970s, the incidence of SCC in the United States has been declining steadily, while the incidence of adenocarcinoma in white males rose by 350 percent from 1974 to 1994. Adenocarcinoma surpassed SCC as the dominant histology in the early 1990s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the same time, there has also been a shift in location of esophageal cancers over time. At present, 86 percent of esophageal cancers arise the distal one-third of the thoracic esophagus, 13 percent in the middle third, and only 1 percent in the upper third or cervical esophagus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More than 90 percent of stomach cancers are adenocarcinomas. In 1930, most cases originated in the distal stomach (gastric body and antrum, (",
"    <a class=\"graphic graphic_figure graphicRef79793 \" href=\"mobipreview.htm?4/45/4817\">",
"     figure 1",
"    </a>",
"    )). Since then, the incidence of distal gastric carcinoma has declined dramatically, while the incidence of adenocarcinoma of the esophagogastric junction (EGJ) and proximal stomach has increased at a rate exceeding that of any other cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/6\">",
"     6",
"    </a>",
"    ]. The increasing incidence has paralleled the rise in incidence of esophageal adenocarcinoma. The term \"EGJ tumor\" reflects the frequent difficulty in separating the primary location of distal esophageal and proximal gastric cancers; their natural history, response to therapy, and overall prognosis appears to be similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=see_link\">",
"     \"Epidemiology of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Taken together, these findings suggest that adenocarcinomas of the distal esophagus, EGJ and proximal stomach share a common pathogenesis that is most likely different from that of proximal esophageal and distal gastric cancers. The marked increase in adenocarcinomas of the distal esophagus, EGJ and proximal stomach has been linked to the rising incidence of Barrett's esophagus and obesity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=see_link\">",
"     \"Pathogenesis of Barrett's esophagus and its malignant transformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evolution of chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy drugs that were tested for esophageal cancer at a time when SCC was the predominant histology (1970s and 1980s) were those initially developed for SCC of the head and neck, including 5-fluorouracil (5-FU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"     vindesine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    . The combination of 5-FU plus cisplatin (FP) was adopted by many as a safe and effective standard regimen, and studies focused on the benefit of adding a third agent to the FP backbone.",
"   </p>",
"   <p>",
"    At the other end of the spectrum, at a time when distal gastric adenocarcinomas were the most common stomach malignancy, most regimens for advanced gastric cancer were based upon 5-FU plus an anthracycline.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    -based combinations (such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    , 5-FU, and cisplatin, ECF) were eventually shown to be superior to",
"    <span class=\"nowrap\">",
"     5-FU/anthracycline-based,",
"    </span>",
"    non-cisplatin-containing regimens and became the reference regimens for advanced gastric cancer. (See",
"    <a class=\"local\" href=\"#H18\">",
"     '5-FU/anthracycline regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Coincident with the epidemiologic changes in histologic and anatomic distribution, the treatment of advanced gastric and esophageal cancers has converged, and the majority of clinical trials conducted since the mid 1990s now include patients with gastric, esophageal, or EGJ cancer, regardless of histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Although SCCs now represent a small minority of patients enrolled on most clinical trials, histologic subtype does not appear to play a major role in response rate or survival duration in patients treated with a variety of regimens for metastatic esophagogastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/10-15\">",
"     10-15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goals of chemotherapy in patients with advanced upper GI cancer are to palliate symptoms, including malignant dysphagia, and improve survival.",
"   </p>",
"   <p>",
"    A number of controlled trials and a meta-analysis provide evidence for the beneficial effect of palliative systemic chemotherapy as compared to supportive care alone for patients with advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. In a meta-analysis of three trials comparing chemotherapy versus best supportive care, there was a significant benefit in overall survival in favor of chemotherapy (hazard ratio [HR] 0.37; 95% CI 0.24 -0.55), which translated into an improvement in median survival from 4.3 to 11 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SINGLE AGENT CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Older single agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until the early 1990s, active chemotherapeutic agents in advanced esophageal or gastric cancer were",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    -C,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 5-fluorouracil (5-FU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . All were associated with modest response rates of short duration (typically less than six months) and infrequent complete responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/22-31\">",
"     22-31",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     Carboplatin",
"    </a>",
"    has not been as widely studied as cisplatin, but it appears to be significantly less active [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Response rates from some of these trials are summarized in the following table (",
"    <a class=\"graphic graphic_table graphicRef71199 \" href=\"mobipreview.htm?27/14/27884\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Newer agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Taxanes, irinotecan and vinorelbine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer agents that have been tested in esophageal and gastric carcinomas include the taxanes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/11-13,35-47\">",
"     11-13,35-47",
"    </a>",
"    ]. The following table summarizes response rates from selected trials of these drugs as single agents in esophageal and gastric cancers (",
"    <a class=\"graphic graphic_table graphicRef75160 \" href=\"mobipreview.htm?17/20/17740\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, response rates are slightly higher than seen with older agents, but toxicity is prominent in many cases, and median survival durations have not been consistently over nine months with any agent. As examples, taxanes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , a topoisomerase I inhibitor, are active as single agents in gastric cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In multiple studies, monotherapy with either single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      produces response rates in the range of 15 to 24 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/12,13,35,36,45,48\">",
"       12,13,35,36,45,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In two reports involving 83 previously untreated patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      was associated with response rates of 14 and 20 percent respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/44,49\">",
"       44,49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although relatively nontoxic, weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was minimally active in a phase II study of 29 patients with previously treated or untreated metastatic upper GI adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/40\">",
"     40",
"    </a>",
"    ]. The response rate was 7 percent, and median progression-free survival (PFS) was only 1.9 months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Oral fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several orally active fluoropyrimidines are available, which, as single agents, are associated with response rates as high as 41 percent, but median survival durations have not exceeded nine months in any report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/50-57\">",
"     50-57",
"    </a>",
"    ]. Phase III studies have demonstrated equivalence between infusional 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , and S-1:",
"   </p>",
"   <p>",
"    S-1 is an oral formulation of the following components in a 1:0.4:1 ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/52\">",
"     52",
"    </a>",
"    ]: tegafur (ftorafur), the prodrug for cytotoxic 5-FU; 5-chloro-2,4-dihydroxypyridine, an inhibitor of dihydropyrimidine dehydrogenase (DPD), which prevents its degradation in the gastrointestinal tract, thus prolonging its half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/53\">",
"     53",
"    </a>",
"    ]; and potassium oxonate, a specific inhibitor of one of the enzymes, orotate phosphoribosyl transferase, which phosphorylates 5-FU in the intestine. Phoshorylated 5-FU is thought to be mainly responsible for treatment-related diarrhea.",
"   </p>",
"   <p>",
"    The efficacy of S-1 alone (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    orally twice a day on days 1 to 28, every six weeks) was shown in the phase III JCOG 9912 trial which was powered to demonstrate noninferiority of S-1 alone and superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    over infusional 5-FU monotherapy in 704 patients with unresectable or recurrent, previously untreated gastric adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the primary endpoint, PFS, S-1 was not inferior to infusional 5-FU, and there were trends suggesting superiority over infusional 5-FU (median PFS 4.2 versus 2.9 months). The response rate was higher with S1 than with 5-FU (28 versus 9 percent), and median overall survival was 11.4 versus 12.3 months. S-1 was associated with more grade 3 or 4 diarrhea than 5-FU (8 versus &lt;1 percent). Otherwise, the side effect profile was comparable.",
"   </p>",
"   <p>",
"    S-1 monotherapy (40 to 60 mg twice daily on days 1 to 28, every six weeks) was directly compared to single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily days 1 to 14, every 21 days) in a Korean randomized phase II trial involving 91 elderly patients with previously untreated advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/55\">",
"     55",
"    </a>",
"    ]. The two regimens were comparable with respect to overall response rate (29 versus 20 percent for S-1, and capecitabine respectively), median TTP (4.2 versus 4.7 months), overall survival (median 8.2 versus 9.5 months), and treatment-related toxicity, with the exception of hand-foot syndrome (zero versus 7 percent).",
"   </p>",
"   <p>",
"    Thus, S-1 monotherapy appears active and well-tolerated in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    - and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -refractory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/56\">",
"     56",
"    </a>",
"    ], but efficacy is more modest in patients with a poor performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/57\">",
"     57",
"    </a>",
"    ]. S-1 is not yet available in the United States. Efficacy of combination regimens of S1 plus cisplatin are discussed below (see",
"    <a class=\"local\" href=\"#H16\">",
"     'S-1'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher response rates (up to 65 percent) are reported in phase II trials evaluating combination therapy in patients with advanced esophageal and gastric cancer. However, almost without exception, response rates have been lower in the setting of randomized trials. Furthermore, whether higher response rates seen with combination as compared to single agent chemotherapy translate into longer response duration or survival remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Combination versus single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the few randomized trials that have been undertaken comparing monotherapy with combination regimens, combination therapy has been associated with better response rates but no clinically meaningful survival differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/26,58-60\">",
"     26,58-60",
"    </a>",
"    ]. However, modern regimens such as ECF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-fluorouracil) and taxane- and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -based combinations have not been tested in such studies. A meta-analysis that included trials performed in patients with advanced gastric cancer (predominantly using older combination regimens) concluded that first-line combination therapy was associated with a modest but statistically significant survival benefit when compared to single agent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ]. The hazard ratio for death was 0.82 (95% CI 0.74-0.90) in favor of combination chemotherapy, but this translated into only a 1.5 month survival advantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Older cisplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     Cisplatin",
"    </a>",
"    has been combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    . Most reported series have included small numbers of patients with either advanced locoregional or metastatic disease and SCC histology. Reported response rates are between 15 and 53 percent, and median survival durations range from 3.2 to 9.8 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/61-68\">",
"     61-68",
"    </a>",
"    ]. The following table summarizes the results of some of these trials (",
"    <a class=\"graphic graphic_table graphicRef68417 \" href=\"mobipreview.htm?27/0/27660\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cisplatin plus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-FU has been one of the most commonly used regimens in both metastatic and localized esophageal cancer due to its activity and well-established toxicity profile. In a randomized phase II study, 88 patients with locally advanced or metastatic esophageal SCC were assigned to either single agent cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every 21 days) or the same dose of cisplatin combined with 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day by continuous infusion, days 1 to 5) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/26\">",
"     26",
"    </a>",
"    ]. Although the response rate was higher for the doublet (35 versus 19 percent), the median survival (33 versus 28 weeks) and one-year survival rate (34 versus 27 percent) were not significantly different. Furthermore, there was a 17 percent treatment-related mortality rate (primarily due to sepsis and cerebrovascular episodes) in the cisplatin and 5-FU arm.",
"   </p>",
"   <p>",
"    A similar degree of activity (response rate of 27 percent; median survival months) was reported with much less toxicity (treatment-related mortality rate 3 percent) in a second study that used split dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day days 1 to 5) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium and bolus 5-FU (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for five days) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU plus an anthracycline are discussed below (see",
"    <a class=\"local\" href=\"#H18\">",
"     '5-FU/anthracycline regimens'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cisplatin plus newer fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to its potential hazards and inconvenience, efforts have been made to replace infusional 5-FU with orally administered fluoropyrimidine derivatives such as uracil-ftorafur (UFT), S1, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Ftorafur",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ftorafur (Tegafur) is a 5-FU prodrug that is converted into 5-FU by liver microsomes. UFT consists of ftorafur plus uracil, a potent inhibitor of dihydropyrimidine dehydrogenase (DPD), the main catabolic enzyme of 5-FU. Inhibition of DPD increases the amount of 5-FU that is available for its antitumor activity.",
"   </p>",
"   <p>",
"    In a phase II trial of 37 patients with advanced esophageal cancer treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , oral UFT and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    calcium, the overall response rate was 46 percent, and median survival was 16 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/70\">",
"     70",
"    </a>",
"    ], with myelosuppression being the most important toxicity. Tegafur is not available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     S-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent DPD inhibitor) and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, which is thought responsible for treatment-related diarrhea). (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Newer agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    S-1 in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is highly active in Asian patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/59,71\">",
"     59,71",
"    </a>",
"    ]. A report from the SPIRITS trial supports a significant benefit for combined S1 plus cisplatin over S1 alone in terms of both response rate (54 versus 31 percent) and median survival (13 versus 11 months, p = 0.04) in an Asian population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/59\">",
"     59",
"    </a>",
"    ]. Rates of grade 3 or 4 neutropenia (40 versus 11 percent), anemia (26 versus 4 percent), nausea (11 versus 1 percent), and anorexia (30 versus 6 percent) were also significantly higher.",
"   </p>",
"   <p>",
"    Ftorafur is metabolized differently in Western and Asian populations on account of polymorphic differences in the CYP2A6 gene; as a result, the maximally tolerated dose (MTD) differs. Western experience with combined S-1 plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for advanced gastric cancer is limited but also promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. As an example, in a multicenter phase II trial in which 72 patients received S-1 (25 mg",
"    <span class=\"nowrap\">",
"     /m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily on days 1 through 21) plus cisplatin (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) every 28 days, the objective response rate was 55 percent, and the median duration of response was &gt;5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/73\">",
"     73",
"    </a>",
"    ]. The safety profile was favorable; the most frequent grade 3 or 4 toxicities were",
"    <span class=\"nowrap\">",
"     fatigue/asthenia",
"    </span>",
"    (24 percent), emesis (17 percent), nausea (15 percent), diarrhea (13 percent) and neutropenia (19 percent).",
"   </p>",
"   <p>",
"    The results from the phase II S-1 plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    trial led to the initiation of a global prospective randomized phase III trial, the FLAGS (First-Line Advanced Gastric Cancer Study) trial, which randomly assigned 1053 patients to cisplatin plus either 5-FU or S-1. Median overall survival (the primary endpoint) was not significantly inferior with",
"    <span class=\"nowrap\">",
"     cisplatin/S-1",
"    </span>",
"    as compared to",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU",
"    </span>",
"    (8.6 versus 7.9 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/74\">",
"     74",
"    </a>",
"    ]. Furthermore,",
"    <span class=\"nowrap\">",
"     cisplatin/S1",
"    </span>",
"    had a more favorable side effect profile than",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU",
"    </span>",
"    (grade 3 or 4 neutropenia in 32 versus 64 percent, stomatitis in 1 versus 14 percent, and hypokalemia in 4 versus 11 percent), and fewer treatment-related deaths (2.5 versus 4.9 percent). The lower cisplatin dose intensity in the",
"    <span class=\"nowrap\">",
"     cisplatin/S-1",
"    </span>",
"    arm (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    versus 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 with",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU)",
"    </span>",
"    may have contributed to the survival and toxicity results.",
"   </p>",
"   <p>",
"    This study was not seen as a success, as many expected superiority of",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     /S1",
"    </span>",
"    over",
"    <span class=\"nowrap\">",
"     cisplatin/FU",
"    </span>",
"    based upon the JCOG 9912 study, described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Oral fluoropyrimidines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    S-1 is not commercially available in the US.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a unique, rationally designed oral fluoropyrimidine that undergoes a three-step enzymatic activation process, the last of which occurs selectively within the tumor tissue itself. The drug passes intact through the bowel and reaches the liver where it is converted first into 5-deoxyfluorocytidine by a carboxylesterase and then to 5-deoxfluorouridine that reaches the tumor where it is transformed into its active form, 5-FU, by thymidine phosphorylase.",
"   </p>",
"   <p>",
"    The comparable efficacy of regimens substituting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for infusional 5-FU was directly studied in the REAL-2 trial, a randomized phase III study in which 1002 patients with advanced gastric cancer were assigned, using a 2 x 2 factorial design, to three week cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and either capecitabine (625",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily, ECX) or infusional 5-FU (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, ECF), or epirubicin (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and either capecitabine (same doses as above, EOX) or infusional 5-FU (same doses as above, EOF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"     75",
"    </a>",
"    ]. The study was sufficiently powered to demonstrate noninferiority.",
"   </p>",
"   <p>",
"    There were no significant differences among the groups in terms of objective response rate (41, 42, 46, and 48 percent with ECF, EOF, ECX, and EOX, respectively) or progression-free survival. There was a statistically significant improvement in overall survival when outcomes of both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    -containing arms were combined and compared to both 5-FU-containing arms (hazard ratio for death 0.86, 95% CI 0.8 to 0.99). Toxic effects of both drugs were similar. The authors concluded that the substitution of capecitabine for infusional 5-FU did not compromise outcomes.",
"   </p>",
"   <p>",
"    The results of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing arms of the REAL2 trial are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Oxaliplatin combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similar results were noted in a randomized trial comparing 21-day cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 days) or infusional 5-FU (800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day days 1 to 5) in 316 patients with advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/76\">",
"     76",
"    </a>",
"    ]. As with the REAL-2 study, this trial was also powered to demonstrate noninferiority. Median PFS (5.6 versus 5.0 months, respectively) and overall survival (10.5 versus 9.3 months, respectively) were comparable in both groups, as was the incidence and severity of adverse effects.",
"   </p>",
"   <p>",
"    A meta-analysis of these two trials concluded that, compared to 5-FU combinations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    combinations were associated with higher response rates (odds ratio 1.38, 95% CI 1.10-1.73) and better overall survival (hazard ratio for death 0.87, 95% CI 0.77-0.98) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taken together, these data suggest that the efficacy of regimens that substitute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    for infusional 5-FU are at least as good. However, while the use of capecitabine allows patients to avoid infusion pumps and a central venous catheter, the out of pocket cost of capecitabine is significantly higher than 5-FU. This may be an important issue for patients whose health insurance coverage requires significant out of pocket expense for the capecitabine. Additionally, an oral chemotherapy agent requires both patient motivation and reliable upper GI tract function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     5-FU/anthracycline regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of 5-FU plus an anthracycline (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    ) has been studied in multiple phase II trials in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    <span class=\"nowrap\">",
"     (FAM/FEM),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    <span class=\"nowrap\">",
"     (FAMTX/FEMTX)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    <span class=\"nowrap\">",
"     (ECF/ACF)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/17,78-95\">",
"     17,78-95",
"    </a>",
"    ]. Many of these early trials were predominantly conducted in patients with advanced gastric adenocarcinoma.",
"   </p>",
"   <p>",
"    Several of these regimens have been compared in randomized trials, many of which enrolled a combined population of esophageal, gastric, and EGJ cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     FAM and FAMTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially promising results with 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C (FAM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/78\">",
"     78",
"    </a>",
"    ] were not confirmed in a randomized trial comparing FAM, FA, or 5-FU alone in 305 patients with advanced gastric or pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, initially encouraging results with high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 5-fluorouracil plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    (FAMTX, 58 percent partial responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/17\">",
"     17",
"    </a>",
"    ]) were not confirmed in subsequent trials (30 to 40 percent partial responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/86-90\">",
"     86-90",
"    </a>",
"    ]). FAMTX fell out of favor when a randomized trial demonstrated better results with ECF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'ECF'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     EAP and ELF",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with FAMTX, initially higher response rates in early studies using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (EAP, 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/91\">",
"     91",
"    </a>",
"    ]) were not confirmed in a later report (response rate 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/92\">",
"     92",
"    </a>",
"    ]). In a trial of EAP versus FAMTX in 60 patients with advanced gastric cancer, EAP was associated with a significantly lower response rate and a higher rate of toxic deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ELF regimen (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , 5-FU, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) was initially developed for patients over the age of 65 and those with active cardiac disease thought unable to tolerate an",
"    <span class=\"nowrap\">",
"     anthracycline/platinum",
"    </span>",
"    combination such as EAP. Although initial reports suggested a high response rate (53 percent), they were not confirmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/93-96\">",
"     93-96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     ECF",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECF (",
"    <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"     table 4",
"    </a>",
"    ) was associated with a response rate of 71 percent in a report involving 128 patients with advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/82\">",
"     82",
"    </a>",
"    ]. In a subsequent randomized trial, 274 patients with advanced esophagogastric adenocarcinoma or undifferentiated cancer were randomly assigned to ECF or FAMTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/8\">",
"     8",
"    </a>",
"    ]. ECF was associated with a superior response rate (45 versus 21 percent) and median survival (8.9 versus 5.7 months). ECF caused more alopecia and nausea while FAMTX was associated with more hematologic toxicity and infections. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major drawback to the ECF regimen is the need for a central venous line. In this randomized trial, central venous line complications occurred in 15 percent of those receiving ECF.",
"   </p>",
"   <p>",
"    ECF was compared to the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every six weeks),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks), and infusional 5-FU (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily) (MCF) in 580 patients with advanced, previously untreated esophagogastric cancer (squamous cell, adenocarcinoma, or undifferentiated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall response rates were similar (42 versus 44 percent for ECF and MCF, respectively) as was median survival (9.4 versus 8.7 months) and toxicity profile; however, quality of life analysis favored ECF.",
"   </p>",
"   <p>",
"    The ECF regimen has been considered by many to be the reference regimen for first-line treatment of advanced upper GI cancer, at least in the US and Europe. The importance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    to this regimen was suggested in the meta-analysis described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ]. Compared to patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU alone, the addition of an anthracycline significantly improved survival (hazard ratio for death 0.82, 95% CI 0.73-0.92). However, newer regimens that combine short-term high-dose infusional 5-FU with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    modulation (eg, FOLFOX) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus cisplatin may be more effective than older regimens in which cisplatin was combined with bolus 5-FU alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/97-100\">",
"     97-100",
"    </a>",
"    ]. A preliminary report of CALGB 80403, a randomized phase II trial in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    was added to ECF,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus cisplatin, or FOLFOX, concluded that response rates, PFS, and median overall survival were similar in the ECF and FOLFOX groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/101\">",
"     101",
"    </a>",
"    ]. Thus, the contribution of the anthracycline to the benefit of the ECF regimen remains an unanswered question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     ECF and the REAL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The REAL trial was a landmark large randomized trial reported in 2008 that compared four different chemotherapy regimens in 1002 patients with advanced gastric cancer: ECF, EC plus the oral fluoropyrimidine",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (ECX, (",
"    <a class=\"graphic graphic_table graphicRef53899 \" href=\"mobipreview.htm?36/58/37806\">",
"     table 5",
"    </a>",
"    )), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and either infusional 5-FU (EOF) or capecitabine (EOX, (",
"    <a class=\"graphic graphic_table graphicRef75288 \" href=\"mobipreview.htm?35/50/36654\">",
"     table 6",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"     75",
"    </a>",
"    ]. The study was sufficiently powered to demonstrate noninferiority. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As noted above, the trial showed that outcomes were comparable when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    was substituted for infusional 5-FU in the ECF regimen, a finding that was reinforced in a subsequent meta-analysis of this and one other trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Capecitabine'",
"    </a>",
"    above.) They also showed (as did the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ]) that outcomes were comparable when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    was substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in the ECF regimen. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Oxaliplatin combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    However, when the four groups were considered separately, median survival in patients treated with EOX was modestly longer when compared to ECF (median 11.2 versus 9.9 months, hazard ratio 0.80, 95% CI 0.66 to 0.97). These data have led some to conclude that EOX is preferred over ECF for first-line therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Taxane-based combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several taxane-containing regimens have been studied, none of which has emerged as clearly superior to any other or to modern",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combinations because so few randomized trials have been carried out [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/102-106\">",
"     102-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Paclitaxel regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many investigators have combined",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    for the treatment of advanced esophageal and gastric cancer using multiple different administration schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/15,107-110\">",
"     15,107-110",
"    </a>",
"    ]. In two studies, an every two week or every three week regimen of cisplatin plus paclitaxel was associated with a response rates of 43 and 49 percent, and median survival durations of 9 and 13 months, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/107,110\">",
"     107,110",
"    </a>",
"    ]. The major toxicity encountered was neutropenia. Other treatment schedules have been associated with comparable antitumor activity but more toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of 5-FU to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was associated with severe neutropenia in 58 percent of patients in one phase II trial (despite the routine use of prophylactic growth factors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/14\">",
"     14",
"    </a>",
"    ]. Rates of grade 3 or 4 thrombocytopenia were 15 percent, and debilitating neuropathy developed in 18 percent. More recently, every other week paclitaxel plus short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    yielded favorable antitumor activity and a better toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A better tolerated combination may be",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    . In two studies of 25 patients with gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/112\">",
"     112",
"    </a>",
"    ] and 33 with esophageal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/113\">",
"     113",
"    </a>",
"    ], the overall response rates were 33 and 43 percent, respectively. Median survival was less than nine months in both studies.",
"   </p>",
"   <p>",
"    The combination of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is active in advanced or metastatic upper GI cancer with an acceptable side effect profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. In one report, paclitaxel (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose), cisplatin (15",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose) and etoposide (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose) was administered twice weekly for three of every four weeks to 25 patients with locally advanced (n = 18) or metastatic upper GI tract cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/114\">",
"     114",
"    </a>",
"    ]. All 22 evaluable patients had an objective radiographic response, three complete. The median overall survival was 12.5 months. Another combined series of 33 patients with gastric or esophagogastric junction (EGJ) cancer treated with the same regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/115\">",
"     115",
"    </a>",
"    ] showed an objective response rate of 70 percent, and median survival of 10 months. Grade 3 or 4 toxicity was observed in 35 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108248034\">",
"    <span class=\"h3\">",
"     Docetaxel regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    combinations with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    are active in advanced gastric and esophageal squamous cell cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/102-104,106,116-126\">",
"     102-104,106,116-126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108248051\">",
"    <span class=\"h4\">",
"     DCF (TCF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     Docetaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU (the DCF or TCF regimen, (",
"    <a class=\"graphic graphic_table graphicRef73324 \" href=\"mobipreview.htm?29/18/29998\">",
"     table 7",
"    </a>",
"    )) was compared to cisplatin and 5-FU alone in a multinational TAX-325 trial that enrolled 457 patients with chemotherapy-naive advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/102\">",
"     102",
"    </a>",
"    ]. Patients received either 21-day cycles of cisplatin (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus infusional 5-FU (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, days 1 to 5) and docetaxel (75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) or 28-day cycles of cisplatin (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus infusional 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day days 1 to 5).",
"    <br/>",
"    <br/>",
"    The group receiving docetaxel did significantly better in terms of response rates (37 versus 25 percent), time to tumor progression (TTP, 5.6 versus 3.7 months) and two-year survival (18 versus 9 percent). Although the incidence of grade 3 or 4 diarrhea (20 versus 8 percent) and neutropenia (30 versus 14 percent) was higher with triple therapy, rates of any grade 3 or 4 toxicity during therapy were high in both groups (81 and 75 percent, respectively). DCF showed significant improvement compared to",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU",
"    </span>",
"    in measures of clinical benefit, including time to definitive worsening of performance status (median 6.1 versus 4.8 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/124\">",
"     124",
"    </a>",
"    ] and in the duration of preserved quality of life (as assessed by the time to 5 percent deterioration in global health status) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/125\">",
"     125",
"    </a>",
"    ]. There were also trends toward a better outcome with DCF, including longer time to definitive weight loss and time to definitive worsening of appetite [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these results,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    is approved in the US and Europe, in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and 5-FU, for the treatment of advanced gastric cancer. However, the contribution of cisplatin remains uncertain. Similar results (overall response rate 38 percent, median survival 9.5 months) are reported using docetaxel and infusional 5-FU without cisplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether DCF is more effective or safer than ECF is unclear. The DCF regimen was directly compared to ECF in a randomized phase II trial involving 81 patients with chemotherapy-naive advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/103\">",
"     103",
"    </a>",
"    ]. Although the trial was not adequately powered to detect superiority, there were trends favoring DCF over ECF in terms of response rate (37 versus 26 percent) and median overall survival (10.4 versus 8.3 months). However, severe neutropenia was more common with DCF (80 versus 59 percent), as was febrile neutropenia (41 versus 18 percent). G-CSF was only used in 10 percent of the DCF cycles.",
"   </p>",
"   <p>",
"    A modified schedule for DCF is associated with preserved efficacy and improved tolerability (",
"    <a class=\"graphic graphic_table graphicRef79612 \" href=\"mobipreview.htm?35/41/36510\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/127\">",
"     127",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108248081\">",
"    <span class=\"h4\">",
"     Docetaxel plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    have produced fairly consistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/119-121,123\">",
"     119-121,123",
"    </a>",
"    ]. In four published reports using capecitabine 825",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily through the entire cycle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/119\">",
"     119",
"    </a>",
"    ] or 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/120,121\">",
"     120,121",
"    </a>",
"    ] in conjunction with docetaxel 75",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/119,120,123\">",
"     119,120,123",
"    </a>",
"    ] or 36",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/121\">",
"     121",
"    </a>",
"    ], response rates have ranged from 39 to 46 percent. The median TTP was between 4.2 and 6.1 months, and median overall survival durations were between 8.4 and 15.8 months.",
"   </p>",
"   <p>",
"    Toxicity rates have been variable. One study reported 10 percent grade 3 or 4 neutropenia, 13 percent hand-foot syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/120\">",
"     120",
"    </a>",
"    ], while another noted grade 3 stomatitis as the worst toxicity and four patients with treatment-related pneumonitis (rate 8.5 percent; all responded to steroid treatment) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/121\">",
"     121",
"    </a>",
"    ]. The trial reporting the longest median survival duration (15.8 months) also reported the worst profile of grade 3 or 4 toxicities (neutropenia in 42 percent, hand foot syndrome in 29 percent, diarrhea and sensory neuropathy in 13 percent each) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A phase II trial investigated the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    to the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"      docetaxel",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"      capecitabine",
"     </a>",
"    </span>",
"    regimen in 25 patients with chemotherapy-naive esophageal or gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/128\">",
"     128",
"    </a>",
"    ]. The trial was uncontrolled and the sample size was small, but the results with triple drug therapy did not seem better than those achieved in trials of",
"    <span class=\"nowrap\">",
"     capecitabine/docetaxel",
"    </span>",
"    alone. The objective response rate was 48 percent, median survival was only eight months, and 48 percent of patients had a grade 3 or 4 toxic event during therapy.",
"   </p>",
"   <p>",
"    Whether either of these regimens is superior to ECF is unknown, as randomized trials are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Oxaliplatin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    combinations have been most extensively studied for metastatic colorectal cancer, they are also active in the treatment of esophagogastric cancer. A variety of different regimens have been studied in phase II trials (FOLFOX, EOF, XELOX [CAPOX], S1 plus oxaliplatin), all of which are associated with response rates in the range of 40 to 67 percent, with median survival durations between 8 and 15 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/98,101,129-138\">",
"     98,101,129-138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"     \"Treatment protocols for esophagogastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two phase III trials have directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -containing regimens (including ECF), both of which suggest at least comparable efficacy when oxaliplatin is substituted for cisplatin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75,98\">",
"     75,98",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      and a fluoropyrimidine was investigated in the previously described REAL-2 trial, a randomized phase III comparison of ECF, ECX (epirubicin, cisplatin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      ), EOF (epirubicin, oxaliplatin, infusional 5-FU), and EOX (epirubicin, oxaliplatin, capecitabine) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"       75",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Progression-free survival (PFS) and response rates did not differ significantly among the four regimens. Survival in the two oxaliplatin-containing arms was comparable to that achieved with the two cisplatin-based regimens. However, in the secondary analysis, when the four groups were considered separately, median survival in patients treated with EOX was modestly longer when compared to ECF (median 11.2 versus 9.9 months, hazard ratio 0.80, 95% CI 0.66 to 0.97).",
"      <br/>",
"      <br/>",
"      While oxaliplatin-treated patients had significantly less grade 3 to 4 neutropenia, alopecia, thromboembolism, and renal dysfunction, they had significantly more peripheral neuropathy and diarrhea.",
"     </li>",
"     <li>",
"      Similar outcomes substituting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      were also found in a phase III trial comparing FLO regimen (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and oxaliplatin 85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      followed by",
"      <sup>",
"      </sup>",
"      infusional 5-FU 2600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours, with all drugs repeated every 14 days) versus FLP (5-FU 2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours plus leucovorin 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly and cisplatin 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 14 days) in 220 patients with metastatic gastroesophageal adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/98\">",
"       98",
"      </a>",
"      ]. There were no statistically significant differences between the two arms in terms of median PFS (the primary endpoint, 5.7 versus 3.9 months), response rate (35 versus 25 percent), or median survival (10.7 versus 8.8 months). FLO was associated with significantly less nausea and vomiting, fatigue, renal toxicity and alopecia, but more grade 3 or 4 sensory neuropathy (14 versus 2 percent, respectively).",
"     </li>",
"     <li>",
"      As noted above, a preliminary report of CALGB 80403, a randomized phase II trial comparing ECF versus FOLFOX, both in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , concluded that response rates, PFS, and median overall survival were similar with either regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    is at least as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in combination regimens for patients with advanced esophagogastric cancer. A meta-analysis of the REAL-2 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"     75",
"    </a>",
"    ] plus two other randomized phase II trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/98,139\">",
"     98,139",
"    </a>",
"    ] that compared oxaliplatin-based and cisplatin-based regimens showed that oxaliplatin was associated with significant improvements in PFS (HR 0.88, 95% CI 0.80 to 0.98) and overall survival (HR for death 0.88, 95% CI 0.78 to 0.99), and less neutropenia, anemia, alopecia and thromboembolic events, but more neurotoxicity and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Irinotecan-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the previously described meta-analysis, the comparison of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    -containing versus non-irinotecan-containing regimens (mainly",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"     )",
"    </span>",
"    revealed a nonstatistically significant trend toward better survival with irinotecan (hazard ratio [HR] for death 0.86, 95% CI 0.73- 1.02) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    has been combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , and fluoropyrimidines. There are no phase III trials comparing an irinotecan-based combination with a cisplatin-based triplet regimen such as ECF, DCF (TCF), or EOX.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Irinotecan plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is active and well tolerated, particularly when administered weekly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/54,141-145\">",
"     54,141-145",
"    </a>",
"    ]. In one report, 38 patients with metastatic gastric cancer received irinotecan and cisplatin, both administered weekly for four of every six weeks (",
"    <a class=\"graphic graphic_table graphicRef62115 \" href=\"mobipreview.htm?21/24/21902\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/143\">",
"     143",
"    </a>",
"    ]. The objective response rate was 58 percent and the median survival was nine months. The most common grade 3 or 4 toxicities were neutropenia, second cycle diarrhea, and fatigue (27, 3, and 41 percent, respectively).",
"   </p>",
"   <p>",
"    The superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 every 28 days) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 15) as compared to infusional 5-FU alone was shown in the phase III JCOG 9912 trial, described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/54\">",
"     54",
"    </a>",
"    ]. Response rate (38 versus 9 percent) and progression-free survival (4.8 versus 2.9 months) were both significantly higher with",
"    <span class=\"nowrap\">",
"     cisplatin/irinotecan.",
"    </span>",
"    However, rates of grade 3 or 4 toxicity were also significantly higher (neutropenia 65 versus 1 percent, hyponatremia 23 versus 6 percent, anorexia 33 versus 13 percent, diarrhea, 9 versus &lt;1 percent, and nausea 21 versus 7 percent). (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Oral fluoropyrimidines'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Irinotecan plus docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    are active but toxic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/146-148\">",
"     146-148",
"    </a>",
"    ]. As an example, the combination of cisplatin (25",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    irinotecan (65",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    and docetaxel (30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    all given on days 1 and 8 every 21 days, was tested in 56 patients with advanced esophageal or gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/146\">",
"     146",
"    </a>",
"    ]. Toxicity was prohibitive in the first 18 patients, and the irinotecan dose was reduced to 50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Overall, there were 30 objective responses (three complete) (response rate 54 percent). Median progression-free and overall survival were 7.1 and 11.9 months, respectively. The grade 3 or 4 toxicities associated with lower dose irinotecan were diarrhea, neutropenia, nausea, fatigue, and",
"    <span class=\"nowrap\">",
"     thrombosis/embolism",
"    </span>",
"    in 26, 21, 18, 16, and 13 percent of patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Irinotecan plus fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term infusional 5-FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (the FOLFIRI regimen, (",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"     table 10",
"    </a>",
"    )) was originally developed for metastatic colorectal cancer. The superiority of FOLFIRI over",
"    <span class=\"nowrap\">",
"     5-FU/leucovorin",
"    </span>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    was shown in a French randomized phase II trial involving 136 patients with advanced gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/149\">",
"     149",
"    </a>",
"    ]. Compared to",
"    <span class=\"nowrap\">",
"     5-FU/leucovorin",
"    </span>",
"    alone or with cisplatin, the group receiving FOLFIRI had significantly higher response rates (40 versus 13 and 27 percent, respectively) and significantly longer median PFS (6.9 versus 3.2 and 4.9 months, respectively) as well as overall survival (11.3 versus 6.8 and 9.5 months, respectively).",
"   </p>",
"   <p>",
"    Roughly similar outcomes (response rates 42 to 44 percent, median survival 10 to 12 months) were obtained using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in combination with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in three phase II studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/150-152\">",
"     150-152",
"    </a>",
"    ], and with irinotecan plus S-1 in a phase III trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether results with FOLFIRI or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or S-1 are better or less toxic than can be achieved using ECF or EC plus capecitabine will require the performance of randomized trials. The only randomized phase III trial of irinotecan in gastric cancer compared FLI (irinotecan 80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (folinic acid) 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours, followed by 5-FU 2000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 22 hours, weekly for six weeks) versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) followed by 5-FU (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    continuous infusion over five days) every four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/154\">",
"     154",
"    </a>",
"    ]. There was no significant benefit of FLI over",
"    <span class=\"nowrap\">",
"     cisplatin/5-FU",
"    </span>",
"    (median survival 9 and 8.7 months respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Irinotecan plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    are highly efficacious and reasonably tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/136,155-157\">",
"     136,155-157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase II trial of first-line FOLFOXIRI (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      day 1, and 5-fluorouracil 2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      by continuous infusion over 48 hours starting day 1, every two weeks) was conducted in 45 patients with metastatic gastric cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/157\">",
"       157",
"      </a>",
"      ]. Independent review confirmed an impressive objective response rate of 67 percent, and median TTP and median survival were 9.6 and 14.8 months, respectively. Grade 3 or 4 toxicities included neutropenia (12 percent) and vomiting (8 percent).",
"     </li>",
"     <li>",
"      Another phase II trial evaluated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      in 40 patients with previously untreated metastatic gastric or EGJ adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/136\">",
"       136",
"      </a>",
"      ]. Overall response rate was 50 percent, and the median time to progression and overall survival were 6.5 and 11.5 months, respectively. Grade 3 or 4 toxicities included neutropenia (48 percent, 8 percent with fever), and diarrhea, vomiting, and mucositis in 10, 8, and 5 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BIOLOGIC AGENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Agents targeting HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 7 to 22 percent of esophagogastric cancers overexpress the type II EGFR (HER2), a similar percentage to that seen in breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/158-163\">",
"     158-163",
"    </a>",
"    ]. HER2 positivity is at least as common in esophageal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/164-166\">",
"     164-166",
"    </a>",
"    ] as in gastric [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/158-160\">",
"     158-160",
"    </a>",
"    ] adenocarcinomas. HER2 positivity is more common with intestinal-type than with diffuse type gastric cancers (32 versus 6 percent in one analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/167\">",
"     167",
"    </a>",
"    ]). As in breast cancer, there is a high concordance between HER2 results obtained on the primary tumor and metastatic sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/168-170\">",
"     168-170",
"    </a>",
"    ]. In contrast to breast cancer, there is no association between HER2 expression and prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/171\">",
"     171",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link\">",
"     \"HER2 and predicting response to therapy in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=see_link\">",
"     \"Pathology and molecular pathogenesis of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    , a therapeutic anti-HER2 monoclonal antibody (MoAb), is approved for treatment of breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in advanced HER2-positive adenocarcinoma of the stomach or esophagogastric junction (EGJ) was addressed in the phase III ToGA trial, which compared standard chemotherapy (six courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus either infusional 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ) with and without trastuzumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    loading dose, then 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every three weeks until disease progression) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/162\">",
"     162",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link&amp;anchor=H958003#H958003\">",
"     \"Treatment protocols for esophagogastric cancer\", section on 'Trastuzumab-containing regimens for HER2-positive advanced disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All tumors were screened for HER2 status by both immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), and patients were eligible if their tumor was positive by either IHC (ie, showing 3+ expression) or FISH (ie, showing a",
"    <span class=\"nowrap\">",
"     HER2/CEP17",
"    </span>",
"    ratio of 2 or greater). Among enrolled patients (n = 594 of the 3807 screened), almost all tumors were FISH-positive, whereas protein expression by IHC varied (47 percent 3+, 30 percent 2+, and 22 percent 0 or 1+). &nbsp;",
"   </p>",
"   <p>",
"    The objective response rate was significantly higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (47 versus 35 percent). At a median follow-up of 17.1 to 18.6 months, median overall survival (the primary endpoint) was significantly better with trastuzumab (13.8 versus 11.1 months). The toxicities in the two arms were comparable, except that a higher number of trastuzumab-treated patients had grade 3 or 4 diarrhea (9 versus 4 percent) and an asymptomatic decrease in left ventricular ejection fraction (LVEF, 5 versus 1 percent). Only one patient developed grade 3 to 4 heart failure (versus two in the control group). Exploratory analysis in subgroups defined by protein expression suggested that trastuzumab was most effective in prolonging survival in the subgroup of patients with IHC 3+ tumors (hazard ratio [HR] for death 0.66, 95% CI 0.50 to 0.87), less effective in patients with IHC 2+ tumors (HR 0.78, 95% CI 0.55 to 1.10), and ineffective in those with HER2 gene-amplified (ie, FISH-positive) but non protein-expressing (IHC 0 or 1+) tumors.",
"   </p>",
"   <p>",
"    Based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was approved, in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and a fluoropyrimidine, for the treatment of patients with metastatic HER2-overexpressing gastric or EGJ adenocarcinomas who have not received prior treatment for metastatic disease. Patients with advanced gastric cancer who are potential candidates for trastuzumab should be screened to determine HER2 status.",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    was studied with",
"    <span class=\"nowrap\">",
"     fluoropyrimidine/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"      cisplatin",
"     </a>",
"    </span>",
"    regimens in the randomized ToGA trial, many clinicians incorporate trastuzumab into their first-line regimen of choice (including cisplatin-free regimens such as FOLFOX) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/172\">",
"     172",
"    </a>",
"    ], despite the absence of published data to support this practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link&amp;anchor=H15190339#H15190339\">",
"     \"Treatment protocols for esophagogastric cancer\", section on 'Regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103667884\">",
"    <span class=\"h4\">",
"     Assessment of HER2 status in upper GI cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2 status in esophagogastric cancers can be assessed using the same FDA-approved HER2 assays as for breast tumors. These typically include an assessment of HER2 protein expression by immunohistochemical staining (IHC) and",
"    <em>",
"     HER2",
"    </em>",
"    gene amplification by fluorescence in situ hybridization (FISH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H6#H6\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Assays for HER2 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in breast cancer, protein expression is categorized into one of four levels (0, 1+, 2+, 3+) based upon a composite score that incorporates the intensity of staining and the percentage of cancer cells demonstrating that intensity (",
"    <a class=\"graphic graphic_table graphicRef83375 \" href=\"mobipreview.htm?19/38/20076\">",
"     table 11",
"    </a>",
"    ). However, interpretive criteria for determining the IHC score in esophagogastric cancers are distinct in two ways from breast tumors, underscoring the importance of utilizing tumor-specific criteria in clinical practice (",
"    <a class=\"graphic graphic_table graphicRef83375 \" href=\"mobipreview.htm?19/38/20076\">",
"     table 11",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H7#H7\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Recommendations of the ASCO/CAP consensus panel'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HER2 protein expression in esophagogastric carcinomas tends to spare the digestive luminal membrane and results in membrane staining that is not completely circumferential [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/173,174\">",
"       173,174",
"      </a>",
"      ]. As a result, an esophagogastric cancer with only partially circumferential (ie, &ldquo;basolateral&rdquo; or &ldquo;lateral&rdquo;) membrane staining can still be categorized as 2+ or 3+ (",
"      <a class=\"graphic graphic_table graphicRef83375 \" href=\"mobipreview.htm?19/38/20076\">",
"       table 11",
"      </a>",
"      ). By contrast, a breast tumor must demonstrate complete circumferential membrane staining to be designated as 2+ or 3+. Accordingly, applying breast cancer criteria to esophagogastric tumors may result in an underestimation of HER2 expression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/158,173,174\">",
"       158,173,174",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A greater degree of intratumoral HER2 heterogeneity has been reported in esophagogastric than in breast tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/173,174\">",
"       173,174",
"      </a>",
"      ], in that HER2-positive clones comprise only a minority of the tumor in esophagogastric cancers. This heterogeneity may increase the likelihood that esophagogastric tissue samples, particularly biopsies, will miss a HER2-positive region of the tumor. As a result, the cutpoint in the percentage of cancer cells that must show HER2 expression is lower in tumor biopsies from esophagogastric as compared to breast cancers. Specifically, an esophagogastric tumor biopsy showing weak-moderate or strong HER2 expression in a tumor cluster comprising as few as five cancer cells is designated 2+ or 3+, respectively (",
"      <a class=\"graphic graphic_table graphicRef83375 \" href=\"mobipreview.htm?19/38/20076\">",
"       table 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/173,174\">",
"       173,174",
"      </a>",
"      ]. In contrast, a joint guideline from the American Society of Clinical",
"      <span class=\"nowrap\">",
"       Oncology/College",
"      </span>",
"      of American Pathologists",
"      <span class=\"nowrap\">",
"       (ASCO/CAP)",
"      </span>",
"      recommended that a positive result for HER2 expression using IHC in breast cancer requires uniform intense membrane staining of &gt;30 percent of tumor cells in the specimen. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H7#H7\">",
"       \"HER2 and predicting response to therapy in breast cancer\", section on 'Recommendations of the ASCO/CAP consensus panel'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These modified criteria for interpreting HER2 by IHC in esophagogastric cancers were developed and validated by an international oncology and pathology panel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/173,174\">",
"     173,174",
"    </a>",
"    ] and utilized to assess eligibility for the ToGA trial. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Trastuzumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Examinations of the relationship between",
"    <em>",
"     HER2",
"    </em>",
"    gene amplification and HER2 protein overexpression esophagogastric cancer, as measured by FISH and IHC, respectively, have found a high concordance for the IHC 0-1+ and IHC 3+ groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/169,173,175\">",
"     169,173,175",
"    </a>",
"    ]. For interpretation of FISH, esophagogastric tumors with a",
"    <span class=\"nowrap\">",
"     HER2/CEP17",
"    </span>",
"    ratio of 2 or greater are considered HER2-amplified (FISH-positive); the value recommended by the",
"    <span class=\"nowrap\">",
"     ASCO/CAP",
"    </span>",
"    panel for breast cancer was 2.2, but they considered values between 1.8 and 2.2 to represent equivocal results for which reflex HER2 testing using an alternative validated assay (eg, IHC) was recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H7#H7\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Recommendations of the ASCO/CAP consensus panel'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103667934\">",
"    <span class=\"h4\">",
"     Selection of patients for trastuzumab therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for selecting patients with esophagogastric cancer for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    based upon HER2 test results are not uniform worldwide. European regulators approved trastuzumab only for metastatic gastric cancers that are IHC 3+ or IHC 2+ with amplification (FISH-positive), based upon an exploratory analysis of the ToGA trial, which showed that trastuzumab benefit was greatest in cases with high protein expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/176\">",
"     176",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Trastuzumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with",
"    <span class=\"nowrap\">",
"     FISH-positive/IHC",
"    </span>",
"    0-1+ tumors did not appear to benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in the exploratory analysis; this represented approximately 22 percent of patients enrolled in ToGA. Together, these data suggest that screening for HER2 status by initial FISH testing may result in a significant percentage of nonresponders and the potential cost-ineffectiveness in treating these patients has been raised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/177,178\">",
"     177,178",
"    </a>",
"    ]. As a result, the European Medicines Agency has recommended that the initial screening test for HER2 should be IHC, followed by confirmatory FISH testing for IHC 2+ cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/176\">",
"     176",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the exploratory analysis had limitations in ruling out",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    benefit in the",
"    <span class=\"nowrap\">",
"     FISH-positive/IHC",
"    </span>",
"    0-1+ subgroup. Eligible patients were not stratified by HER2 levels at the time of randomization; as a result, factors other than HER2 protein expression that are associated with decreased trastuzumab benefit may have been overrepresented in the IHC 0-1+ subgroup. Moreover, there were only 113 overall survival events in the",
"    <span class=\"nowrap\">",
"     FISH-positive/IHC",
"    </span>",
"    0-1+ subgroup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/179\">",
"     179",
"    </a>",
"    ]. In addition, the reported frequencies of FISH-positivity in IHC 0-1+ cases have varied in the literature, particularly in the IHC 1+ group; in this regard, the largest studies utilizing tumor-specific IHC criteria have shown a FISH-positive rate of 0 to 3.6 percent in IHC 0 cases and 0.6 to 18 percent in IHC 1+ cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/158,168,180\">",
"     158,168,180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these issues, the US FDA approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    for patients with metastatic esophagogastric adenocarcinoma whose HER2 status meet the eligibility criteria of the ToGA trial (ie, FISH-positive or IHC 3+) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our view, although questions remain as to the best definition of HER2 positivity in esophagogastric cancers and the correlation between HER2 gene amplification and protein expression in gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/182\">",
"     182",
"    </a>",
"    ], pending further information, it is reasonable to add",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    to standard chemotherapy if the tumor is IHC 3+ or IHC 2+ plus FISH-positive. Controversy exists on whether to recommend trastuzumab in IHC 0-1+ cases that are FISH-positive; exploratory analysis of phase III data suggests that these patients do not benefit from trastuzumab, but benefit has not been definitively ruled out. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=see_link&amp;anchor=H6#H6\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Assays for HER2 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While there are no published guidelines for exclusion of patients for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    on the basis of excess cardiac risk, many clinicians caring for patients with breast cancer use the cardiac ineligibility criteria from the North American adjuvant trastuzumab trials (",
"    <a class=\"graphic graphic_table graphicRef74571 \" href=\"mobipreview.htm?10/30/10731\">",
"     table 12",
"    </a>",
"    ). It seems reasonable to adopt this approach in esophagogastric cancer as well.",
"   </p>",
"   <p>",
"    At the time of disease progression on a first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    -containing regimen for HER2-positive disease, there are no data addressing the benefit of continuing trastuzumab with the second-line regimen. However, extrapolating from the experience in breast cancer, many oncologists continue trastuzumab as long as it is well tolerated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H111525572#H111525572\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Second or later line treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Lapatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/23/9592?source=see_link\">",
"     Lapatinib",
"    </a>",
"    , an orally active small molecule inhibitor of both epidermal growth factor receptor (EGFR) type I and II (HER2), is under study in combination with weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    versus paclitaxel alone in patients with previously treated advanced gastric cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Agents targeting the EGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor overexpression of EGFR correlates with poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/183\">",
"     183",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Cetuximab and panitumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety and efficacy of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to first-line chemotherapy has been tested in multiple studies of advanced esophagogastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/184-188\">",
"     184-188",
"    </a>",
"    ]. All suggest that this approach is safe and in some cases, objective response rates are over 50 percent; yet with a single exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/188\">",
"     188",
"    </a>",
"    ], median survival is &le;10 months.",
"   </p>",
"   <p>",
"    Whether these results are better than can be achieved with chemotherapy alone is unclear. The benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-FU was addressed in a randomized phase II German trial of 66 previously untreated patients with metastatic squamous cell cancer (SCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/189\">",
"     189",
"    </a>",
"    ]. The objective response rate was only slightly higher (19 versus 13 percent), and there was a trend toward longer median PFS (5.7 versus 3.6 months) and overall survival (9.5 versus 5.5 months) when cetuximab was added to the CF backbone. Conclusions regarding the clinical utility of cetuximab in patients with advanced esophagogastric cancer await data from randomized phase III trials.",
"   </p>",
"   <p>",
"    The benefit of adding an anti-EGFR agent to first-line chemotherapy has been called into question by a preliminary report of a phase III trial, the REAL3 trial, comparing chemotherapy with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    , another MoAb targeting the EGFR that at least in advanced colorectal cancer, appears to have comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , but causes fewer infusion reactions because it is fully humanized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H38#H38\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Are cetuximab and panitumumab interchangeable?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the REAL3 trial, 553 patients with previously untreated advanced unselected esophagogastric cancer were randomly assigned to EOC (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), or modified EOC (with a reduction in oxaliplatin to 100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    and capecitabine to 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/190\">",
"     190",
"    </a>",
"    ]. In a preliminary report presented at the 2012 ASCO meeting, the addition of panitumumab was associated with a similar response rate but a significantly worse overall survival (median 8.8 versus 11.3 months). The authors postulated that the lower chemotherapy doses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    higher toxicity rates in the panitumumab arm may have compromised outcomes in this group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4478438\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Give these results, the addition of an anti-EGFR antibody to cytotoxic chemotherapy should not be considered a standard approach and only be pursued within the context of a clinical trial. An important point is that none of the trials examining the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    have selected patients based upon biomarkers. At least in advanced colorectal cancer, the benefit of these agents is limited to patients whose tumors lack mutated Kras. In the REAL3 study biomarker analysis was performed in the first 200 patients treated; as compared to colorectal cancer, the rate of K-ras mutations in this patient population was low, approximately 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/190\">",
"     190",
"    </a>",
"    ]. Mutation rates for other potentially predictive biomarkers such as PI3K, PTEN, and HER2 were also so low that it was difficult to draw any information from their analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H6688281#H6688281\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Agents targeting the EGFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Small molecule tyrosine kinase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another means of interfering with EGFR signaling is through the use of orally active tyrosine kinase inhibitors (TKIs), small molecules that block the binding site of the EGFR TK.",
"   </p>",
"   <p>",
"    Small molecule TKIs that have been tested as single agents in phase II trials in esophagogastric cancers are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108248092\">",
"    <span class=\"h4\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    has been tested for first-line and second-line therapy of metastatic esophageal or gastric cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/191-193\">",
"     191-193",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II study of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (500 mg daily) in 36 patients who had failed one prior therapy for advanced esophageal cancer, there was only one partial response, but 10 patients (28 percent) had stable disease for at least eight weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/191\">",
"       191",
"      </a>",
"      ]. For unclear reasons, a higher disease control rate was noted in women (55 versus 20 percent in men) and in SCC compared to adenocarcinoma (55 versus 20 percent). In addition, six of nine patients whose tumors were characterized by high levels of EGFR expression experienced disease control and the TTP was significantly longer in this group compared to those with week to moderate EGFR immunohistochemistry (153 versus 55 days, respectively). Treatment was reasonably well tolerated.",
"     </li>",
"     <li>",
"      In another trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (500 mg daily) was administered to 27 patients with advanced inoperable esophageal adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/192\">",
"       192",
"      </a>",
"      ]. There were three partial responses, and seven had stable disease. No comment was made as to a differential response in women as compared to men. Drug-related adverse events were generally mild with the exception of grade 3 diarrhea in three and grade 3 rash in five.",
"     </li>",
"     <li>",
"      A survival benefit for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      could not be shown in the only phase III trial, the Cancer Oesophagus Gefitinib (COG) trial, which randomly assigned 450 patients progressing after one prior chemotherapy regimen to gefitinib 500 mg daily or placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/193\">",
"       193",
"      </a>",
"      ]. Patients were not selected for EGFR amplification. In a preliminary report presented at the 2012 NCRI (National Cancer Research Institute) Cancer Conference, there was no significant benefit for gefitinib for overall survival (median 3.73 versus 3.6 months), and the statistically significant improvement in PFS was only two weeks duration (median 49 versus 35 days, p=0.017). In a later analysis of patient reported outcomes presented at the 2013 ASCO Gastrointestinal Cancers Symposium, patients receiving gefitinib had better quality of life and fewer problems with odynophagia, but more diarrhea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/194\">",
"       194",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data are insufficient to conclude that there is meaningful activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    in either the first-line or second-line setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108248117\">",
"    <span class=\"h4\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;An early report suggests that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    is active against adenocarcinomas involving the esophagogastric junction (EGJ) but not the distal stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/195\">",
"     195",
"    </a>",
"    ]. In this SWOG trial, 70 patients with unresectable or metastatic adenocarcinoma originating in the EGJ or stomach received first line treatment with erlotinib. Six patients had an objective response rate (9 percent, one complete), all of whom had EGJ tumors. The most frequent toxicities were as expected, fatigue and skin rashes. No molecular parameters of EGFR expression or mutations were predictive of clinical outcome. The reason for the apparent differential sensitivity of EGJ and gastric carcinomas to EGFR blockade using erlotinib is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Agents targeting VEGF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum and tumor levels of vascular endothelial growth factor (VEGF) are associated with a poor prognosis in patients with resectable gastric cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/196-198\">",
"     196-198",
"    </a>",
"    ]. These data, in conjunction with the demonstrated benefit of adding the anti-VEGF monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to chemotherapy in metastatic colorectal cancer, non-small cell lung cancer, and breast cancer provide the rationale to study these targeted therapies in advanced upper GI cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promising results were reported in phase II studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    as single agents, with adverse effect profiles that were quantitatively similar to those reported with other bevacizumab-containing chemotherapy regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/199,200\">",
"     199,200",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H44#H44\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Agents targeting VEGF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a survival benefit for adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    could not be shown in the global phase III AVAGAST trial, in which 774 patients with previously untreated locally advanced unresectable or metastatic (98 percent) gastric or EGJ cancer were randomly assigned to capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days) plus cisplatin (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) with either bevacizumab (7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    day 1) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/201\">",
"     201",
"    </a>",
"    ]. Cycles were repeated every three weeks for a maximum of six cycles of cisplatin; thereafter, capecitabine plus either bevacizumab or placebo was continued until disease progression. Although the addition of bevacizumab to chemotherapy significantly improved both objective response rate (46 versus 37 percent) and median progression-free survival (6.7 versus 5.3 months, HR 0.80, 95% CI 0.68 to 0.93]), there was no significant survival benefit (median 12.1 versus 10.1 months, HR 0.87, 95% CI 0.73 to 1.03).",
"   </p>",
"   <p>",
"    In an unplanned subset analysis, there were significant regional differences in efficacy, with the highest survival, but smallest impact from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    noted in Asia (median overall survival with bevacizumab versus placebo 13.9 versus 12.1 months, HR 0.97, 95% CI 0.75 to 1.25), and the shortest median survival but greatest impact from the addition of bevacizumab noted in the Americas, which enrolled only one-fifth of patients (median overall survival 11.5 versus 6.8 months, HR 0.63, 95% CI 0.43, 0.94). Although the explanation for this geographic heterogeneity was not obvious, Asian patients had fewer EGJ primaries, a lower frequency of liver metastases, and received second-line chemotherapy more often than did American patients (66 versus 21 percent).",
"   </p>",
"   <p>",
"    A similar lack of benefit for the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to chemotherapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) in Asian patients was also noted in a preliminary report of the AVATAR study, presented at the 2012 ASCO Gastrointestinal Cancers symposium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/202\">",
"     202",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biomarkers may prove useful for identifying those patients with advanced gastric cancer who might benefit from the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to cytotoxic chemotherapy, but this is not yet established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/203\">",
"     203",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Sunitinib and sorafenib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    are small molecule TKIs that inhibit the VEGF receptor tyrosine kinase (TK), as well as other TKs; they are referred to as multitargeted TKIs. Early studies have shown mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a preliminary report of a phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      monotherapy for second-line treatment of metastatic gastric cancer, only one of 21 patients had an objective partial response, while four others had stable disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/204\">",
"       204",
"      </a>",
"      ]. Seven patients experienced serious adverse events.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      (37.5 mg every day) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      every three weeks) was compared to docetaxel monotherapy (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      every three weeks) in an open-label randomized phase II trial for the second-line treatment of patients with unresectable or metastatic gastric cancer (n=107) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/205\">",
"       205",
"      </a>",
"      ]. Although combined therapy was associated with a significantly higher objective response rate, neither time to disease progression (the primary endpoint, 3.9 versus 2.6 months), nor overall survival (8.0 versus 6.6 months) was significantly improved.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"       sorafenib",
"      </a>",
"      (400 mg orally twice daily continuously) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 1) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV on day 1) was studied in a phase II trial of 44 chemotherapy-na&iuml;ve patients with locally advanced or metastatic (80 percent) gastric or EGJ adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/206\">",
"       206",
"      </a>",
"      ]. Objective responses were noted in 41 percent, and the median overall survival was 13.6 months; the major grade 3 or 4 toxicity was neutropenia (64 percent). Whether these results are better than with docetaxel plus cisplatin alone will require a randomized trial. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94799878\">",
"    <span class=\"h1\">",
"     DURATION OF FIRST-LINE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Response is assessed using a combination of interval radiographic evaluation (typically every two to three cycles), serum tumor markers such as carcinoembryonic antigen (CEA) (if elevated at baseline), and clinical status of the patient. Radiographic tumor response is usually quantified using RECIST (Response Evaluation Criteria In Solid Tumors) (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 13",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/207,208\">",
"     207,208",
"    </a>",
"    ]. While persistently rising levels of a serum tumor marker suggests disease progression, this should be confirmed by radiologic studies prior to a change in therapeutic strategy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\", section on 'Serologic markers'",
"    </a>",
"    .) The patient&rsquo;s clinic status should always be taken into consideration in combination with radiologic and tumor marker data, where patients with clinical benefit from treatment may stay on that treatment regimen despite possible radiologic progression.",
"   </p>",
"   <p>",
"    The duration of treatment in responding patients with advanced esophagogastric cancer has not been specifically studied.&nbsp;There are no data that pertain to discontinuation of a treatment regimen prior to disease progression or on modified maintenance therapy regimens. In general, regimens are given until the patient has progressive disease or cannot tolerate further treatment with the regimen. We recommend that each patient&rsquo;s treatment plan be individualized, depending upon tolerance and response to the treatment regimen, as well as the patient&rsquo;s wishes as to treatment breaks or modifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     SECOND-LINE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, clinical trials assessing the efficacy of a variety of second-line chemotherapy regimens after failure of the first-line regimen have shown that response rates are lower than they are in previously untreated patients, and toxicity rates tend to be higher [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/123,209-227\">",
"     123,209-227",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The survival benefit of second-line therapy was addressed in the following three randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Korean trial, 202 patients with advanced gastric cancer, prior exposure to fluoropyrimidines and a platinum agent, and a performance status of 0 or 1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 14",
"      </a>",
"      ) were randomly assigned to best supportive care with or without chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every two weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/228\">",
"       228",
"      </a>",
"      ]. Second-line chemotherapy was associated with a significant improvement in median overall survival (5.3 versus 3.8 months) and patients were also significantly more likely to receive further salvage chemotherapy.",
"     </li>",
"     <li>",
"      Similar results were noted in a smaller randomized trial in which 40 patients with objective tumor progression after first-line chemotherapy and a performance status of 0, 1, or 2 were randomly assigned to BSC or single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/229\">",
"       229",
"      </a>",
"      ]. Patients assigned to chemotherapy had a significantly longer median survival (4 versus 2.4 months).",
"     </li>",
"     <li>",
"      Likewise, a modest survival benefit for single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      was noted in a preliminary report of the phase III COUGAR-02 trial in which 168 patients who progressed within six months of a",
"      <span class=\"nowrap\">",
"       platinum/fluoropyrimidine",
"      </span>",
"      chemotherapy regimen were assigned to active symptom control with or without docetaxel (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/230\">",
"       230",
"      </a>",
"      ]. In a preliminary report presented at the 2013 ASCO GI Cancers Symposium, the addition of docetaxel to supportive care was associated with few objective responses (7 percent), stable disease in 46 percent, a modest but statistically significant prolongation of median survival (5.2 versus 3.6 months). Despite the high rate of grade 4 toxicity (21 percent), global and functional quality of life scores did not decline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of regimen is empiric. No single regimen has emerged as a clear \"winner\", and few trials have compared different regimens. A preliminary report of a Japanese trial comparing second-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    monotherapy (150",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 and 15, every four weeks) versus weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (80",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, and 15 every four weeks) concluded that neither regimen was superior in terms of efficacy or tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/231\">",
"     231",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, there is no standard approach for second-line therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/232,233\">",
"     232,233",
"    </a>",
"    ]. For patients who retain an adequate performance status, utilization of other active agents not used in the first-line regimen is reasonable, either in combination or as serial single agents. For example, patients who received ECF or EOX initially could be offered single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , a taxane, or irinotecan plus",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    (eg, FOLFIRI, (",
"    <a class=\"graphic graphic_table graphicRef76300 \" href=\"mobipreview.htm?19/2/19502\">",
"     table 10",
"    </a>",
"    )) Particularly in view of the lack of data showing benefit of multiagent versus monotherapy in any setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/234\">",
"     234",
"    </a>",
"    ], quality of life and minimization of side effects are key considerations when choosing the regimen.",
"   </p>",
"   <p>",
"    The criteria to select patients for second-line chemotherapy have not been established. In one study, five factors were identified that were independently associated with poor survival: performance status 2, hemoglobin &le;11.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    serum carcinoembryonic antigen (CEA) level &gt;50",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    three or more metastatic sites, and time to progression &le;6 months after the first-line regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/235\">",
"     235",
"    </a>",
"    ]. A prognostic index was developed which divided patients into low- (no risk factors), intermediate- (one or two risk factors) or high-risk (three or more risk factors) groups with different median survival durations (12.7, 7.1, and 3.3 months, respectively). The authors concluded that these factors could be used to predict which patients might benefit from a second-line regimen.",
"   </p>",
"   <p>",
"    However, in clinical practice, we do not use this specific algorithm to select patients for second-line treatment. Instead, we prefer to make this decision on a case-by-case basis, after consulting with the patient and assessing their overall medical condition and disease status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     INTRAPERITONEAL CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high frequency with which gastric cancer spreads to the peritoneum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/236\">",
"     236",
"    </a>",
"    ] has led several investigators to examine the utility of intraperitoneal (IP) chemotherapy for both the prevention and treatment of peritoneal carcinomatosis. Although postoperative administration of IP chemotherapy is feasible and well tolerated by the majority of patients, questions persist as to the survival benefit of this approach. This subject is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=see_link\">",
"     \"Adjuvant and neoadjuvant treatment of gastric cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with documented peritoneal carcinomatosis have a particularly short survival (median 3 to 6 months, less in the setting of ascites or peritoneal masses larger than 2 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/237\">",
"     237",
"    </a>",
"    ]. At least in principle, the delivery of chemotherapy directly into the peritoneum in such cases is attractive because of the high intracavitary drug concentrations that can be achieved and because of the limitation of drug exposure to the rest of the body.",
"   </p>",
"   <p>",
"    Uncontrolled studies suggest that, in selected patients, the natural history of peritoneal carcinomatosis may be altered by the multimodality approach of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/238-245\">",
"     238-245",
"    </a>",
"    ]. A systematic review of 10 published studies of cytoreductive surgery plus HIPEC (one non-randomized prospective controlled trial, six prospective case series, and three retrospective case series) found average one and two-year survival rates of 43 (range 22 to 68) and 18 (range 11 to 50), percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/242\">",
"     242",
"    </a>",
"    ]. Outcomes were most favorable among patients who were able to undergo complete or nearly complete surgical cytoreduction prior to intraperitoneal chemotherapy instillation (median survival 15 months versus 7.9 months in all treated patients). The average procedure-related mortality rate was 4.8 percent (range 0-14.3), and the overall major morbidity rate was 22 percent (mostly abscesses, fistulas, and anastomotic leaks).",
"   </p>",
"   <p>",
"    The independent contributions of HIPEC and cytoreductive surgery to outcomes are unclear. This issue was addressed in a randomized phase III trial comparing cytoreductive surgery with and without HIPEC in 68 patients with advanced gastric cancer and peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/241\">",
"     241",
"    </a>",
"    ]. The combined approach was associated with a significantly longer median overall survival (11 versus 6.5 months), and this was not counterbalanced by a significantly higher adverse event rate. However, only 2 of the 34 patients undergoing combined therapy (6 percent) remained alive at three years (versus 0 patients undergoing cytoreductive surgery alone).",
"   </p>",
"   <p>",
"    There is a need for confirmation of benefit for this approach relative to modern combination chemotherapy in well-conducted prospective randomized trials. These procedures are technically challenging, and expertise is limited to few centers worldwide. Given the high treatment-related morbidity rates, particularly in inexperienced hands, and the absence of randomized controlled trials demonstrating benefit, cytoreductive surgery with HIPEC for patients with peritoneal carcinomatosis should ideally be undertaken within the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=see_link\">",
"       \"Patient information: Esophageal cancer (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/28/32195?source=see_link\">",
"       \"Patient information: Stomach cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with esophageal or gastric cancer will require palliative treatment at some point in the course of their disease. Cytotoxic chemotherapy can provide symptom palliation, improve quality of life, and prolong survival in patients with advanced esophageal or gastric cancer. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Chemotherapy versus best supportive care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     First-line chemotherapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coincident with epidemiologic changes in histologic and anatomic distribution, the treatment of advanced gastric and esophageal cancers has converged, and the majority of patients with gastric, esophageal, or esophagogastric junction (EGJ) cancers are treated similarly, regardless of histology. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evolution of chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite a large number of randomized trials, there is no consensus as to the best agent or regimen. In general, combination chemotherapy regimens provide higher response rates than do single agents, but this translates into only modestly longer durations of disease control and survival that are measured in weeks to a few months. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Combination versus single agent therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In randomized trials, the ECF (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"       epirubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , infusional 5-FU, (",
"      <a class=\"graphic graphic_table graphicRef62502 \" href=\"mobipreview.htm?35/44/36558\">",
"       table 4",
"      </a>",
"      )) and DCF (TCF,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , cisplatin, infusional 5-FU, (",
"      <a class=\"graphic graphic_table graphicRef73324 \" href=\"mobipreview.htm?29/18/29998\">",
"       table 7",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef79612 \" href=\"mobipreview.htm?35/41/36510\">",
"       table 8",
"      </a>",
"      )) combinations have emerged as standard regimens for first-line treatment. A major problem with these regimens is the need for central venous access and an ambulatory infusion pump. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'ECF'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Data from the REAL-2 trial suggest that outcomes are comparable if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      is substituted for infusional 5-FU, and when",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      is substituted for cisplatin in the ECF regimen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"       75",
"      </a>",
"      ]. When both oxaliplatin and capecitabine are substituted in the ECF regimen, outcomes are at least as good as with ECF, and trend towards better.",
"      <br/>",
"      <br/>",
"      For these reasons, we suggest epirubicin, oxaliplatin and capecitabine (EOX, (",
"      <a class=\"graphic graphic_table graphicRef75288 \" href=\"mobipreview.htm?35/50/36654\">",
"       table 6",
"      </a>",
"      )) rather than ECF or TCF for first-line treatment (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). While the use of capecitabine allows patients to avoid infusion pumps and a central venous catheter, the costs of capecitabine and oxaliplatin are significantly higher than with 5-FU and cisplatin, and toxicity is not necessarily less. FOLFOX (",
"      <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"       table 15",
"      </a>",
"      ) is another reasonable option. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Capecitabine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Oxaliplatin combinations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=see_link\">",
"       \"Treatment protocols for esophagogastric cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with advanced gastric or esophageal adenocarcinoma who are potential candidates for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef74571 \" href=\"mobipreview.htm?10/30/10731\">",
"       table 12",
"      </a>",
"      ) should have their tumors assayed for the presence of HER2 overexpression utilizing tumor-specific criteria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gene amplification. We suggest the addition of trastuzumab to chemotherapy in patients with HER2-positive tumors (as defined by 3+ immunohistochemical staining or FISH positivity), as long as they do not have a contraindication to trastuzumab (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Trastuzumab'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H103667934\">",
"       'Selection of patients for trastuzumab therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For elderly patients or those with a poor performance status, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU alone or single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Other reasonable alternatives include single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , or low-dose weekly taxanes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Single agent chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Second line chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standard approach for second-line therapy after failure of the first-line regimen. For patients who retain an adequate performance status, utilization of other active agents not used in the first-line regimen is reasonable, either in combination or as serial single agents. Quality of life and minimization of side effects are key considerations when choosing the therapeutic approach. (See",
"    <a class=\"local\" href=\"#H43\">",
"     'Second-line chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Intraperitoneal chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria for selecting patients who are most likely to benefit from surgical cytoreduction and intraperitoneal chemotherapy are not well defined, and whether this approach is superior to modern conventional chemotherapy is unknown. We discuss this therapeutic option only with fit patients who have isolated small-volume intraperitoneal metastases and no evidence of extraperitoneal disease spread. We refer interested patients to centers with extensive experience with these techniques where clinical trials may be available. (See",
"    <a class=\"local\" href=\"#H44\">",
"     'Intraperitoneal chemotherapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     SEER Cancer Statistics file://www.seer.cancer.gov/statistics/ (Accessed on March 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/2\">",
"      Nigro JJ, Hagen JA, DeMeester TR, et al. Occult esophageal adenocarcinoma: extent of disease and implications for effective therapy. Ann Surg 1999; 230:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/3\">",
"      Rice TW, Zuccaro G Jr, Adelstein DJ, et al. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg 1998; 65:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/4\">",
"      Folli S, Morgagni P, Roviello F, et al. Risk factors for lymph node metastases and their prognostic significance in early gastric cancer (EGC) for the Italian Research Group for Gastric Cancer (IRGGC). Jpn J Clin Oncol 2001; 31:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/5\">",
"      Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/6\">",
"      Salvon-Harman JC, Cady B, Nikulasson S, et al. Shifting proportions of gastric adenocarcinomas. Arch Surg 1994; 129:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/7\">",
"      Wijnhoven BP, Siersema PD, Hop WC, et al. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group. Br J Surg 1999; 86:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/8\">",
"      Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/9\">",
"      Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/10\">",
"      Chau I, Norman AR, Cunningham D, et al. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Ann Oncol 2009; 20:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/11\">",
"      Ilson DH, Wadleigh RG, Leichman LP, Kelsen DP. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol 2007; 18:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/12\">",
"      Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/13\">",
"      Einzig AI, Neuberg D, Remick SC, et al. Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/14\">",
"      Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/15\">",
"      Petrasch S, Welt A, Reinacher A, et al. Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer. Br J Cancer 1998; 78:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/16\">",
"      Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993; 72:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/17\">",
"      Pyrh&ouml;nen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995; 71:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/18\">",
"      Glimelius B, Ekstr&ouml;m K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/19\">",
"      Wagner AD, Grothe W, Haerting J, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24:2903.",
"     </a>",
"    </li>",
"    <li>",
"     Thuss-Patience PC, Kretzschmar A, Deist T, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeninschaft Internistische Onkologie (AIO) (abstract 4540). J Clin Oncol 2009; 27:211s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/21\">",
"      Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; :CD004064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/22\">",
"      Ezdinli EZ, Gelber R, Desai DV, et al. Chemotherapy of advanced esophageal carcinoma: Eastern Cooperative Oncology Group experience. Cancer 1980; 46:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/23\">",
"      Advani SH, Saikia TK, Swaroop S, et al. Anterior chemotherapy in esophageal cancer. Cancer 1985; 56:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/24\">",
"      Earl HM, Coombes RC, Schein PS. Cytotoxic chemotherapy for cancer of the stomach. Clinics in Oncology 1984; 3:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/25\">",
"      Whittington RM, Close HP. Clinical experience with mitomycin C (NSC-26980). Cancer Chemother Rep 1970; 54:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/26\">",
"      Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 1997; 33:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/27\">",
"      Beer M, Cocconi G, Ceci G, et al. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983; 19:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/28\">",
"      Bruckner HW, Lokich JJ, Stablein DM. Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report. Cancer Treat Rep 1982; 66:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/29\">",
"      Study of the clinical efficiency of bleomycin in human cancer. Br Med J 1970; 2:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/30\">",
"      Kok TC, van der Gaast A, Splinter TA. 5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. Ann Oncol 1996; 7:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/31\">",
"      Alberts AS, Schoeman L, Burger W, et al. A phase II study of 5-fluorouracil and leucovorin in advanced carcinoma of the esophagus. Am J Clin Oncol 1992; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/32\">",
"      Sternberg C, Kelsen D, Dukeman M, et al. Carboplatin: a new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 1985; 69:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/33\">",
"      Queisser W, Preusser P, Mross KB, et al. Phase II evaluation of carboplatin in advanced esophageal carcinoma. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society. Onkologie 1990; 13:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/34\">",
"      Mannell A, Winters Z. Carboplatin in the treatment of oesophageal cancer. S Afr Med J 1989; 76:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/35\">",
"      Ajani JA, Ilson DH, Daugherty K, et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/36\">",
"      Mavroudis D, Kourousis C, Androulakis N, et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/37\">",
"      Kanat O, Evrensel T, Manavoglu O, et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer. Tumori 2003; 89:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/38\">",
"      Conroy T, Etienne PL, Adenis A, et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 1996; 14:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/39\">",
"      Bang YJ, Kang WK, Kang YK, et al. Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol 2002; 32:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/40\">",
"      Kulke MH, Muzikansky A, Clark J, et al. A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinoma. Cancer Invest 2006; 24:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/41\">",
"      Einzig AI, Lipsitz S, Wiernik PH, Benson AB 3rd. Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT). The Eastern Cooperative Oncology group (ECOG) results. Invest New Drugs 1995; 13:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/42\">",
"      Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1998; 4:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/43\">",
"      Futatsuki K, Wakui A, Nakao I, et al. [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group]. Gan To Kagaku Ryoho 1994; 21:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/44\">",
"      K&ouml;hne CH, Catane R, Klein B, et al. Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 2003; 89:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/45\">",
"      Sulkes A, Smyth J, Sessa C, et al. Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer 1994; 70:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/46\">",
"      Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol 1998; 21:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/47\">",
"      Kii T, Takiuchi H, Gotoh M, et al. [Weekly administration regimen of paclitaxel (PTX) in patient with inoperable or recurrent gastric cancer]. Gan To Kagaku Ryoho 2006; 33:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/48\">",
"      Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol 2011; 67:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/49\">",
"      Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci 2005; 50:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/50\">",
"      Hong YS, Song SY, Lee SI, et al. A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. Ann Oncol 2004; 15:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/51\">",
"      Koizumi W, Saigenji K, Ujiie S, et al. A pilot phase II study of capecitabine in advanced or recurrent gastric cancer. Oncology 2003; 64:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/52\">",
"      Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/53\">",
"      van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000; 18:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/54\">",
"      Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/55\">",
"      Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/56\">",
"      Lee SJ, Cho SH, Yoon JY, et al. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Cancer Chemother Pharmacol 2009; 65:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/57\">",
"      Jeung HC, Rha SY, Shin SJ, et al. A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status. Br J Cancer 2007; 97:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/58\">",
"      Ohtsu A, Shimada Y, Shirao K, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/59\">",
"      Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/60\">",
"      Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/61\">",
"      Coonley CJ, Bains M, Hilaris B, et al. Cisplatin and bleomycin in the treatment of esophageal carcinoma. A final report. Cancer 1984; 54:2351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/62\">",
"      Marcuello E, Alba E, G&oacute;mez de Segura G, et al. Cisplatin and intravenous continuous infusion of bleomycin in advanced and metastatic esophageal cancer. Eur J Cancer Clin Oncol 1988; 24:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/63\">",
"      Iizuka T, Kakegawa T, Ida H, et al. Phase II evaluation of combined cisplatin and vindesine in advanced squamous cell carcinoma of the esophagus: Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1991; 21:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/64\">",
"      Dinwoodie WR, Bartolucci AA, Lyman GH, et al. Phase II evaluation of cisplatin, bleomycin, and vindesine in advanced squamous cell carcinoma of the esophagus: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/65\">",
"      Kelsen D, Hilaris B, Coonley C, et al. Cisplatin, vindesine, and bleomycin chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med 1983; 75:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/66\">",
"      Kok TC, Van der Gaast A, Dees J, et al. Cisplatin and etoposide in oesophageal cancer: a phase II study. Rotterdam Oesophageal Tumour Study Group. Br J Cancer 1996; 74:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/67\">",
"      Spiridonidis CH, Laufman LR, Jones JJ, et al. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma. Cancer 1996; 78:2070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/68\">",
"      Conroy T, Etienne PL, Adenis A, et al. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann Oncol 2002; 13:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/69\">",
"      Warner E, Jensen JL, Cripps C, et al. Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. Acta Oncol 1999; 38:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/70\">",
"      Choi IK, Seo HY, Sung HJ, et al. Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. Med Oncol 2007; 24:33.",
"     </a>",
"    </li>",
"    <li>",
"     Jin M, Lu H, Li J, et al. Randomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients with advanced gastric cancer: SC-101 study (abstract). J Clin Oncol 2008; 26:221s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/72\">",
"      Ajani JA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/73\">",
"      Lenz HJ, Lee FC, Haller DG, et al. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. Cancer 2007; 109:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/74\">",
"      Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 2010; 28:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/75\">",
"      Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/76\">",
"      Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/77\">",
"      Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009; 20:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/78\">",
"      MacDonald JS, Schein PS, Woolley PV, et al. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/79\">",
"      Haim N, Cohen Y, Honigman J, Robinson E. Treatment of advanced gastric carcinoma with 5-fluorouracil adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 1982; 8:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/80\">",
"      Cascinu S, Latini L, Fedeli A, et al. The clinical impact of FEM regimen (5-fluorouracil, 4-epidoxorubicin and mitomycin-C) in advanced gastric cancer patients. Anticancer Res 1995; 15:2781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/81\">",
"      Klein HO, Wickramanayake PD, Dieterle F, et al. High-dose MTX/5-FU and adriamycin for gastric cancer. Semin Oncol 1983; 10:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/82\">",
"      Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/83\">",
"      Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer 1995; 76:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/84\">",
"      Kulke MH, Wu B, Clark JW, et al. A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus. Cancer Invest 2006; 24:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/85\">",
"      Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/86\">",
"      Wils JA, Klein HO, Wagener DJ, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991; 9:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/87\">",
"      Weh HJ, Platz D, Garbrecht M, et al. [The results of a modified FAMeth chemotherapy protocol in metastatic stomach carcinoma]. Dtsch Med Wochenschr 1989; 114:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/88\">",
"      Wils J, Bleiberg H, Dalesio O, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986; 4:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/89\">",
"      Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 1992; 10:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/90\">",
"      Cocconi G, Carlini P, Gamboni A, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 2003; 14:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/91\">",
"      Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989; 7:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/92\">",
"      Lerner A, Gonin R, Steele GD Jr, Mayer RJ. Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 1992; 10:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/93\">",
"      Wilke H, Preusser P, Fink U, et al. High dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer--a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 1990; 8:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/94\">",
"      di Bartolomeo M, Bajetta E, de Braud F, et al. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. Oncology 1995; 52:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/95\">",
"      Partyka S, Dumas P, Ajani J. Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. Cancer 1999; 85:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/96\">",
"      Vanhoefer U, Rougier P, Wilke H, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 2000; 18:2648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/97\">",
"      Lutz MP, Wilke H, Wagener DJ, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2007; 25:2580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/98\">",
"      Al-Batran SE, Hartmann JT, Probst S, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435.",
"     </a>",
"    </li>",
"    <li>",
"     Ridwelski K, Fahlke J, Kettner E, et al. Docetaxel-cisplatini (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study (abstract). J Clin Oncol 2008; 26:216s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/100\">",
"      Yun J, Lee J, Park SH, et al. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer 2010; 46:885.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: A randomized phase II stidu of three standard chemotherapy regimens (SCF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer (Abstract 4006). J Clin Oncol 2010; 28:302s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/102\">",
"      Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/103\">",
"      Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol 2007; 25:3217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/104\">",
"      Ajani JA, Fodor MB, Tjulandin SA, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 2005; 23:5660.",
"     </a>",
"    </li>",
"    <li>",
"     Tebbutt N, Sournina T, Strickland A, et al. ATTAX: Randomized phase II study evaluating weekly docetaxel- based chemotherapy combinations in advanced esophagogastric cancer: final results of an AGITG trial (abstract). J Clin Oncol 2007; 25:204s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/106\">",
"      Thuss-Patience PC, Kretzschmar A, Repp M, et al. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 2005; 23:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/107\">",
"      Polee MB, Eskens FA, van der Burg ME, et al. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002; 86:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/108\">",
"      Ilson DH, Forastiere A, Arquette M, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/109\">",
"      Kornek GV, Raderer M, Sch&uuml;ll B, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. Br J Cancer 2002; 86:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/110\">",
"      Zhang X, Shen L, Li J, et al. A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus. Am J Clin Oncol 2008; 31:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/111\">",
"      Wang F, Wang Z, Zhou N, et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol 2011; 34:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/112\">",
"      Gadgeel SM, Shields AF, Heilbrun LK, et al. Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer. Am J Clin Oncol 2003; 26:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/113\">",
"      El-Rayes BF, Shields A, Zalupski M, et al. A phase II study of carboplatin and paclitaxel in esophageal cancer. Ann Oncol 2004; 15:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/114\">",
"      Lokich JJ, Sonneborn H, Anderson NR, et al. Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas. Cancer 1999; 85:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/115\">",
"      Sharma A, Raina V, Lokeshwar N, et al. Phase II study of cisplatin, etoposide and paclitaxel in locally advanced or metastatic adenocarcinoma of gastric/gastroesophageal junction. Indian J Cancer 2006; 43:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/116\">",
"      Takahashi H, Arimura Y, Yamashita K, et al. Phase I/II study of docetaxel/cisplatin/fluorouracil combination chemotherapy against metastatic esophageal squamous cell carcinoma. J Thorac Oncol 2010; 5:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/117\">",
"      Park SR, Chun JH, Kim YW, et al. Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma. Am J Clin Oncol 2005; 28:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/118\">",
"      Park SR, Chun JH, Yu MS, et al. Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 2006; 94:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/119\">",
"      Giordano KF, Jatoi A, Stella PJ, et al. Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/120\">",
"      Kim JG, Sohn SK, Kim DH, et al. Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer. Oncology 2005; 68:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/121\">",
"      Chun JH, Kim HK, Lee JS, et al. Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer. Am J Clin Oncol 2005; 28:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/122\">",
"      Overman MJ, Kazmi SM, Jhamb J, et al. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer 2010; 116:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/123\">",
"      Lorenzen S, Duyster J, Lersch C, et al. Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 2005; 92:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/124\">",
"      Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/125\">",
"      Ajani JA, Moiseyenko VM, Tjulandin S, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007; 25:3210.",
"     </a>",
"    </li>",
"    <li>",
"     Kelsen D, Jhawer M, Ilson D, et al. Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF) and bevacizumab (BEV) in patinets with metastatic gastrooestophageal (GE) adenocarcinoma: Results of a phase II clinical trial (abstract #4512). J Clin Oncol 2009; 27:204s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/127\">",
"      Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 2011; 29:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/128\">",
"      Evans D, Miner T, Iannitti D, et al. Docetaxel, capecitabine and carboplatin in metastatic esophagogastric cancer: a phase II study. Cancer Invest 2007; 25:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/129\">",
"      van Meerten E, Eskens FA, van Gameren EC, et al. First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer 2007; 96:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/130\">",
"      Louvet C, Andr&eacute; T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol 2002; 20:4543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/131\">",
"      Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 2004; 22:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/132\">",
"      Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 2006; 17:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/133\">",
"      Park YH, Kim BS, Ryoo BY, Yang SH. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer. Br J Cancer 2006; 94:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/134\">",
"      Neri B, Pantaleo P, Giommoni E, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study. Br J Cancer 2007; 96:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/135\">",
"      Liu ZF, Guo QS, Zhang XQ, et al. Biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX-4 regimen) as first-line chemotherapy for elderly patients with advanced gastric cancer. Am J Clin Oncol 2008; 31:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/136\">",
"      Di Lauro L, Nunziata C, Arena MG, et al. Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Br J Cancer 2007; 97:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/137\">",
"      Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer 2012; 48:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/138\">",
"      Wang J, Chang J, Yu H, et al. A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemother Pharmacol 2013; 71:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/139\">",
"      Popov I, Radosevic-Jelic L, Jezdic S, et al. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. J BUON 2008; 13:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/140\">",
"      Montagnani F, Turrisi G, Marinozzi C, et al. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/141\">",
"      Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology (Williston Park) 2004; 18:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/142\">",
"      Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol 1999; 17:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/143\">",
"      Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer 2002; 94:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/144\">",
"      Shirao K, Shimada Y, Kondo H, et al. Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J Clin Oncol 1997; 15:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/145\">",
"      Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999; 17:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/146\">",
"      Enzinger PC, Ryan DP, Clark JW, et al. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer. Ann Oncol 2009; 20:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/147\">",
"      Jatoi A, Tirona MT, Cha SS, et al. A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 2002; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/148\">",
"      Burtness B, Gibson M, Egleston B, et al. Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer. Ann Oncol 2009; 20:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/149\">",
"      Bouch&eacute; O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803. J Clin Oncol 2004; 22:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/150\">",
"      Oh SC, Sur HY, Sung HJ, et al. A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer. Br J Cancer 2007; 96:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/151\">",
"      Moehler M, Kanzler S, Geissler M, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2010; 21:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/152\">",
"      Luo HY, Wang ZQ, Wang FH, et al. Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. Am J Clin Oncol 2011; 34:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/153\">",
"      Narahara H, Iishi H, Imamura H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011; 14:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/154\">",
"      Dank M, Zaluski J, Barone C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/155\">",
"      Cao W, Yang W, Lou G, et al. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs 2009; 20:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/156\">",
"      W&ouml;ll E, K&uuml;hr T, Eisterer W, et al. Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the Arbeitsgemeinschaft Medikament&ouml;se Tumortherapie (AGMT). Anticancer Res 2008; 28:2901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/157\">",
"      Lee J, Kang WK, Kwon JM, et al. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Ann Oncol 2007; 18:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/158\">",
"      Park YS, Hwang HS, Park HJ, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol 2012; 43:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/159\">",
"      Barros-Silva JD, Leit&atilde;o D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/160\">",
"      Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer 2002; 98:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/161\">",
"      Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer 2008; 8:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/162\">",
"      Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/163\">",
"      Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol 2011; 18:2833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/164\">",
"      Yoon HH, Shi Q, Sukov WR, et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012; 18:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/165\">",
"      Schoppmann SF, Jesch B, Friedrich J, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol 2010; 34:1868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/166\">",
"      Hu Y, Bandla S, Godfrey TE, et al. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol 2011; 24:899.",
"     </a>",
"    </li>",
"    <li>",
"     Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (abstract). J Clin Oncol 2009; 27:215s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/168\">",
"      Kim MA, Lee HJ, Yang HK, et al. Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma. Histopathology 2011; 59:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/169\">",
"      Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009; 40:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/170\">",
"      Bozzetti C, Negri FV, Lagrasta CA, et al. Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma. Br J Cancer 2011; 104:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/171\">",
"      Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol 2012; 23:2656.",
"     </a>",
"    </li>",
"    <li>",
"     Hegewisch-Becker S, Moorahrend E, Kroning H, et al. Trastuzumab in combination with different first-line chemtoehrapies for treatmentof HEr2-positive metastatic gastric or gastroesophgeal junction cancer (MGC)L Findings from the German noninterventional observational study HerMES (abstract). J Clin Oncol 30, 2012 (suppl; abstr 4065).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/173\">",
"      Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008; 52:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/174\">",
"      R&uuml;schoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing. Virchows Arch 2010; 457:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/175\">",
"      Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep 2006; 15:65.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency. Post-authorisation summary of positive opinion for Herceptin. file://www.emea.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000278/WC500059913.pdf (Accessed on April 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/177\">",
"      Munro AJ, Niblock PG. Cancer research in the global village. Lancet 2010; 376:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/178\">",
"      Shiroiwa T, Fukuda T, Shimozuma K. Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trial. Br J Cancer 2011; 105:1273.",
"     </a>",
"    </li>",
"    <li>",
"     Administration, US FDA. Final Labeling Text: Herceptin 2010. file://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5250lbl.pdf (Accessed on April 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/180\">",
"      Bilous M, Osamura RY, R&uuml;schoff J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2010; 41:304.",
"     </a>",
"    </li>",
"    <li>",
"     NCI. FDA Approval for Trastuzumab:HER2-overexpressing Metastatic Gastric or Gastroesophageal (GE) Junction Adenocarcinoma. 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/182\">",
"      Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol 2011; 18:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/183\">",
"      Kopp R, Ruge M, Rothbauer E, et al. Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. Anticancer Res 2002; 22:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/184\">",
"      Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 2007; 18:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/185\">",
"      Pinto C, Di Fabio F, Barone C, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 2009; 101:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/186\">",
"      Lordick F, Luber B, Lorenzen S, et al. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 2010; 102:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/187\">",
"      Moehler M, Mueller A, Trarbach T, et al. Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011; 22:1358.",
"     </a>",
"    </li>",
"    <li>",
"     Iqbal S, El-Khoueiry AB, Yang D, et al. A phase II study of capecitabine-oxaliplatin and cetuximab in patients with advanced/metastatic gastric canceror gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 30, 2012 (suppl abstr 4096). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=100490 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/189\">",
"      Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 2009; 20:1667.",
"     </a>",
"    </li>",
"    <li>",
"     Waddell TS, et al. A randomized multicenter trial of epiprubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in addvanced esophagogastric cancer (REAL3). J Clin Oncol 30, 2012 (suppl; abstr LBA4000). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=94595 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/191\">",
"      Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol 2006; 24:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/192\">",
"      Ferry DR, Anderson M, Beddard K, et al. A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response. Clin Cancer Res 2007; 13:5869.",
"     </a>",
"    </li>",
"    <li>",
"     Ferry DR, Dutton SJ, Mansoor W, et al. Phase III multi-centre, randomised, double-blind, placebo-controlled trial of gefitinib versus placebo in oesophageal cancer progressing after chemotherapy , COG (Cancer Oesophagus Gefitinib) (abstract). Data presented at the 8th National Cancer Research Institute Cancer Conference, November 4-7, 2012, Liverpool, UK. Abstract available online at file://www.ncri.org.uk/ncriconference/2012abstracts/abstracts/ClinicalShowcase4.html (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     Dutton SJ, Blazeby JM, Petty RD,  et al. PAtient-reported outcomes from a phase III multicenter randomized double-blind placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy: Cancer Oesophagus Gefitinib (COG). (abstract). Data presented at the 2013 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013. Abstract available online at file://www.asco.org/portal/site/ascov2/gsasearch?src=abstracts&amp;return_page=menuitem.a1c60e38cd6d5b9f01ae0094ef37a01d&amp;return_channel=874911ff7fefd110VgnVCM100000ed730ad1RCRD&amp;q=noQstring&amp;search_mode=adv&amp;vmview=abst_meeting_categories_view&amp;the_meeting_ids=133&amp;confID=133&amp;the_title=&amp;ab_auth_last_name=&amp;th (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/195\">",
"      Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol 2006; 24:4922.",
"     </a>",
"    </li>",
"    <li>",
"     Pera M, Vidal O, Elizade J, et al. Tumor VEGF expression and serum VEGF levels are independent prognostic factors in curatively resected gastric cancer patients (abstract). J Clin Oncol 2006; 24:183s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/197\">",
"      Fondevila C, Metges JP, Fuster J, et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004; 90:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/198\">",
"      Yao JC, Wang L, Wei D, et al. Association between expression of transcription factor Sp1 and increased vascular endothelial growth factor expression, advanced stage, and poor survival in patients with resected gastric cancer. Clin Cancer Res 2004; 10:4109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/199\">",
"      Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:5201.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger PC, Fidias, P, Meyerhardt, J, et al. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer (abstract). Data presented at the 2006 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 27, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/201\">",
"      Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29:3968.",
"     </a>",
"    </li>",
"    <li>",
"     Shen L, Li J, Xu JM, et al. Efficacy and tolerability of bevacizumab plus capecitabine and cisplatin in Chinese patients with locally advanced or metastatic gastric/gastroesophgeal junction cancer: Results from the AVATAR study (abstract). J Clin Oncol 2012; 30 (suppl 4):abstr 73. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88633 (Accessed on March 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/203\">",
"      Van Cutsem E, de Haas S, Kang YK, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol 2012; 30:2119.",
"     </a>",
"    </li>",
"    <li>",
"     Bang Y, Kang Y, Kang, et al. Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study (abstract). J Clin Oncol 2007; 25:223s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/205\">",
"      Yi JH, Lee J, Lee J, et al. Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. Br J Cancer 2012; 106:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/206\">",
"      Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 2010; 28:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/207\">",
"      Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/208\">",
"      Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/209\">",
"      Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal cancer: a phase II Southwest Oncology Group Study (abstract). J Clin Oncol 2008; 26:222s.",
"     </a>",
"    </li>",
"    <li>",
"     Kim Y, Park S, Park J, et al. Oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX4) combination chemotherapy as salvage treatment in pretreated patients with advanced gastric cancer (abstract). J Clin Oncol 2008; 26:232s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/211\">",
"      Kodera Y, Ito S, Mochizuki Y, et al. A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res 2007; 27:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/212\">",
"      Hartmann JT, Pintoffl JP, Al-Batran SE, et al. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. Onkologie 2007; 30:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/213\">",
"      Yoshida T, Yoshikawa T, Tsuburaya A, et al. Feasibility study of biweekly CPT-11 plus CDDP for S-1- and paclitaxel-refractory, metastatic gastric cancer. Anticancer Res 2006; 26:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/214\">",
"      Cho BC, Kim JH, Kim CB, et al. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep 2006; 15:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/215\">",
"      Sym SJ, Ryu MH, Lee JL, et al. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol 2008; 31:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/216\">",
"      Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol 2004; 34:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/217\">",
"      Kim SH, Lee GW, Go SI, et al. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol 2010; 33:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/218\">",
"      Giuliani F, Gebbia V, De Vita F, et al. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res 2003; 23:4219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/219\">",
"      Cascinu S, Graziano F, Cardarelli N, et al. Phase II study of paclitaxel in pretreated advanced gastric cancer. Anticancer Drugs 1998; 9:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/220\">",
"      Burkart C, Bokemeyer C, Klump B, et al. A phase II trial of weekly irinotecan in cisplatin-refractory esophageal cancer. Anticancer Res 2007; 27:2845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/221\">",
"      Lordick F, von Schilling C, Bernhard H, et al. Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 2003; 89:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/222\">",
"      Hironaka S, Zenda S, Boku N, et al. Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/223\">",
"      Graziano F, Catalano V, Baldelli AM, et al. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol 2000; 11:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/224\">",
"      Seo HY, Kim DS, Choi YS, et al. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol 2009; 63:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/225\">",
"      Jeong J, Jeung HC, Rha SY, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol 2008; 19:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/226\">",
"      Baize N, Abakar-Mahamat A, Mounier N, et al. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 2009; 64:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/227\">",
"      Lee JL, Ryu MH, Chang HM, et al. A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy. Cancer Chemother Pharmacol 2008; 61:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/228\">",
"      Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/229\">",
"      Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47:2306.",
"     </a>",
"    </li>",
"    <li>",
"     Ford H, MArshall A, Wadsley J, et al. Cougar-02: a randomized phase III study of docetaxel versus active symptom control in advanced esophagogastric carcinoma (abstract). J Clin Oncol 30: 2012 (suppl 34: abstr LBA4). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=105311 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     Ueda S, Hironaka S, Yasui H,  et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer refractory to combination chemotherapy of fluoropyrimidine plus platinum: WJOG4007 trial. J Clin Oncol 30, 2012 (suppl; abstr 4002). Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=92145 (Accessed on June 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/232\">",
"      Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 2009; 10:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/233\">",
"      Thallinger CM, Raderer M, Hejna M. Esophageal cancer: a critical evaluation of systemic second-line therapy. J Clin Oncol 2011; 29:4709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/234\">",
"      Sym SJ, Hong J, Park J, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemother Pharmacol 2013; 71:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/235\">",
"      Catalano V, Graziano F, Santini D, et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/236\">",
"      Schwarz RE, Zagala-Nevarez K. Recurrence patterns after radical gastrectomy for gastric cancer: prognostic factors and implications for postoperative adjuvant therapy. Ann Surg Oncol 2002; 9:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/237\">",
"      Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/238\">",
"      Yang XJ, Li Y, Yonemura Y. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol 2010; 101:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/239\">",
"      Hall JJ, Loggie BW, Shen P, et al. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg 2004; 8:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/240\">",
"      Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 2010; 17:2370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/241\">",
"      Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/242\">",
"      Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011; 104:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/243\">",
"      Scaringi S, Kianmanesh R, Sabate JM, et al. Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol 2008; 34:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/244\">",
"      Roviello F, Marrelli D, Neri A, et al. Treatment of peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion (IHCP): postoperative outcome and risk factors for morbidity. World J Surg 2006; 30:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?43/10/44202/abstract/245\">",
"      Yonemura Y, Kawamura T, Bandou E, et al. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 2005; 92:370.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2473 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-0E3ADE63EF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44202=[""].join("\n");
var outline_f43_10_44202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTOLOGY, ANATOMIC DISTRIBUTION, AND EVOLUTION OF CHEMOTHERAPY STRATEGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evolution of chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHEMOTHERAPY VERSUS BEST SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SINGLE AGENT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Older single agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Newer agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Taxanes, irinotecan and vinorelbine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Oral fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COMBINATION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Combination versus single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Older cisplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cisplatin plus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cisplatin plus newer fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Ftorafur",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - S-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      5-FU/anthracycline regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - FAM and FAMTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - EAP and ELF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - ECF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - ECF and the REAL trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Taxane-based combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Paclitaxel regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108248034\">",
"      - Docetaxel regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108248051\">",
"      DCF (TCF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108248081\">",
"      Docetaxel plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Oxaliplatin combinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Irinotecan-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Irinotecan plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Irinotecan plus docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Irinotecan plus fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Irinotecan plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BIOLOGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Agents targeting HER2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103667884\">",
"      Assessment of HER2 status in upper GI cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H103667934\">",
"      Selection of patients for trastuzumab therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Lapatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Agents targeting the EGFR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Cetuximab and panitumumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4478438\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Small molecule tyrosine kinase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108248092\">",
"      Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H108248117\">",
"      Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Agents targeting VEGF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Sunitinib and sorafenib",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94799878\">",
"      DURATION OF FIRST-LINE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      SECOND-LINE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      INTRAPERITONEAL CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      First-line chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Second line chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Intraperitoneal chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2473|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/45/4817\" title=\"figure 1\">",
"      Parts of the stomach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/14/27884\" title=\"table 1\">",
"      Old single agts chemo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/20/17740\" title=\"table 2\">",
"      New single agts chemo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/0/27660\" title=\"table 3\">",
"      Phase II trials cispl comb",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/44/36558\" title=\"table 4\">",
"      ECF for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/58/37806\" title=\"table 5\">",
"      ECX for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/50/36654\" title=\"table 6\">",
"      EOX for advanced esophagogastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/18/29998\" title=\"table 7\">",
"      DCF for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/41/36510\" title=\"table 8\">",
"      Modified DCF for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/24/21902\" title=\"table 9\">",
"      Irinotecan plus cisplatin for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/2/19502\" title=\"table 10\">",
"      FOLFIRI regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/38/20076\" title=\"table 11\">",
"      Criteria HER2 IHC gastric v breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/30/10731\" title=\"table 12\">",
"      Card inelig adjuv trastuz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 13\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 14\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 15\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/38/11882?source=related_link\">",
"      Adjuvant and neoadjuvant treatment of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/1/42006?source=related_link\">",
"      Endoscopic palliation of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/35/4661?source=related_link\">",
"      Epidemiology of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33018?source=related_link\">",
"      Invasive gastric cancer: Surgery and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19333?source=related_link\">",
"      Local palliation for advanced gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30106?source=related_link\">",
"      Management of locally advanced unresectable esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/12/8391?source=related_link\">",
"      Pathogenesis of Barrett's esophagus and its malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/26/33194?source=related_link\">",
"      Pathology and molecular pathogenesis of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/17/9491?source=related_link\">",
"      Patient information: Esophageal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/28/32195?source=related_link\">",
"      Patient information: Stomach cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/23/43378?source=related_link\">",
"      Treatment protocols for esophagogastric cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f43_10_44203="Rapid HIV tests";
var content_f43_10_44203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of rapid HIV tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Specimens",
"      </td>",
"      <td class=\"subtitle1\">",
"       CLIA status",
"      </td>",
"      <td class=\"subtitle1\">",
"       Time (min)",
"      </td>",
"      <td class=\"subtitle1\">",
"       HIV 1 + 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       OraQuick",
"      </td>",
"      <td>",
"       Blood, plasma oral fluid",
"      </td>",
"      <td>",
"       Waived",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       HIV 1 &amp; 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       UniGold",
"      </td>",
"      <td>",
"       Blood/plasma/serum",
"      </td>",
"      <td>",
"       Waived",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       HIV-1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Reveal G2",
"      </td>",
"      <td>",
"       Plasma/serum",
"      </td>",
"      <td>",
"       Mod complex",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       HIV-1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multispot",
"      </td>",
"      <td>",
"       Serum",
"      </td>",
"      <td>",
"       Mod complex",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       HIV-1 &amp; 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clearview",
"      </td>",
"      <td>",
"       Blood/serum",
"      </td>",
"      <td>",
"       Waived",
"      </td>",
"      <td>",
"       15-20",
"      </td>",
"      <td>",
"       HIV-1 &amp; 2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       VITROS",
"      </td>",
"      <td>",
"       Serum",
"      </td>",
"      <td>",
"       Mod complex",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       HIV-1 &amp; 2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    CLIA: Clinical Laboratory Improvement Amendments",
"    <br>",
"     Waived tests are cleared by the United States Food and Drug Administration to be performed without the requirement for a laboratory with particular personnel qualifications. Tests classified as moderately complex should be performed in a laboratory by&nbsp;personnel who meet CLIA requirements for performing such tests.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of John G. Bartlett, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44203=[""].join("\n");
var outline_f43_10_44203=null;
var title_f43_10_44204="LMWH ASGE";
var content_f43_10_44204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=8\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ASGE recommendations regarding low molecular weight heparin (LMWH)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute GI hemorrhage in the patient taking LMWH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The decision to reverse or to stop this therapy, risking an adverse ischemic event or a thromboembolic complication, must be weighed against the risk of continued bleeding by maintaining continued systemic anticoagulation. Because of the short half-life of the LMWHs, the anticoagulant effect may be reversed within 8 hours of the last dose. If quick reversal is required, intravenous protamine sulfate can be used. Note that the administration of protamine sulfate can cause severe hypotension and anaphylactoid reactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Elective endoscopic procedures in the patient taking LMWH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A decision regarding discontinuation of therapy before endoscopy has to be weighed against the patient's risk of developing an adverse ischemic event or thromboemboli complication. Endoscopic procedures have been previously categorized as low or high risk for bleeding (table). Low- or high-risk clinical conditions for thromboembolic complications also have been previously defined.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Low-risk procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No adjustments in anticoagulation need be made, irrespective of the underlying condition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High-risk procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discontinue LMWH at least 8 hours before the anticipated therapeutic endoscopy*. The decision as to when to restart therapy should be individualized.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Elective endoscopic procedure in the patient taking warfarin who may need bridge therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LMWH may be useful in extending the period of systemic anticoagulation while the effects of long-acting warfarin are allowed to dissipate. LMWH may replace the previous standard of \"heparin window\" in high-risk patients. Considerations in favor of LMWH would be the enhanced quality of life for the patient (ie, no therapeutic monitoring, avoidance of hospitalization, no need for intravenous access) and the possible economic savings of outpatient LMWH compared with a hospital-based \"heparin window.\" LMWH should not be used in pregnant women with mechanical prosthetic heart valves. In non-pregnant patients with mechanical valves, short-term use appears to be safe but prospective controlled data are lacking.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Low-risk procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No adjustments in anticoagulation need to be made, irrespective of the underlying condition.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        High-risk procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discontinue warfarin 3 to 5 days before the procedure and concomitantly begin administering LMWH. Consider using dose ranges as for the treatment of patients with acute DVT (eg, enoxaparin 1 mg/kg subcutaneously every 12 hours). Discontinue LMWH for at least 8 hours before the therapeutic endoscopy. The decision as to when to restart therapy should be individualized.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * This recommendation differs from the 2012 American College of Chest Physicians guideline that suggests stopping LMWH 24 hours prior to the procedure (Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S).&nbsp;Our practice is to discontinue LMWH 24 hours prior to the procedure.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE). Gastrointest Endosc 2005; 61:189.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44204=[""].join("\n");
var outline_f43_10_44204=null;
var title_f43_10_44205="Rx hyperlipidemia after OLT";
var content_f43_10_44205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacotherapy for hyperlipidemia after liver transplantation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual starting dose*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected drug interactions",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        HMG CoA reductase inhibitors (\"statins\")",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pravastatin",
"       </td>",
"       <td>",
"        10 or 20 mg once per day",
"       </td>",
"       <td>",
"        Approximately 50 percent is renally cleared as unchanged drug. Smaller amounts are cleared by biliary excretion or undergo non-CYP and CYP 3A4 hepatic transformation. Pravastatin is a substrate of P-gp.",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Cyclosporine: increased risk of myopathy due to additive toxicity and elevation of statin serum level by competitive inhibition of CYP 3A4 and/or P-gp. Pravastatin and fluvastatin are less likely than other statins to interact significantly with cyclosporine.",
"        </p>",
"        <p>",
"         Sirolimus, everolimus: increased serum levels of sirolimus and everolimus in combination with atorvastatin due to inhibition of P-gp.",
"        </p>",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Gastrointestinal intolerance, CK elevations, transaminase elevations, muscle toxicity, rhabdomyolysis (rare).",
"        </p>",
"        <p>",
"         Close monitoring of transaminases may provide early evidence of elevated statin levels and toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvastatin",
"       </td>",
"       <td>",
"        10 or 20 mg once per day",
"       </td>",
"       <td>",
"        Approximately 75 percent undergoes hepatic transformation by CYP 2C9 and 20 percent by CYP 3A4. Fluvastatin inhibits, and can interact with other drugs metabolized by CYP 2C9.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rosuvastatin",
"       </td>",
"       <td>",
"        5 or 10 mg once per day. Maximum 5 mg per day with cyclosporine.",
"       </td>",
"       <td>",
"        Most clearance occurs as unchanged drug. Approximately 10 percent undergoes CYP 2C9 transformation to a partially active metabolite.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atorvastatin",
"       </td>",
"       <td>",
"        5 or 10 mg once per day. Maximum10 mg per day with cyclosporine.",
"       </td>",
"       <td>",
"        Undergoes extensive CYP 3A4 transformation to active metabolites. Atorvastatin is a substrate and inhibitor of P-gp.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Simvastatin",
"       </td>",
"       <td>",
"        5 or 10 mg once per day. Avoid use with cyclosporine.",
"       </td>",
"       <td>",
"        Undergoes extensive CYP 3A4 transformation to active and inactive metabolites.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Cholesterol absorption inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ezetimibe",
"       </td>",
"       <td>",
"        10 mg once per day",
"       </td>",
"       <td>",
"        Undergoes glucuronide conjugation in small intestine and liver to form active metabolite. Most clearance occurs by enterohepatic recycling and fecal excretion.",
"       </td>",
"       <td>",
"        <p>",
"         Statins: useful for added LDL lowering in combination with a statin or as single agent if statin not tolerated.",
"        </p>",
"        <p>",
"         Fibrate: increased serum level of ezetimibe; theoretic increased risk of cholelithiasis.",
"        </p>",
"        <p>",
"         Cyclosporine: increased serum level of ezetimibe and possible alteration of cyclosporine level. 5 mg ezetimibe daily may suffice for LDL lowering effect in combination with cyclosporine.",
"        </p>",
"       </td>",
"       <td>",
"        Gastrointestinal intolerance, headache. In combination with statin, slightly higher incidence of serum transaminase elevations than statin monotherapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Refractory severe hypertriglyceridemia (&ge;500 mg/dL [5.6 mmol/L])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gemfibrozil",
"       </td>",
"       <td>",
"        600 mg twice per day",
"       </td>",
"       <td>",
"        Undergoes non CYP transformation by glucuronide conjugation with small amount of CYP 3A4 transformation. Gemfibrozil inhibits and can interact with other drugs metabolized by CYP 2C8, 2C9, 2C19 and OATP1B1.",
"       </td>",
"       <td>",
"        <p>",
"         Statins: increased risks of hepatotoxicity, myopathy, and rhabdomyolysis due to additive toxicity and elevation of statin serum level. Avoid combining gemfibrozil with statins.",
"        </p>",
"        <p>",
"         Cyclosporine: additive risk of nephrotoxicity and altered serum concentration of cyclosporine.",
"        </p>",
"       </td>",
"       <td rowspan=\"2\">",
"        Gastrointestinal intolerance, muscle toxicity, cholelithiasis, rhabdomyolysis (rare).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fenofibrate",
"       </td>",
"       <td>",
"        40 to 67 mg once per day depending on preparation",
"       </td>",
"       <td>",
"        Hydrolysed to active intermediary by plasma and tissue esterases. Undergoes non CYP metabolism by glucuronide conjugation.",
"       </td>",
"       <td>",
"        <p>",
"         Statins: increased risk of myopathy and rhabdomyolysis due to additive toxicity. If combination with a statin is unavoidable, fenofibrate with fluvastatin or pravastatin may be less likely to interact significantly than gemfibrozil with a statin.",
"        </p>",
"        <p>",
"         Cyclosporine: additive risk of nephrotoxicity and altered serum concentration of cyclosporine.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Omega-3-acid ethyl esters",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1 to 2 grams twice per day",
"       </td>",
"       <td>",
"        Inadequately defined.",
"       </td>",
"       <td>",
"        CYP mediated interactions with immunosuppressive agents, statins, fibrates or ezetimibe are not expected based on in vitro data.",
"       </td>",
"       <td>",
"        Dyspepsia, fishy taste, modest increase in LDL-C (5 percent). Modest increase in bleeding time that is insignificant for patients with functional hemostasis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CYP: cytochrome P450; OATP1B1: organic anion transporting polypeptide 1B1; P-gp: P-glycoprotein transporter.",
"     <br>",
"      * Adult doses, oral administration. Post liver transplant patients with compromised renal function are at elevated risk of adverse effects due to statins and other hypolipidemic drugs. Limited dose titration or dose reduction may be necessary.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Shows metabolism and disposition of drug reaching systemic circulation. Statins undergo extensive pre-systemic clearance in gastric mucosa and/or liver. Patients with hepatic insufficiency may have increased systemic exposure.",
"       <br>",
"        &Delta; For additional information, see Lexi-Interact&trade; drug interactions application included with UpToDate.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Potential option. Inadequate data and experience in patients with hepatic insufficiency and/or post liver transplant. If used, a licensed standardized preparation (eg, Lovaza&reg;) appears to be preferable.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44205=[""].join("\n");
var outline_f43_10_44205=null;
var title_f43_10_44206="ICD versus amiodarone CIDS";
var content_f43_10_44206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68588&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    There is an insignificant reduction in mortality with the implantable cardioverter defibrillator",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The CIDS trial randomized 659 patients with a sustained ventricular tachyarrhythmia or syncope judged to be due to an arrhythmia to a implantable cardioverter defibrillator (ICD) or amiodarone. After a five year follow-up there was an insignificant reduction in total mortality with the ICD (8.3 versus 10.2 percent per year with amiodarone, p = 0.142).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Connolly, SJ, Gent, M, Roberts, RJ, Circulation 2000; 101:1297.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44206=[""].join("\n");
var outline_f43_10_44206=null;
var title_f43_10_44207="Polymyositis whole body MRI";
var content_f43_10_44207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51395&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    56-year-old man with suspected polymyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 192px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whole-body turbo short tau inversion recovery MR image (TR/TE, 4000/30; inversion time, 160 msec) of posterior aspect of upper torso shows extensive inflammation in deltoid, trapezius, triceps and latissimus dorsi muscles bilaterally (straight arrows) and further muscle edema and inflammation in vastus medialis and lateralis muscles of left thigh (curved arrow). Note susceptibility artifact at site of right hip prosthesis, limiting assessment of muscles adjacent to this site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     O'Connell MJ, Powell T, Brennan D, et al. Whole-body MR imaging in the dianosis of polymyositis. Am J Roentgenol 2002; 179:967. Reprinted with permission from the American Journal of Roentgenology. Copyright &copy; 2002 American Roentgen Ray Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f43_10_44207=[""].join("\n");
var outline_f43_10_44207=null;
